chr7:140453136:A>T Detail (hg19) (BRAF)

Information

Genome

Assembly Position
hg19 chr7:140,453,136-140,453,136
hg38 chr7:140,753,336-140,753,336 View the variant detail on this assembly version.

HGVS

Type Transcript Protein
RefSeq NM_004333.4:c.1919T>A NP_004324.2:p.Val640Glu
Ensemble ENST00000288602.11:c.1919T>A ENST00000288602.11:p.Val640Glu
ENST00000496384.7:c.1799T>A ENST00000496384.7:p.Val600Glu
Summary

MGeND

Clinical significance Pathogenic not provided
Variant entry 306
GWAS entry
Disease area statistics Show details

Frequency

JP HGVD:[No Data.]
ToMMo:[No Data.]
NCBN:[No Data.]
NCBN(Hondo):[No Data.]
NCBN(Ryukyu):[No Data.]
East asia ExAC:<0.001

Prediction

ClinVar

Clinical Significance Pathogenic Likely pathogenic
Review star
Show details
Links
Type Database ID Link
Gene MIM 164757 OMIM
HGNC 1097 HGNC
Ensembl ENSG00000157764 Ensembl
NCBI NCBI
Gene Cards Gene Cards
OncoKB OncoKB
Type Database ID Link
Variant TogoVar
COSMIC COSM476 COSMIC
MONDO
Disease area statistics
MGeND
Clinical significance Last evaluated Condition Origin Submission ID Submitter Institute Citation Comment Image
not provided fundus of stomach not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided ileum not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided caecum not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided transverse colon not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided descending colon not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided colon, unspecified not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided malignant neoplasm of rectum not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided bronchus or lung, unspecified not provided MGS000041
(TMGS000094) 		Hitoshi Nakagama National Cancer Center Japan
not provided cervical part of oesophagus not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided caecum not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided appendix not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided ascending colon not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided transverse colon not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided descending colon not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided sigmoid colon not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided colon, unspecified not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided malignant neoplasm of rectum not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided extrahepatic bile duct not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
not provided ill-defined sites within the digestive system not provided MGS000040
(TMGS000095) 		Hitoshi Nakagama National Cancer Center Japan
Pathogenic Colorectal somatic MGS000038
(TMGS000091) 		Manabu Muto
Ichiro Kinoshita		 Kyoto University
Department of Medical Oncology Faculty of Medicine and Graduate School of Medicine Hokkaido University
not provided Cholangiocarcinoma of biliary tract (disorder) unknown MGS000021
(TMGS000080) 		Manabu Muto Kyoto University
not provided Malignant tumor of rectum (disorder) unknown MGS000024
(TMGS000083) 		Manabu Muto Kyoto University
not provided Non-small cell lung cancer somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
not provided Glioma somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
not provided Breast cancer somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
not provided Thymic carcinoma somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
not provided Soft tissue sarcoma somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
not provided colorectal cancer somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
not provided Wilms tumor somatic MGS000018
(TMGS000110) 		Hitoshi Nakagama National Cancer Center Japan 30742731
Pathogenic congenital anaplastic astrocytoma somatic MGS000001
(TMGS000138) 		Kenjiro Kosaki Keio University
Pathogenic a linear syringocystadenoma papilliferum somatic MGS000001
(TMGS000138) 		Kenjiro Kosaki Keio University
Pathogenic ocular abnormalities somatic MGS000001
(TMGS000138) 		Kenjiro Kosaki Keio University
Pathogenic Glioblastoma somatic MGS000001
(TMGS000179) 		Kenjiro Kosaki Keio University
Pathogenic papillary thyroid carcinoma somatic MGS000001
(TMGS000179) 		Kenjiro Kosaki Keio University
Pathogenic epitheloid glioblastoma (E-GBM) somatic MGS000001
(TMGS000179) 		Kenjiro Kosaki Keio University
not provided other somatic MGS000039
(TMGS000092) 		Hitoshi Nakagama National Cancer Center Japan 29659903
not provided carcinoma of pancreas somatic MGS000039
(TMGS000092) 		Hitoshi Nakagama National Cancer Center Japan 29659903
not provided caecum not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided appendix not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided ascending colon not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided transverse colon not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided descending colon not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided sigmoid colon not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided colon, unspecified not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided malignant neoplasm of rectosigmoid junction not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided malignant neoplasm of rectum not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided intrahepatic bile duct carcinoma not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided extrahepatic bile duct not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided ill-defined sites within the digestive system not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
not provided bronchus or lung, unspecified not provided MGS000042
(TMGS000093) 		Hitoshi Nakagama National Cancer Center Japan
ClinVar
Clinical significance Last evaluated Review status Condition Origin Links
Pathogenic 2014-09-04 no assertion criteria provided Carcinoma of colon somatic Detail
Pathogenic 2014-09-04 no assertion criteria provided Papillary thyroid carcinoma somatic Detail
Pathogenic 2014-09-04 no assertion criteria provided Astrocytoma, low-grade, somatic somatic Detail
Pathogenic 2014-09-04 no assertion criteria provided Nongerminomatous germ cell tumor somatic Detail
Pathogenic 2009-05-29 no assertion criteria provided Non-small cell lung carcinoma somatic Detail
Pathogenic 2016-03-10 no assertion criteria provided melanoma somatic Detail
Pathogenic 2014-07-11 criteria provided, multiple submitters, no conflicts not provided germline somatic unknown Detail
not provided no assertion provided Cardio-facio-cutaneous syndrome somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided Malignant melanoma of skin somatic Detail
Likely pathogenic 2015-07-14 no assertion criteria provided Colonic neoplasm somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided Squamous cell carcinoma of the head and neck somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided glioblastoma somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided lung adenocarcinoma somatic Detail
Likely pathogenic 2019-08-31 no assertion criteria provided multiple myeloma somatic Detail
Pathogenic 2014-10-02 no assertion criteria provided Neoplasm of ovary somatic Detail
Pathogenic 2014-10-02 no assertion criteria provided lung carcinoma somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided Neoplasm of brain somatic Detail
Pathogenic 2014-10-02 no assertion criteria provided gastrointestinal stromal tumor somatic Detail
Likely pathogenic 2016-05-31 no assertion criteria provided Papillary renal cell carcinoma, sporadic somatic Detail
Likely pathogenic 2016-05-13 no assertion criteria provided Neoplasm somatic Detail
Pathogenic 2016-05-31 no assertion criteria provided Neoplasm of the large intestine somatic Detail
Pathogenic 2015-05-07 no assertion criteria provided Cystic epithelial invagination containing papillae lined by columnar epithelium somatic Detail
Pathogenic no assertion criteria provided Cerebral arteriovenous malformation somatic Detail
Pathogenic 2019-02-15 no assertion criteria provided nephroblastoma somatic Detail
Likely pathogenic no assertion criteria provided Malignant neoplastic disease unknown Detail
Pathogenic 2022-02-09 no assertion criteria provided lymphangioma somatic Detail
Pathogenic 2023-10-22 criteria provided, single submitter Vascular malformation somatic Detail
Likely pathogenic 2022-05-23 criteria provided, single submitter germline Detail
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
melanoma Selumetinib,Dactolisib D Predictive Supports Sensitivity/Response Somatic 2 26678033 Detail
thyroid gland papillary carcinoma B Prognostic Does Not Support Poor Outcome Somatic 5 24354346 Detail
colorectal cancer B Prognostic Supports Poor Outcome Somatic 5 24594804 Detail
melanoma B Prognostic Supports Poor Outcome Somatic 3 24388723 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome Somatic 3 21594703 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome Somatic 3 24396464 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome Somatic 3 21594703 Detail
hairy cell leukemia B Diagnostic Supports Positive Somatic 4 21663470 Detail
cancer Cobimetinib D Predictive Supports Sensitivity/Response Somatic 3 23934108 Detail
colorectal cancer Cetuximab B Predictive Supports Resistance Somatic 3 20619739 Detail
melanoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 5 24508103 Detail
colorectal cancer Vemurafenib B Predictive Does Not Support Sensitivity/Response Somatic 4 26460303 Detail
colorectal cancer Dabrafenib B Predictive Does Not Support Sensitivity/Response Somatic 3 22608338 Detail
colorectal cancer Cetuximab,Vemurafenib,Gefitinib D Predictive Supports Sensitivity/Response Somatic 3 22281684 Detail
skin melanoma Vemurafenib A Predictive Supports Sensitivity/Response Somatic 5 21639808 Detail
skin melanoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 3 22356324 Detail
colorectal cancer Panitumumab,Vemurafenib B Predictive Does Not Support Sensitivity/Response Somatic 3 25589621 Detail
thyroid gland papillary carcinoma Vemurafenib C Predictive Supports Sensitivity/Response Somatic 4 24987354 Detail
melanoma Cobimetinib,Vemurafenib B Predictive Supports Sensitivity/Response Somatic 4 25265494 Detail
colorectal cancer GDC-0879,Dactolisib D Predictive Supports Sensitivity/Response Somatic 3 23549875 Detail
gastrointestinal neuroendocrine tumor Trametinib,Dabrafenib,Vemurafenib C Predictive Supports Sensitivity/Response Somatic 3 27048246 Detail
colorectal cancer B Prognostic Supports Poor Outcome Somatic 3 27404270 Detail
hairy cell leukemia Vemurafenib B Predictive Supports Sensitivity/Response Somatic 2 26352686 Detail
colorectal cancer Panitumumab,Vemurafenib C Predictive Supports Sensitivity/Response Somatic 2 27325282 Detail
thyroid gland papillary carcinoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 3 27460442 Detail
multiple myeloma Vemurafenib C Predictive Supports Sensitivity/Response Somatic 3 24997557 Detail
multiple myeloma Vemurafenib C Predictive Supports Sensitivity/Response Somatic 2 24997557 Detail
melanoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 4 20818844 Detail
colorectal cancer Irinotecan,Cetuximab,Vemurafenib B Predictive Supports Sensitivity/Response Somatic 4 27729313 Detail
colorectal cancer B Prognostic Supports Poor Outcome Somatic 4 27302369 Detail
colorectal cancer Panitumumab,Cetuximab B Predictive Supports Resistance Somatic 3 19001320 Detail
colorectal cancer Oxaliplatin B Predictive Supports Resistance Somatic 3 19603024 Detail
colorectal cancer Irinotecan B Predictive Supports Resistance Somatic 3 19603024 Detail
colorectal cancer Bevacizumab B Predictive Supports Resistance Somatic 19571295 Detail
melanoma Trametinib B Predictive Supports Sensitivity/Response Somatic 22663011 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome Somatic 4 18682506 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome Somatic 3 21882184 Detail
lung non-small cell carcinoma Dabrafenib,Trametinib A Predictive Supports Sensitivity/Response Somatic 4 27283860 Detail
colorectal cancer Cetuximab B Predictive Supports Resistance Somatic 25666295 Detail
melanoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 23569304 Detail
melanoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 26557775 Detail
melanoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 25524477 Detail
skin melanoma Dabrafenib,Trametinib B Predictive Supports Sensitivity/Response Somatic 4 25399551 Detail
ganglioglioma Vemurafenib C Predictive Supports Sensitivity/Response Somatic 25524464 Detail
ovarian cystadenocarcinoma Vemurafenib C Predictive Supports Sensitivity/Response Somatic 26490654 Detail
multiple myeloma B Prognostic Supports Poor Outcome Somatic 3 23612012 Detail
cholangiocarcinoma Trametinib Dimethyl Sulfoxide,Dabrafenib C Predictive Supports Sensitivity/Response Somatic 3 28480077 Detail
cholangiocarcinoma Trametinib Dimethyl Sulfoxide,Dabrafenib C Predictive Supports Sensitivity/Response Somatic 3 28078132 Detail
cholangiocarcinoma Dabrafenib,Trametinib Dimethyl Sulfoxide C Predictive Supports Sensitivity/Response Somatic 3 25435907 Detail
cholangiocarcinoma Vemurafenib,Irinotecan,Panitumumab C Predictive Supports Sensitivity/Response Somatic 3 26687137 Detail
lung non-small cell carcinoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 4 29320312 Detail
ovarian cancer Vemurafenib B Predictive Supports Sensitivity/Response Somatic 3 29320312 Detail
colorectal cancer Vemurafenib C Predictive Supports Sensitivity/Response Somatic 2 29320312 Detail
Anaplastic thyroid carcinoma Vemurafenib,Pertuzumab C Predictive Supports Sensitivity/Response Somatic 3 29320312 Detail
laryngeal squamous cell carcinoma Vemurafenib C Predictive Supports Sensitivity/Response Somatic 3 29320312 Detail
Anaplastic thyroid carcinoma Vemurafenib B Predictive Supports Sensitivity/Response Somatic 3 26287849 Detail
colorectal cancer Dabrafenib,Panitumumab,Trametinib B Predictive Supports Sensitivity/Response Somatic 4 29431699 Detail
colorectal adenocarcinoma Trametinib,Panitumumab B Predictive Does Not Support Sensitivity/Response Somatic 3 29431699 Detail
melanoma Trametinib,Dabrafenib B Predictive Supports Sensitivity/Response Somatic 5 28891408 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome Somatic 5 25024077 Detail
melanoma Trametinib,Dabrafenib B Predictive Supports Sensitivity/Response Somatic 5 25265492 Detail
melanoma Trametinib,Dabrafenib B Predictive Supports Sensitivity/Response Somatic 4 23020132 Detail
Anaplastic thyroid carcinoma Dabrafenib,Trametinib B Predictive Supports Sensitivity/Response Somatic 4 29072975 Detail
colorectal cancer B Prognostic Supports Poor Outcome Somatic 4 20008640 Detail
colorectal cancer B Prognostic Supports Poor Outcome Somatic 4 21502544 Detail
Pediatric Low-grade Glioma (PLGG) B Prognostic Supports Poor Outcome Somatic 4 29948154 Detail
melanoma Pictilisib C Predictive Supports Sensitivity/Response Somatic 2 25370471 Detail
thyroid cancer B Diagnostic Supports Positive Somatic 3 21594703 Detail
thyroid gland papillary carcinoma B Diagnostic Supports Positive Somatic 5 24570209 Detail
colorectal cancer Panitumumab,Cetuximab B Predictive Does Not Support Resistance Somatic 4 25989278 Detail
melanoma B Prognostic Does Not Support Poor Outcome Somatic 2 24586605 Detail
melanoma MEK Inhibitor PD0325901,Trametinib D Predictive Does Not Support Resistance Somatic 3 24576830 Detail
colorectal cancer Panitumumab,Sorafenib D Predictive Supports Sensitivity/Response Somatic 3 19001320 Detail
melanoma Vemurafenib D Predictive Supports Resistance Somatic 3 24576830 Detail
lung non-small cell carcinoma Dabrafenib C Predictive Supports Resistance Somatic 2 23524406 Detail
melanoma Trametinib,Dabrafenib B Predictive Supports Sensitivity/Response Somatic 5 24583796 Detail
colorectal cancer PI3K Inhibitor GDC-0941 Bismesylate,PLX4720 D Predictive Supports Sensitivity/Response Somatic 3 23845441 Detail
colorectal cancer PLX4720,Nutlin-3 D Predictive Supports Sensitivity/Response Somatic 2 23812671 Detail
colorectal cancer Capecitabine,Bevacizumab,Vemurafenib D Predictive Supports Sensitivity/Response Somatic 2 22180495 Detail
colorectal cancer Vemurafenib D Predictive Supports Sensitivity/Response Somatic 2 22180495 Detail
DisGeNET
Score Disease name Description Source Pubmed Links
0.236 melanoma BRAF(V600E) mutation was detected in 50% of the acquired nevi and in 70% of the ... BeFree 18408659 Detail
0.007 Histiocytosis, Langerhans-Cell Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocyt... BeFree 25118810 Detail
0.003 Melanocytic nevus of skin All neoplastic melanocytes within such a nevus would be expected to carry the BR... BeFree 23690527 Detail
0.007 Histiocytosis, Langerhans-Cell BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohisto... BeFree 24625419 Detail
0.002 multiple myeloma We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chron... BeFree 26071465 Detail
0.132 hairy cell leukemia In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who l... BeFree 25700421 Detail
0.020 melanoma RAF is among the most frequently mutated kinases, where BRAF V600E mutation occu... BeFree 25034364 Detail
<0.001 melanoma In this study, we show that the expression of LAT1 and ASCT2 is significantly in... BeFree 24531984 Detail
0.020 colon carcinoma The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and ... BeFree 17096326 Detail
0.007 Histiocytosis, Langerhans-Cell Reported herein is a case of LCH in non-twin siblings (younger sister and elder ... BeFree 23782385 Detail
0.017 Secondary malignant neoplasm of lymph node Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a young... BeFree 24612623 Detail
0.006 Metastatic melanoma Studies presented or published during the European Society for Medical Oncology ... BeFree 25477091 Detail
0.129 Glioma Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade g... BeFree 25346165 Detail
0.024 Malignant tumor of colon The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and ... BeFree 17096326 Detail
0.431 melanoma Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of hu... BeFree 21107323 Detail
0.017 melanoma Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma pro... BeFree 24425783 Detail
<0.001 Histiocytosis, Langerhans-Cell Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (E... BeFree 25324352 Detail
0.001 Melanocytic nevus of skin The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus ha... BeFree 15009715 Detail
0.001 Carcinogenesis We propose that continuously activated BRAF(V600E) signaling may be a possible m... BeFree 22430208 Detail
0.049 Metastatic melanoma Trametinib, as compared with chemotherapy, improved rates of progression-free an... BeFree 22663011 Detail
0.004 Nevus The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus ha... BeFree 15009715 Detail
0.018 Malignant tumor of colon BRAF(V600E) efficient transformation and induction of microsatellite instability... BeFree 19881948 Detail
<0.001 giant cell glioblastoma The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomo... BeFree 25885250 Detail
0.074 colorectal carcinoma Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for... BeFree 18428050 Detail
0.431 melanoma The primary melanoma expressed mutant BRAF-V600E and possessed a homozygous dele... BeFree 25407517 Detail
0.007 Hyperplastic Polyp BRAF V600E mutation analysis was performed in 148 selected cases; mutations were... BeFree 19126563 Detail
0.049 Metastatic melanoma Of the drugs tested to date in patients with metastatic melanoma, those that hav... BeFree 22261672 Detail
0.002 Undifferentiated carcinoma The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of p... BeFree 17714762 Detail
0.144 Carcinogenesis Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in M... BeFree 24717435 Detail
0.173 Glioma In this study a retrospective cohort of 198 pediatric low-grade gliomas (includi... BeFree 22492957 Detail
0.003 Melanocytic nevus of skin Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 ... BeFree 15373778 Detail
0.272 melanoma Our data indicate that the C57BL/6J Tyr::CreER(T2);PTEN(F-/-);BRAF(F-V600E/+) me... BeFree 22796458 Detail
<0.001 Tubular adenoma These expression profiles were associated with V600E BRAF mutation, a progressiv... BeFree 23425390 Detail
<0.001 Non-small cell lung carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.007 Histiocytosis, Langerhans-Cell High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in ot... BeFree 22879539 Detail
0.023 melanoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.431 melanoma Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens r... BeFree 25228337 Detail
0.074 colorectal carcinoma To summarize the usefulness of several recently discovered immunohistochemical m... BeFree 25549141 Detail
0.029 melanoma Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V6... BeFree 24970815 Detail
0.027 Thyroid Nodule BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nod... BeFree 23775008 Detail
0.001 Acral Lentiginous Malignant Melanoma We further showed that BRAF, a downstream signaling molecule of ARMS in ERK path... BeFree 18089783 Detail
0.003 Melanocytic nevus of skin However, using immunomagnetic separation or laser-capture microdissection, we ex... BeFree 19752400 Detail
0.160 colorectal cancer miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regul... BeFree 24242331 Detail
0.325 Papillary thyroid carcinoma The prevalence (90%) of the BRAF (V600E) mutation in this study is the highest e... BeFree 23179992 Detail
0.007 Histiocytosis, Langerhans-Cell Consistent with our findings in humans, expression of BRAF-V600E in BM DC progen... BeFree 24638167 Detail
<0.001 Erdheim-Chester disease Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (E... BeFree 25324352 Detail
0.002 Follicular neoplasm None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspici... BeFree 21239517 Detail
0.128 Anaplastic thyroid carcinoma BRAF V600E and RAS mutations were mutually exclusive; all ATC cell lines exhibit... BeFree 25576899 Detail
0.015 Malignant neoplasm of lung Colorectal and lung cancers associated with the BRAF V600E mutation often demons... BeFree 23370429 Detail
0.122 Hereditary Nonpolyposis Colorectal Cancer HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of... BeFree 24196786 Detail
0.003 neurofibromatosis 1 Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS muta... BeFree 23190154 Detail
0.020 melanoma The activating BRAF mutation V600E and related mutations in this codon are most ... BeFree 24756795 Detail
0.055 adenocarcinoma Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (... BeFree 25273224 Detail
0.032 Malignant neoplasm of thyroid Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biops... BeFree 24570209 Detail
0.017 Nevus Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E)... BeFree 24614711 Detail
0.004 neurofibromatosis 1 Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS muta... BeFree 23190154 Detail
0.023 Melanocytic nevus Differential gene expression in melanocytic nevi with the V600E BRAF mutation. BeFree 17696195 Detail
0.003 colorectal cancer Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2... BeFree 18806830 Detail
0.431 melanoma Approximately 40-60% of melanomas from Caucasian populations carry activating mu... BeFree 22614711 Detail
<0.001 hypothyroidism Screening for activating BRAF mutations in a series of 83 PTCs identified the mo... BeFree 18426810 Detail
0.003 glioblastoma BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) a... BeFree 21479234 Detail
0.431 melanoma Patients aged 18 years or older with previously untreated, stage IV or unresecta... BeFree 22735384 Detail
0.431 melanoma The treatment of malignant melanoma with inhibitors targeting the BRAF V600E mut... BeFree 24048637 Detail
0.431 melanoma Molecular platforms utilized to detect BRAF V600E mutation in melanoma. BeFree 23174497 Detail
0.431 melanoma Thus, Wnt/β-catenin signaling and AXIN1 may regulate the efficacy of inhibitors ... BeFree 22234612 Detail
0.129 Glioma These data suggest that p16 deletion adversely impacts the outcomes of BRAF-driv... BeFree 22492957 Detail
<0.001 intrahepatic cholangiocarcinoma BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary t... BeFree 24309328 Detail
0.124 Follicular thyroid carcinoma In 137 specimens of FNAB (107 papillary thyroid carcinomas (PTC); 3 follicular t... BeFree 17054470 Detail
0.032 Malignant neoplasm of thyroid We developed an allele-specific real-time PCR method for the detection of BRAF(T... BeFree 19850689 Detail
<0.001 colorectal carcinoma We demonstrate that SSA-associated synchronous colorectal carcinomas have a stri... BeFree 23887157 Detail
0.029 melanoma Interestingly, PI3K inhibition forestalled the onset of MEK inhibitor resistance... BeFree 25472943 Detail
0.049 Metastatic melanoma Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastati... BeFree 23581649 Detail
0.002 benign neoplasm The presence of BRAF V600E and mitogen-activated protein kinase activation in a ... BeFree 22727996 Detail
0.274 colorectal cancer The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CR... BeFree 17942460 Detail
<0.001 melanoma We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 g... BeFree 25073704 Detail
0.027 Thyroid Nodule The V600E mutation of BRAF (BRAF(V600E)) was detected in 141 of 170 malignant th... BeFree 22358007 Detail
0.431 melanoma Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the d... BeFree 24710085 Detail
0.431 melanoma Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (ve... BeFree 22281684 Detail
0.032 Malignant neoplasm of thyroid Mitogen-inducible gene-6 expression correlates with survival and is an independe... BeFree 19040996 Detail
0.001 Malignant neoplasm of endometrium This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
0.007 Hyperplastic Polyp BRAF V600E mutations were seen in 83% of proximal and 74% of distal hyperplastic... BeFree 19855373 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.431 melanoma The absence of the BRAF V600E mutation in Spitz's nevi may serve as a molecular ... BeFree 15811117 Detail
0.135 colon carcinoma BRAF V600E was associated with advanced TNM (P &lt; 0.001), more distant metasta... BeFree 25367198 Detail
0.012 colorectal cancer Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.008 Anaplastic thyroid carcinoma The next generation of orthotopic thyroid cancer models: immunocompetent orthoto... BeFree 24295207 Detail
0.016 Colorectal cancer metastatic BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies th... BeFree 25429742 Detail
0.004 Solid tumour A substantial proportion of solid tumors carry the BRAF V600E mutation, which ca... BeFree 23354848 Detail
0.431 melanoma We also observed that pharmacological inhibition of oncogenic BRAF(V600E) using ... BeFree 22911700 Detail
0.074 colorectal carcinoma We have prospectively studied a series of 1624 consecutive colorectal carcinomas... BeFree 24768606 Detail
0.274 colorectal cancer Since RAC1b has been associated with the BRAF(V600E) mutation, associated with p... BeFree 24833563 Detail
0.002 Undifferentiated carcinoma The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cas... BeFree 25894433 Detail
0.431 melanoma Vemurafenib, a selective BRAF (v-raf murine sarcoma viral oncogene homologue B1)... BeFree 23909652 Detail
0.431 melanoma Knockdown of Apollon, by siRNA, triggered apoptosis and/or significantly enhance... BeFree 22553342 Detail
0.060 Thyroid carcinoma When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific ... BeFree 23559083 Detail
0.003 Erdheim-Chester disease Anecdotal responses have been reported in a few patients with LCH and Erdheim-Ch... BeFree 24857137 Detail
0.431 melanoma Using a transgenic BRAF(V600E) mouse model previously generated in our laborator... BeFree 23650282 Detail
0.007 Histiocytosis, Langerhans-Cell Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: ... BeFree 24703101 Detail
0.074 colorectal carcinoma In conclusion, miR-145 might be used as a therapeutic target in the treatment of... BeFree 24248543 Detail
0.004 sarcoma Frequent somatic mutations of BRAF (v-raf murine sarcoma viral oncogene homolog ... BeFree 21326296 Detail
0.055 Neoplasm Metastasis Additional analyses of multiple metastatic samples from individual patients usin... BeFree 22235286 Detail
0.002 Tumor Progression Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. BeFree 23825589 Detail
0.017 Cutaneous Melanoma BRAF(V600E) is the most common mutation in cutaneous melanoma and has become the... BeFree 23211290 Detail
<0.001 Histiocytic and Dendritic Cell Neoplasm Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell ne... BeFree 24720374 Detail
0.057 Colorectal cancer metastatic These data suggest that combined therapy with RAF and EGFR inhibitors could be a... BeFree 25589621 Detail
<0.001 Tumor Initiation They include BRAF(V600E) and AKT that affect tumor initiation, progression and m... BeFree 24362526 Detail
0.007 Histiocytosis, Langerhans-Cell Our findings indicate that the association of LCH and ECD is not fortuitous and ... BeFree 24894769 Detail
0.002 HIV Infections We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors spec... BeFree 15208655 Detail
<0.001 Adenocarcinoma of colon Caco-2 human colon adenocarcinoma cells were stably transfected with BRAF(V600E)... BeFree 19881948 Detail
<0.001 Colonic Neoplasms The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. BeFree 24244575 Detail
0.325 Papillary thyroid carcinoma In PTC specimens without a BRAF mutation, two CpGs were more heavily methylated ... BeFree 21449767 Detail
0.017 Nevus However, using immunomagnetic separation or laser-capture microdissection, we ex... BeFree 19752400 Detail
0.431 melanoma In addition, targeting components of the MAPK pathway have also demonstrated sur... BeFree 22091682 Detail
0.049 Metastatic melanoma B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progres... BeFree 22726224 Detail
<0.001 melanoma To address this question, we developed a metastatic BRAF(V600E)-mutant melanoma ... BeFree 25351955 Detail
0.144 Carcinogenesis To determine the occurrence of BRAF V600E gene mutations and copy number changes... BeFree 21693616 Detail
0.002 colorectal cancer The use of COLD-PCR in apparently wild-type samples allowed us to identify 15 ne... BeFree 20616366 Detail
0.431 melanoma In total, we found 21 (70%) out of 30 melanoma cell lines with BRAF mutations in... BeFree 15948220 Detail
0.431 melanoma In addition to metastatic lesions, we also examined 20 primary melanomas for the... BeFree 23211290 Detail
0.049 Metastatic melanoma Vemurafenib and dabrafenib, two potent tyrosine kinase inhibitors (TKIs) of the ... BeFree 26601866 Detail
0.274 colorectal cancer BRAF V600E mutation in colorectal cancer is associated with right-sided tumours ... BeFree 25862899 Detail
0.002 Xenograft Model The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF... BeFree 24132923 Detail
0.007 Histiocytosis, Langerhans-Cell All patients were refractory to first-line treatment and harbored a BRAF(V600E) ... BeFree 25422482 Detail
<0.001 plasmacytoma We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chron... BeFree 26071465 Detail
0.120 Nonseminomatous germ cell tumor NA CLINVAR Detail
0.024 colon carcinoma A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails ... BeFree 22393095 Detail
0.003 colorectal carcinoma Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2... BeFree 18806830 Detail
0.001 fibrillary astrocytoma A BRAF p.Thr599dup or p.V600E mutation was identified by Sanger sequencing in on... BeFree 24767714 Detail
0.002 thyroiditis The presence of BRAF V600E was only associated with extrathyroidal extension and... BeFree 25266729 Detail
0.032 Malignant neoplasm of thyroid The BRAF V600E mutation is the most common genetic alteration in thyroid cancer. BeFree 25266729 Detail
<0.001 Carcinogenesis Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in M... BeFree 24717435 Detail
0.431 melanoma The BRAF V600E mutant melanoma cell line, A375, was used as an in-vitro model sy... BeFree 25974027 Detail
0.431 melanoma SIRT1 inhibition decreases melanoma cell growth and rescues the sensibility to P... BeFree 24742694 Detail
0.431 melanoma Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. BeFree 24670642 Detail
0.135 colon carcinoma BRAF(V600E) efficient transformation and induction of microsatellite instability... BeFree 19881948 Detail
0.431 melanoma We present a case of a 56-year old woman with a history of stage IIIA malignant ... BeFree 25576527 Detail
0.001 Benign melanocytic nevus The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus ha... BeFree 15009715 Detail
0.080 colorectal carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.004 colorectal cancer miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regul... BeFree 24242331 Detail
0.030 adenoma BRAF V600E mutation analysis was performed in 148 selected cases; mutations were... BeFree 19126563 Detail
0.007 Hyperplastic Polyp The BRAF V600E mutation is one of the most frequent molecular abnormalities iden... BeFree 26030242 Detail
0.006 Cutaneous Melanoma We investigated the associations between BRAF(V600E) and NRAS(Q61R) mutations an... BeFree 25048604 Detail
0.431 melanoma Effective inhibition of cell growth and invasion of melanoma by combined suppres... BeFree 16052531 Detail
0.004 Metastatic malignant neoplasm to brain However, relatively little is known about the intracranial effectiveness of vemu... BeFree 23036672 Detail
<0.001 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.325 Papillary thyroid carcinoma Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous b... BeFree 22033631 Detail
0.332 Hereditary Nonpolyposis Colorectal Cancer The BRAF-V600E hotspot mutation was found in 40% (82/206) of the sporadic MSI-H ... BeFree 15342696 Detail
0.431 melanoma Performance comparison of three BRAF V600E detection methods in malignant melano... BeFree 25318602 Detail
0.027 Thyroid Nodule Incidence and predictive factors of inadequate fine-needle aspirates for BRAF(V6... BeFree 24450682 Detail
0.049 Metastatic melanoma Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic m... BeFree 25942671 Detail
0.030 adenoma Our BRAF(V600E) GEMM presented with sessile serrated adenomas/polyps, as seen in... BeFree 23549875 Detail
0.020 melanoma To anticipate potential mechanisms of acquired resistance to RAF inhibitors duri... BeFree 18559533 Detail
0.012 Gastrointestinal Stromal Tumors V600E BRAF mutations are alternative early molecular events in a subset of KIT/P... BeFree 19561230 Detail
0.002 pleomorphic xanthoastrocytoma An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial... BeFree 25346165 Detail
0.001 Xenograft Model In a BRAF(V600E)-containing xenograft model of human melanoma, orally administer... BeFree 23844038 Detail
0.019 polyps BRAF((V600E)) mutation is not a frequent event in right colon serrated polyps in... BeFree 24570042 Detail
0.121 ameloblastoma High frequency of BRAF V600E mutations in ameloblastoma. BeFree 24374844 Detail
0.002 Stage IV Skin Melanoma In this phase 3 trial, we randomly assigned 423 previously untreated patients wh... BeFree 25265492 Detail
0.074 colorectal carcinoma To determine the prognostic significance of deficient mismatch repair (dMMR) and... BeFree 25624727 Detail
0.009 Malignant neoplasm of thyroid Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.431 melanoma Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induc... BeFree 22850568 Detail
0.431 melanoma This focus has been justified by the recent success of BRAF and MEK inhibitors i... BeFree 24352648 Detail
0.010 Malignant neoplasm of thyroid Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.004 ovarian carcinoma Genetic analyses have identified BRAF V600E mutations in a subset of ovarian car... BeFree 22820660 Detail
0.325 Papillary thyroid carcinoma Association between BRAF V600E mutation and regional lymph node metastasis in pa... BeFree 25755776 Detail
0.131 Non-small cell lung carcinoma IHC using the VE1 clone is a specific and sensitive method for the detection of ... BeFree 23131393 Detail
0.132 Astrocytoma The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF... BeFree 24132923 Detail
0.431 melanoma Dabrafenib joins vemurafenib to confirm the superior clinical outcome of the BRA... BeFree 24259661 Detail
0.288 Thyroid Neoplasm In conclusion, our study showed a high implication of TSHR gene methylation and ... BeFree 24927793 Detail
<0.001 Hereditary Nonpolyposis Colorectal Cancer HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of... BeFree 24196786 Detail
0.082 colorectal carcinoma The aim of our study was to test sebaceous neoplasms for V600E BRAF or KRAS muta... BeFree 24767862 Detail
0.431 melanoma BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) o... BeFree 22012135 Detail
<0.001 papillary renal cell carcinoma We detected a BRAF mutation (V600E) in only one papillary renal cell carcinoma c... BeFree 22727996 Detail
0.001 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
<0.001 Gastrointestinal Stromal Tumors BRAF V600E detection in the tumor does not induce a higher expression of the B-r... BeFree 20023270 Detail
0.288 Thyroid Neoplasm The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 convention... BeFree 16268813 Detail
0.113 Malignant neoplasm of lung Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are... BeFree 23825589 Detail
0.055 Neoplasm Metastasis There was a significant size-dependent relationship between the presence of the ... BeFree 22488961 Detail
0.008 Anaplastic thyroid carcinoma Three of the lines carried a heterozygous BRAF mutation V600E, which is in line ... BeFree 17465858 Detail
0.002 Anaplasia The highest frequencies of BRAF (V600E) mutations were found in WHO grade II ple... BeFree 21274720 Detail
0.032 Malignant neoplasm of thyroid PCCl3 rat thyroid cells, PCCl3 cells overexpressing BRAF(V600E), or primary cult... BeFree 24400871 Detail
0.007 melanoma Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed... BeFree 20149136 Detail
0.029 melanoma Here, CDK2/4 inhibition statistically significantly augmented the effects of BRA... BeFree 22997239 Detail
<0.001 hairy cell leukemia HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma ... BeFree 26145173 Detail
0.060 Thyroid carcinoma On ultrasound, papillary thyroid carcinomas with the BRAF(V600E) mutation tended... BeFree 20410389 Detail
0.017 Secondary malignant neoplasm of lymph node In 26 studies, compared with the patients who had the wild-type BRAF genes, the ... BeFree 21882184 Detail
0.020 melanoma MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased product... BeFree 16801397 Detail
0.027 Thyroid Nodule Despite its high specificity, our meta-analysis shows that BRAF(V600E) mutation ... BeFree 26232865 Detail
<0.001 Papillary thyroid carcinoma Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in pa... BeFree 21249150 Detail
0.028 melanoma RAF is among the most frequently mutated kinases, where BRAF V600E mutation occu... BeFree 25034364 Detail
0.003 Erdheim-Chester disease Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF... BeFree 24531980 Detail
<0.001 Nodule Before undergoing thyroidectomy, we performed molecular diagnostic tests that re... BeFree 21048359 Detail
0.060 Thyroid carcinoma The influence of the BRAF V600E mutation in thyroid cancer cell lines on the ant... BeFree 21795305 Detail
0.074 colorectal carcinoma The aim of this study was to relate the CpG island methylator phenotype (CIMP; c... BeFree 20197478 Detail
<0.001 Central Nervous System Neoplasms Our studies indicate CNS tumor cells with BRAF(V600E) mutant cells (but not wild... BeFree 25484091 Detail
0.080 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
0.274 colorectal cancer The V600E mutation of BRAF was initially described in 2002 and has been found at... BeFree 23406774 Detail
0.004 Papillary thyroid carcinoma The objective of the study was to investigate the effects of the BRAF V600E muta... BeFree 16772349 Detail
<0.001 giant cell glioblastoma We further investigated the utility of combined BRAF V600E (VE1) and p16 analysi... BeFree 24345274 Detail
0.007 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.014 colorectal carcinoma To summarize the usefulness of several recently discovered immunohistochemical m... BeFree 25549141 Detail
0.160 colorectal cancer The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CR... BeFree 17942460 Detail
0.055 Neoplasm Metastasis In patients with conventional papillary thyroid cancer, BRAF V600E mutation was ... BeFree 17717450 Detail
0.001 Nevi and Melanomas Research has shown that a majority of melanomas and nevi exhibit an activating V... BeFree 15811117 Detail
0.002 follicular adenoma The molecular genetic study of the BRAF gene showed the presence of a missense t... BeFree 15126572 Detail
0.431 melanoma Interestingly, this combination was also effective against BRAF V600E-mutant mel... BeFree 22865452 Detail
0.017 Cutaneous Melanoma About 40% to 60% of cutaneous melanomas have BRAF mutations, and 90% of the muta... BeFree 25046227 Detail
<0.001 Classical Glioblastoma Adult classical glioblastoma with a BRAF V600E mutation. BeFree 25885250 Detail
0.002 Metastatic melanoma Mutationally activated BRAF(V600E) cooperates with PTEN silencing in the convers... BeFree 24425783 Detail
0.325 Papillary thyroid carcinoma An occult micro-PTC with BRAF(V600E) mutation was also detected. BeFree 24879726 Detail
0.003 glioblastoma Intratumoral heterogeneity of genomic imbalance in a case of epithelioid gliobla... BeFree 24354918 Detail
0.032 Malignant neoplasm of thyroid BRAF V600E mutational status in pediatric thyroid cancer. BeFree 24677749 Detail
0.179 Papillary thyroid carcinoma BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in... BeFree 12881714 Detail
0.431 melanoma Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ER... BeFree 23770856 Detail
0.080 Carcinogenesis The presence of BRAF V600E and mitogen-activated protein kinase activation in a ... BeFree 22727996 Detail
0.132 hairy cell leukemia Advanced molecular techniques have identified distinct molecular aberrations in ... BeFree 24652320 Detail
0.123 Liver neoplasms To summarize the usefulness of several recently discovered immunohistochemical m... BeFree 25549141 Detail
0.179 Papillary thyroid carcinoma The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%... BeFree 21498916 Detail
0.017 Secondary malignant neoplasm of lymph node We found that the BRAF(V600E) mutation was significantly associated with the cla... BeFree 23163107 Detail
0.144 Carcinogenesis These data suggest that the BRAF V600E mutation is not the target gene for abnor... BeFree 19424571 Detail
0.003 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.431 melanoma A significant difference between the control group and invasive melanomas (p&lt;... BeFree 20576522 Detail
0.005 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.274 colorectal cancer BRAF V600E mutation was analyzed in CRC patients with MMR deficiencies (microsat... BeFree 18096441 Detail
0.325 Papillary thyroid carcinoma Thus, VE1 antibody can be used on thyroid microhistologic specimens to detect BR... BeFree 24570209 Detail
0.160 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.431 melanoma BRAF V600E appeared to be the most commonly mutated gene in both the melanocytic... BeFree 18945298 Detail
0.060 Thyroid carcinoma Transgenic induction of BRAF(V600E)in the thyroid gland results in cancers resem... BeFree 21249150 Detail
0.074 colorectal carcinoma Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and py... BeFree 25280751 Detail
0.003 colorectal carcinoma CIMP-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathw... BeFree 20027224 Detail
0.160 colorectal cancer Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and py... BeFree 25280751 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CR... BeFree 17942460 Detail
0.431 melanoma BRAF(V600E) is the most common oncogenic lesion in melanoma and results in const... BeFree 25542448 Detail
0.001 Thyroid carcinoma In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.009 Malignant neoplasm of thyroid Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.002 Malignant melanoma, metastatic Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastati... BeFree 25576527 Detail
0.431 melanoma Suppression of BRAF(V599E) in human melanoma abrogates transformation. BeFree 14500344 Detail
<0.001 Malignant neoplasm of thyroid Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24... BeFree 24382015 Detail
0.029 melanoma The activating BRAF mutation V600E and related mutations in this codon are most ... BeFree 24756795 Detail
0.002 Rectal Tumors Our investigation evaluates associations between active and passive smoking and ... BeFree 19358278 Detail
0.002 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.360 adenocarcinoma We analyzed 222 adenocarcinomas of lung lacking KRAS and EGFR mutations and iden... BeFree 18636014 Detail
0.003 colorectal carcinoma We used preclinical models of CRC to demonstrate (18)F-FLT PET as a sensitive pr... BeFree 23341544 Detail
0.017 Cutaneous Melanoma We have evaluated five different methods: the Cobas test, Sanger sequencing, pyr... BeFree 23159593 Detail
0.431 melanoma We have evaluated five different methods: the Cobas test, Sanger sequencing, pyr... BeFree 23159593 Detail
0.074 colorectal carcinoma These results seem to indicate that Cdx2 may play a role in the serrated pathway... BeFree 24166180 Detail
0.060 Thyroid carcinoma Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.431 melanoma Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence... BeFree 24703243 Detail
<0.001 biliary tract cancer BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary t... BeFree 24309328 Detail
0.055 Neoplasm Metastasis The activating mutation BRAF(V600E) is a frequent genetic event in papillary thy... BeFree 19861538 Detail
0.023 Melanocytic nevus BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting... BeFree 21430779 Detail
0.082 colorectal carcinoma Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and py... BeFree 25280751 Detail
0.028 melanoma Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence ... BeFree 21725359 Detail
0.244 Papillary thyroid carcinoma To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (F... BeFree 17727338 Detail
0.005 endometrial carcinoma Analysis of a correlation between the BRAF V600E mutation and abnormal DNA misma... BeFree 19424571 Detail
0.135 colon carcinoma Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mut... BeFree 17293392 Detail
<0.001 Torre-Muir syndrome We conclude that a V600E BRAF mutation may not be helpful in distinguishing spor... BeFree 24767862 Detail
0.002 Dysplastic Nevus BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. BeFree 25607474 Detail
0.371 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.003 Malignant neoplasm of thyroid BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.002 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
<0.001 Colorectal cancer metastatic Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E... BeFree 20485284 Detail
0.001 Adenocarcinoma of the gastroesophageal junction To summarize the usefulness of several recently discovered immunohistochemical m... BeFree 25549141 Detail
0.134 pilocytic astrocytoma Activating point mutations of BRAF, such as BRAF (V600E), also lead to pilocytic... BeFree 23439714 Detail
0.009 Hashimoto Disease Clinical and pathological features and the BRAF(V600E) mutation in patients with... BeFree 19014278 Detail
0.016 ovarian neoplasm Expression of BRAF V600E mutant protein in epithelial ovarian tumors. BeFree 22820660 Detail
0.055 adenocarcinoma Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investig... BeFree 18636014 Detail
<0.001 histiocytic sarcoma BRAF(V600E) was not limited to LCH and was detected more frequently in histiocyt... BeFree 24720374 Detail
<0.001 keratoacanthoma RAF inhibitors are effective against melanomas with BRAF V600E mutations but may... BeFree 22067401 Detail
0.030 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.060 Thyroid carcinoma Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and... BeFree 23533235 Detail
0.431 melanoma MEK inhibitors are clinically active in BRAF(V600E) melanomas but only marginall... BeFree 24746704 Detail
0.135 colon carcinoma Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback acti... BeFree 22281684 Detail
0.016 Colorectal cancer metastatic BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotyp... BeFree 21289333 Detail
0.325 Papillary thyroid carcinoma Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid ... BeFree 23496275 Detail
0.086 Carcinoma, Papillary BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.005 melanoma Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma sho... BeFree 25037456 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the di... BeFree 17566669 Detail
0.001 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.008 Glioma BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phos... BeFree 24721513 Detail
<0.001 Poorly Differentiated Thyroid Carcinoma Combination of the BRAF(V600E) mutation and its splicing variants may contribute... BeFree 19156774 Detail
0.431 melanoma Sodium arsenite- or statin-induced apoptosis was independent of BRAF status (wil... BeFree 21910007 Detail
0.055 adenocarcinoma IHC using the VE1 clone and FLEX linker is a specific method for the detection B... BeFree 23927882 Detail
0.005 Benign melanocytic nevus Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E)... BeFree 24614711 Detail
0.001 colorectal carcinoma We demonstrate that SSA-associated synchronous colorectal carcinomas have a stri... BeFree 23887157 Detail
<0.001 differentiated thyroid gland carcinoma We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7... BeFree 25121551 Detail
<0.001 Papillary Thyroid Microcarcinoma BRAF V600E and decreased NIS and TPO expression are associated with aggressivene... BeFree 26338373 Detail
0.288 Thyroid Neoplasm The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyro... BeFree 22998776 Detail
0.347 acute promyelocytic leukemia Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
<0.001 IMMUNE SUPPRESSION This study reveals a novel mechanism of immune suppression sensitive to BRAF(V60... BeFree 22850568 Detail
0.008 Anaplastic thyroid carcinoma BRAF V600E and RAS mutations were mutually exclusive; all ATC cell lines exhibit... BeFree 25576899 Detail
<0.001 IMMUNE SUPPRESSION This study reveals a novel mechanism of immune suppression sensitive to BRAF(V60... BeFree 22850568 Detail
0.001 Thyroid carcinoma We tested the combinations of the Akt inhibitors MK2206 or perifosine with the B... BeFree 22090271 Detail
<0.001 Papillary thyroid carcinoma Clinicopathological characteristics were evaluated according to the Notch1/Notch... BeFree 22118425 Detail
<0.001 Metastatic Malignant Peripheral Nerve Sheath Tumor A patient with sporadic metastatic MPNST and the BRAF V600E mutation was treated... BeFree 24335681 Detail
0.005 Precancerous Conditions Mutations in the BRAF gene causing a V599E amino acid substitution that enhance ... BeFree 14522889 Detail
0.274 colorectal cancer Through an RNAi screen, here we identify the transcriptional repressor MAFG as t... BeFree 25219500 Detail
0.049 Metastatic melanoma The BRAF mutant, BRAF(V600E), is expressed in nearly half of melanomas, and oral... BeFree 23454771 Detail
0.009 Hashimoto Disease We analyzed the correlation between the presence/absence of the BRAF(V600E) muta... BeFree 24721322 Detail
<0.001 Desmoplastic Absence of V599E BRAF mutations in desmoplastic melanomas. BeFree 15641040 Detail
0.060 Thyroid carcinoma miR-146b is highly expressed in adult papillary thyroid carcinomas with high ris... BeFree 20406109 Detail
<0.001 high-grade childhood cerebral astrocytoma Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multi... BeFree 24725538 Detail
0.132 hairy cell leukemia Application of a BRAF V600E mutation-specific antibody for the diagnosis of hair... BeFree 22531170 Detail
0.002 melanoma Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy,... BeFree 23802768 Detail
0.003 ganglioglioma Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: r... BeFree 25015869 Detail
0.134 pilocytic astrocytoma Neither CD34 expression nor BRAF(V600E) status was predictive of prognosis, exce... BeFree 23442159 Detail
0.431 melanoma Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inh... BeFree 24884503 Detail
0.032 Malignant neoplasm of thyroid From September 2008 to December 2009, we performed routine analysis of the BRAF(... BeFree 21803329 Detail
<0.001 Adenocarcinoma of colon We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immu... BeFree 25602793 Detail
0.160 colorectal cancer The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests ... BeFree 15782118 Detail
0.431 melanoma Similarly, activation of Notch1 signaling promoted acquired resistance to MAPK i... BeFree 25538079 Detail
0.082 colorectal carcinoma Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability spor... BeFree 19190129 Detail
0.325 Papillary thyroid carcinoma We aimed to analyze the expression of RAC1b in PTC and correlate its expression ... BeFree 23482591 Detail
0.080 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) is present in PTC, both in the classic form and in follicular varian... BeFree 16452550 Detail
0.074 colorectal carcinoma Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability spor... BeFree 19190129 Detail
0.274 colorectal cancer Performance comparison of three BRAF V600E detection methods in malignant melano... BeFree 25318602 Detail
0.002 leukemia Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. BeFree 24433452 Detail
0.132 hairy cell leukemia Evaluation of allele-specific PCR and immunohistochemistry for the detection of ... BeFree 25511147 Detail
<0.001 granular cell tumor We investigated 7 spindle cell oncocytomas, 4 pituicytomas, and 3 granular cell ... BeFree 23887161 Detail
0.002 Thyroid carcinoma Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A n... BeFree 23931930 Detail
0.014 colorectal carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.074 colorectal carcinoma Somatic BRAF-V600E mutations in familial colorectal cancer. BeFree 17119056 Detail
0.272 melanoma Cell sensitivity to PLX4032 was dependent on BRAF(V600E) and independent from ot... BeFree 22241959 Detail
0.005 Thyroid carcinoma PTC, the most frequent thyroid carcinoma histotype, is associated with gene rear... BeFree 23132790 Detail
0.002 follicular adenoma BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along wi... BeFree 19269016 Detail
0.274 colorectal cancer To determine the prognostic significance of deficient mismatch repair (dMMR) and... BeFree 25624727 Detail
0.274 colorectal cancer We hypothesized it would be more commonly methylated and inactivated in serrated... BeFree 25613750 Detail
0.082 colorectal carcinoma The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests ... BeFree 15782118 Detail
0.060 Thyroid carcinoma Differential effects of MAPK pathway inhibitors on migration and invasiveness of... BeFree 26384551 Detail
<0.001 Desmoplastic infantile astrocytoma BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/gan... BeFree 23822828 Detail
<0.001 melanoma Further supporting a crucial role of PDH in OIS, enforced normalization of eithe... BeFree 23685455 Detail
0.003 Erdheim-Chester disease High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in ot... BeFree 22879539 Detail
0.001 hairy cell leukemia Advanced molecular techniques have identified distinct molecular aberrations in ... BeFree 24652320 Detail
0.007 Hyperplastic Polyp BRAF((V600E)) mutations were found in 14.3% of SSAs and 7.1% of RHPs. BeFree 24570042 Detail
0.007 Histiocytosis, Langerhans-Cell BRAF(V600E) was not limited to LCH and was detected more frequently in histiocyt... BeFree 24720374 Detail
<0.001 renal cell carcinoma Thus, BRAF V600E immunostaining is a helpful marker for pediatric metanephric ad... BeFree 26014474 Detail
0.012 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.007 Hyperplastic Polyp BRAF mutations (V600E) were observed in 45.8% (11 of 24) of HPs, 60.9% (14 of 23... BeFree 21263251 Detail
<0.001 Tumor Initiation They include BRAF(V600E) and AKT that affect tumor initiation, progression and m... BeFree 24362526 Detail
<0.001 Anaplasia This last observation led us to investigate the role of BRAF(V600E) and the MEK-... BeFree 16601293 Detail
0.027 Thyroid Nodule Using pyrosequencing and quantitative methylation-specific PCR (Q-MSP) methods, ... BeFree 24588959 Detail
0.431 melanoma Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. BeFree 25442222 Detail
0.002 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.007 Histiocytosis, Langerhans-Cell These results indicate that cfDNA BRAF(V600E) mutational analysis in plasma and ... BeFree 25324352 Detail
<0.001 Non-toxic nodular goiter BRAF(V600E) allele was detected and quantified by an allele-specific real-time q... BeFree 23788690 Detail
0.144 Carcinogenesis BRAF(V600E) mutation is an early event in thyroid carcinogenesis, and is associa... BeFree 22918165 Detail
0.004 Metastatic melanoma To evaluate the latter possibility, a mutated NRAS(Q61R) oncogene was expressed,... BeFree 16818621 Detail
0.032 Malignant neoplasm of thyroid When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific ... BeFree 23559083 Detail
0.134 pilocytic astrocytoma This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E... BeFree 24532263 Detail
0.002 Malignant melanoma, metastatic Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(... BeFree 24023633 Detail
0.005 Thyroid carcinoma BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.005 melanoma MEK inhibitors are clinically active in BRAF(V600E) melanomas but only marginall... BeFree 24746704 Detail
0.431 melanoma Our data demonstrate that MEK inhibition of BRAF(V600E)-positive melanoma cells ... BeFree 24970815 Detail
0.011 melanoma Activating mutations in the BRAF serine/threonine kinase are found in &gt;70% of... BeFree 14500344 Detail
<0.001 Nodule Before undergoing thyroidectomy, we performed molecular diagnostic tests that re... BeFree 21048359 Detail
<0.001 Malignant neoplasm of thyroid Furthermore, ICAM-1 upregulation correlated with aggressive tumor features such ... BeFree 21879273 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer MSI-H colorectal carcinomas were divided into sporadic (112/1292, 8.7%) and LS/p... BeFree 24034859 Detail
0.074 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.009 Prostatic Neoplasms In the course of modeling malignant melanoma in a tyrosinase promoter transgenic... BeFree 19079609 Detail
0.274 colorectal cancer Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer ca... BeFree 23462926 Detail
0.431 melanoma CH5126766/RO5126766 induced G1 cell cycle arrest in two melanoma cell lines with... BeFree 25422890 Detail
0.049 Metastatic melanoma To evaluate the latter possibility, a mutated NRAS(Q61R) oncogene was expressed,... BeFree 16818621 Detail
0.004 neurofibromatosis 1 These tumors have been reported to show increased activity in the mitogen-activa... BeFree 24335681 Detail
0.003 glioblastoma An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial... BeFree 25346165 Detail
0.031 Malignant neoplasm of thyroid Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.074 colorectal carcinoma We previously reported the concurrent methylation of the mismatch repair gene ML... BeFree 21102416 Detail
0.132 Astrocytoma With regard to implications for therapy, our results support evaluation of BRAF(... BeFree 22038996 Detail
0.431 melanoma Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling i... BeFree 19682280 Detail
0.431 melanoma In clinical trials trametinib, a MEK inhibitor (MEKi) increases BRAFi therapy ef... BeFree 24345644 Detail
0.002 Follicular neoplasm Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy i... BeFree 21948220 Detail
<0.001 Tubular adenoma BRAF V600E mutation was not observed in any tubular adenoma or tubulovillous/vil... BeFree 17950780 Detail
0.055 Neoplasm Metastasis On PTC univariate analysis, EGFR-H correlated with increasing stage, extrathyroi... BeFree 23746767 Detail
<0.001 inflammatory myofibroblastic tumor In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a p... BeFree 20393746 Detail
0.001 B-Cell Lymphomas Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell ... BeFree 26071465 Detail
0.015 Malignant neoplasm of lung The incidence of BRAF mutations other than V600E is significantly higher in lung... BeFree 21483012 Detail
0.023 Melanocytic nevus BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent i... BeFree 21326296 Detail
0.014 melanoma Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma pro... BeFree 24425783 Detail
0.004 melanoma Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. BeFree 23802768 Detail
0.055 Neoplasm Metastasis Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) m... BeFree 22435913 Detail
<0.001 Hereditary Nonpolyposis Colorectal Cancer Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in... BeFree 17065421 Detail
0.032 Malignant neoplasm of thyroid The inability of MEK and RAF inhibitors, U0126 and sorafenib, respectively, to b... BeFree 20926530 Detail
0.120 B-Cell Lymphomas Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... BeFree 22575864 Detail
0.007 Hyperplastic Polyp These findings indicate that adenomas might be less important in the cancer deve... BeFree 17119056 Detail
<0.001 Stage III Colon Cancer AJCC v7 The BRAF V600E mutation is an independent prognostic factor for survival in stag... BeFree 20501503 Detail
0.431 melanoma Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in... BeFree 23489023 Detail
<0.001 Hepatolenticular Degeneration Cu chelators used in the treatment of Wilson disease decreased tumour growth of ... BeFree 24717435 Detail
0.008 Anaplastic thyroid carcinoma We used RNA interference to evaluate the effect of BRAF knockdown in the human a... BeFree 16533790 Detail
0.012 colorectal cancer We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell... BeFree 23251002 Detail
0.032 Malignant neoplasm of thyroid BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive c... BeFree 21447745 Detail
0.074 colorectal carcinoma Association between methylation in mismatch repair genes, V600E BRAF mutation an... BeFree 21681432 Detail
0.007 Carcinoma, Papillary BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
<0.001 Hereditary Nonpolyposis Colorectal Cancer Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in... BeFree 17065421 Detail
0.431 melanoma Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advance... BeFree 25643238 Detail
0.124 Follicular thyroid carcinoma : The prevalence of BRAF V600E mutation was higher in conventional papillary thy... BeFree 17717450 Detail
<0.001 Thyroid Neoplasm The increase in radioiodide accumulation by Apigenin with Akt inhibition was als... BeFree 24400871 Detail
0.020 melanoma The development of RAF inhibitors targeted against BRAF V600E mutant melanoma ce... BeFree 23174497 Detail
0.005 Benign melanocytic nevus Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 ... BeFree 15373778 Detail
0.004 Papillary Thyroid Microcarcinoma The BRAF(V600E) mutation can be used as a potential prognostic factor in PTMC pa... BeFree 19710001 Detail
0.004 Papillary Thyroid Microcarcinoma BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration bio... BeFree 23192956 Detail
0.001 metanephric adenoma Thus, BRAF V600E immunostaining is a helpful marker for pediatric metanephric ad... BeFree 26014474 Detail
0.431 melanoma Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E)... BeFree 24614711 Detail
0.002 Papillary microcarcinoma Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyr... BeFree 22181337 Detail
<0.001 colorectal cancer Through an RNAi screen, here we identify the transcriptional repressor MAFG as t... BeFree 25219500 Detail
<0.001 Diffuse melanocytosis Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. BeFree 25257244 Detail
0.012 colorectal carcinoma Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.288 Thyroid Neoplasm Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyr... BeFree 21512141 Detail
0.288 Thyroid Neoplasm The increase in radioiodide accumulation by Apigenin with Akt inhibition was als... BeFree 24400871 Detail
0.074 colorectal carcinoma The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests ... BeFree 15782118 Detail
0.028 melanoma RAF inhibitors are effective against melanomas with BRAF V600E mutations but may... BeFree 22067401 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome... BeFree 23897252 Detail
0.017 Cutaneous Melanoma The classical V600E BRAF mutation was not found; instead a novel V600L was obser... BeFree 21750866 Detail
0.325 Papillary thyroid carcinoma The probability of PTC for thyroid nodules with intermediate-risk (IR) US and at... BeFree 26020381 Detail
0.060 Thyroid carcinoma Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillar... BeFree 23161556 Detail
0.003 Anaplastic thyroid carcinoma We used RNA interference to evaluate the effect of BRAF knockdown in the human a... BeFree 16533790 Detail
0.431 melanoma Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence ... BeFree 21725359 Detail
<0.001 Metastatic papillary thyroid carcinoma Clinical responses to vemurafenib in patients with metastatic papillary thyroid ... BeFree 23489023 Detail
0.360 melanoma In the course of modeling malignant melanoma in a tyrosinase promoter transgenic... BeFree 19079609 Detail
<0.001 Papillary Meningioma Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to per... BeFree 25116269 Detail
0.431 melanoma These results clarify that the mutated BRAF (V599E) is essentially involved in m... BeFree 15208655 Detail
0.002 pilocytic astrocytoma This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E... BeFree 24532263 Detail
0.074 melanoma Discoveries of frequent mutations involving BRAF(V600E), developmental and oncog... BeFree 22661227 Detail
0.431 melanoma SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway i... BeFree 15313890 Detail
0.027 Thyroid Nodule We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7... BeFree 25121551 Detail
0.007 Hyperplastic Polyp We investigated 194 serrated lesions of the colon, comprising 42 sessile serrate... BeFree 23887306 Detail
<0.001 Histiocytosis, Langerhans-Cell Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (E... BeFree 25324352 Detail
0.049 Metastatic melanoma Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E ad... BeFree 24504441 Detail
0.431 melanoma Immunohistochemistry as a quick screening method for clinical detection of BRAF(... BeFree 24563339 Detail
0.004 Anaplastic thyroid carcinoma Combined, these data demonstrate that the BRAF(V600E) cooperates with either PIK... BeFree 24770869 Detail
<0.001 anthrax disease Anthrax lethal toxin (LT), a virulence factor secreted by Bacillus anthracis, is... BeFree 17974567 Detail
0.431 melanoma Assaying for BRAF V600E in tissue and blood in melanoma. BeFree 24258977 Detail
<0.001 Pineal Gland Neoplasm The demonstration of the BRAF V600E mutation in the pineal tumor made the patien... BeFree 25976339 Detail
0.274 colorectal cancer Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic s... BeFree 17065421 Detail
0.004 melanoma In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four paren... BeFree 25300205 Detail
<0.001 Congenital chromosomal disease However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/... BeFree 22558328 Detail
0.027 Thyroid Nodule Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of th... BeFree 23717622 Detail
0.028 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
<0.001 Pituitary Diseases VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex wi... BeFree 24838325 Detail
<0.001 Anaplastic thyroid carcinoma Additionally, preclinical and clinical studies investigating combination therapy... BeFree 21900390 Detail
<0.001 Isovaleryl-CoA dehydrogenase deficiency In contrast, age- and size-matched classic papillary microcarcinomas (n=26) show... BeFree 23682579 Detail
0.431 melanoma Our findings offer evidence of the potent antitumor activity of RG7204 against m... BeFree 20551065 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.005 Brain Neoplasms An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial... BeFree 25346165 Detail
0.431 melanoma The low incidence of BRAF(V600E)(-) mutant melanoma among Irish patients was con... BeFree 25746038 Detail
0.003 differentiated thyroid gland carcinoma Neither the presence of V600E BRAF mutations nor that of a well-differentiated t... BeFree 24777145 Detail
0.003 colorectal cancer CIMP-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathw... BeFree 20027224 Detail
0.431 melanoma Improved survival with vemurafenib in melanoma with BRAF V600E mutation. BeFree 21639808 Detail
<0.001 diffuse large B-cell lymphoma Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... BeFree 22575864 Detail
0.431 melanoma Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 ... BeFree 15373778 Detail
0.012 colorectal cancer We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell... BeFree 23251002 Detail
0.060 Thyroid carcinoma The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid ca... BeFree 18202121 Detail
0.060 Thyroid carcinoma BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary th... BeFree 15126572 Detail
0.016 Colorectal cancer metastatic IHC using the VE1 clone is a specific and sensitive method for the detection of ... BeFree 24798160 Detail
0.001 Malignant neoplasm of thyroid We tested the combinations of the Akt inhibitors MK2206 or perifosine with the B... BeFree 22090271 Detail
0.002 Undifferentiated carcinoma The molecular genetic study of the BRAF gene showed the presence of a missense t... BeFree 15126572 Detail
0.004 Papillary thyroid carcinoma In conclusion, we provide evidences that BRAF (V600E) is non-associated with Gal... BeFree 23203004 Detail
0.055 Neoplasm Metastasis In line with the previous reports, NRAS/BRAF mutations were rare; only one metas... BeFree 16098043 Detail
0.431 melanoma Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating V... BeFree 22576211 Detail
0.027 Thyroid Nodule BRAF(T1799A) mutation improves the diagnosis of PTC on FNAB, mainly because of t... BeFree 22504197 Detail
0.005 Malignant tumor of colon The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and ... BeFree 17096326 Detail
0.431 melanoma Accordingly, therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramm... BeFree 24610826 Detail
0.003 Erdheim-Chester disease These results indicate that cfDNA BRAF(V600E) mutational analysis in plasma and ... BeFree 25324352 Detail
<0.001 Adenoma of lung Our results describe a lung cell population in neonates mice where expression of... BeFree 23825589 Detail
0.325 Papillary thyroid carcinoma The five conventional PTC cell lines carry the BRAF V600E mutation and the folli... BeFree 25427145 Detail
0.027 Thyroid Nodule Treatment of patients with thyroid nodules is guided by FNA biopsy, which can be... BeFree 22156469 Detail
0.431 melanoma Activation of the mitogen-activated protein kinase pathway in malignant melanoma... BeFree 20605766 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in ... BeFree 23553055 Detail
0.049 Metastatic melanoma In vitro, we showed that ABCB5-expressing cells selectively survive when exposed... BeFree 22675422 Detail
0.135 colon carcinoma Prognostic significance of defective mismatch repair and BRAF V600E in patients ... BeFree 18519771 Detail
<0.001 Stage 0 Skin Melanoma BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. BeFree 25607474 Detail
0.049 Metastatic melanoma We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutat... BeFree 26037941 Detail
0.325 Papillary thyroid carcinoma However, as in humans, BRAF(V600E)-induced mouse PTC is indolent and does not le... BeFree 24770869 Detail
0.144 Carcinogenesis Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insuff... BeFree 22586120 Detail
0.002 Malignant melanoma, metastatic Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600... BeFree 23031422 Detail
0.004 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
<0.001 Adenocarcinoma of colon We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immu... BeFree 25602793 Detail
<0.001 Papillary thyroid carcinoma The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid ca... BeFree 18202121 Detail
0.431 melanoma Further supporting a crucial role of PDH in OIS, enforced normalization of eithe... BeFree 23685455 Detail
0.431 melanoma Distinct clinical and pathological features are associated with the BRAF(T1799A(... BeFree 17159915 Detail
0.057 Colorectal cancer metastatic Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodi... BeFree 24390240 Detail
0.001 keratoacanthoma Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop i... BeFree 24345644 Detail
0.274 colorectal cancer Association between methylation in mismatch repair genes, V600E BRAF mutation an... BeFree 21681432 Detail
0.017 Cutaneous Melanoma We performed an integrative analysis of transcriptomic and epigenomic changes di... BeFree 25890285 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRA... BeFree 19213871 Detail
0.010 melanoma This study provides a foundation for future investigations designed to improve B... BeFree 21717063 Detail
0.431 melanoma Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melano... BeFree 17409425 Detail
<0.001 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.001 Papillary thyroid carcinoma BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cy... BeFree 23203004 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.262 Hereditary Nonpolyposis Colorectal Cancer We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immu... BeFree 25602793 Detail
0.006 adenoma KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 met... BeFree 21457162 Detail
<0.001 melanoma CAST-PCR gave rapid and accurate results for the common V600E and V600K mutation... BeFree 23584600 Detail
0.325 Papillary thyroid carcinoma This review focuses on the recent progress in understanding the role of BRAF(V60... BeFree 21447745 Detail
0.325 Papillary thyroid carcinoma Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid... BeFree 17727338 Detail
0.431 melanoma BRAF(V600E) mutation was detected in 50% of the acquired nevi and in 70% of the ... BeFree 18408659 Detail
0.244 Adenocarcinoma of lung (disorder) The activating BRAF mutation p.V600E has been identified in many cancers, includ... BeFree 25583765 Detail
0.018 Malignant tumor of colon The prevalence of BRAF(V600E) was considerably higher in older (age &gt; 70) fem... BeFree 20635392 Detail
0.431 melanoma The BRAF kinase is mutated, typically Val 600→Glu (V600E), to induce an active o... BeFree 24717435 Detail
0.131 Non-small cell lung carcinoma BRAF(V600E) cells with EGFR-driven resistance are characterized by hyperphosphor... BeFree 24550319 Detail
0.431 melanoma Expression of AID in malignant melanoma with BRAF(V600E) mutation. BeFree 24684646 Detail
0.030 colorectal carcinoma Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.019 polyps All polyps showed the BRAF-V600E mutation. BeFree 23648458 Detail
0.325 Papillary thyroid carcinoma Association between BRAF V600E mutation and recurrence of papillary thyroid canc... BeFree 25332244 Detail
0.192 colorectal cancer Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
<0.001 Erdheim-Chester disease Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (E... BeFree 25324352 Detail
0.431 melanoma Discoveries of frequent mutations involving BRAF(V600E), developmental and oncog... BeFree 22661227 Detail
0.082 colorectal carcinoma A correlation between MLH1 promoter methylation, specifically the 'C' region, an... BeFree 23880961 Detail
0.032 Malignant neoplasm of thyroid Notch functions as an oncogene or tumor suppressor according to the type of mali... BeFree 22118425 Detail
0.325 Papillary thyroid carcinoma Influence of the BRAF V600E mutation on expression of vascular endothelial growt... BeFree 16772349 Detail
<0.001 colorectal carcinoma Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2... BeFree 18806830 Detail
0.012 colorectal cancer Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation analysis from May-Grünwald Giemsa-stained cytological sampl... BeFree 21948220 Detail
0.004 sarcoma Vemurafenib, a selective BRAF (v-raf murine sarcoma viral oncogene homologue B1)... BeFree 23909652 Detail
0.074 colorectal carcinoma Thus, large-scale KRAS mutation screening is needed for efficient patient manage... BeFree 21516079 Detail
0.017 Nevus The absence of the BRAF V600E mutation within a changing naevus supports the the... BeFree 25380183 Detail
0.002 Stage IV Skin Melanoma Researchers retrospectively reviewed medical records of all patients at our inst... BeFree 25746037 Detail
0.086 Carcinoma, Papillary The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cas... BeFree 25894433 Detail
<0.001 Hairy cell leukemia variant BRAF p.V600E mutation was present in all HCL cases and absent in all HCL-v. Our ... BeFree 22706871 Detail
0.001 Central Nervous System Neoplasms The BRAF V600E missense mutation is known to be present in a subset of central n... BeFree 24821190 Detail
0.002 Thyroid Neoplasm Treatment of the most resistant cell line, 8505c, using lexatumumab in combinati... BeFree 24603332 Detail
<0.001 Central Nervous System Neoplasms Our studies indicate CNS tumor cells with BRAF(V600E) mutant cells (but not wild... BeFree 25484091 Detail
0.325 Papillary thyroid carcinoma Significance of allelic percentage of BRAF c.1799T &gt; A (V600E) mutation in pa... BeFree 24748129 Detail
0.004 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.431 melanoma Finally, we conclude that inhibition of SHH-GLI signaling pathway in human melan... BeFree 23935925 Detail
0.005 Benign melanocytic nevus The absence of the BRAF V600E mutation within a changing naevus supports the the... BeFree 25380183 Detail
0.002 colorectal cancer We used preclinical models of CRC to demonstrate (18)F-FLT PET as a sensitive pr... BeFree 23341544 Detail
0.325 Papillary thyroid carcinoma Genome-wide alterations in gene methylation by the BRAF V600E mutation in papill... BeFree 21937738 Detail
0.431 melanoma NRAS mutations were associated with thicker tumors and higher rates of mitosis w... BeFree 21615881 Detail
0.004 Papillary Thyroid Microcarcinoma The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation ... BeFree 24354346 Detail
0.135 Thyroid Neoplasm The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyro... BeFree 22998776 Detail
0.012 colorectal cancer Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.001 melanoma In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four paren... BeFree 25300205 Detail
0.017 Secondary malignant neoplasm of lymph node Subtype stratification demonstrated that the BRAF V600E mutation was associated ... BeFree 19152441 Detail
0.325 Papillary thyroid carcinoma Association between expression of X-linked inhibitor of apoptosis protein and th... BeFree 24124924 Detail
0.325 Papillary thyroid carcinoma Additionally, preclinical and clinical studies investigating combination therapy... BeFree 21900390 Detail
0.055 Neoplasm Metastasis Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggr... BeFree 21447745 Detail
0.329 Hereditary Nonpolyposis Colorectal Cancer We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immu... BeFree 25602793 Detail
0.017 Cutaneous Melanoma A 49-year-old man initially diagnosed in 1995 with cutaneous melanoma presented ... BeFree 24616537 Detail
0.005 Thyroid Neoplasm Treatment of the most resistant cell line, 8505c, using lexatumumab in combinati... BeFree 24603332 Detail
0.135 colon carcinoma Though such data suggest that BRAF mutation is likely an early initiating event ... BeFree 18473997 Detail
0.002 pilocytic astrocytoma Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600... BeFree 23196000 Detail
0.032 Malignant neoplasm of thyroid Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24... BeFree 24382015 Detail
0.004 Malignant neoplasm of endometrium This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
0.055 Neoplasm Metastasis All four patients with distant metastasis had BRAF(V600E) mutation. BeFree 22767446 Detail
0.001 Sentinel node (disorder) We also studied the role of BRAF V600E mutation in a set of melanoma patients wh... BeFree 25442222 Detail
0.060 Thyroid carcinoma Mitogen-inducible gene-6 expression correlates with survival and is an independe... BeFree 19040996 Detail
0.052 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.004 Thyroid Nodule To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (F... BeFree 17727338 Detail
0.032 Malignant neoplasm of thyroid Differential effects of MAPK pathway inhibitors on migration and invasiveness of... BeFree 26384551 Detail
0.431 melanoma Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted ... BeFree 23603840 Detail
0.009 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.492 Turcot syndrome (disorder) This study compared two biomarkers in tumours with mismatch repair deficiency; q... BeFree 25280751 Detail
0.027 Thyroid Nodule Does addition of BRAF V600E mutation testing modify sensitivity or specificity o... BeFree 23476074 Detail
0.074 colorectal carcinoma BRAF V600E mutations were not identified in the early-onset colorectal carcinoma... BeFree 22481281 Detail
0.135 colon carcinoma We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer i... BeFree 16024606 Detail
<0.001 keratosis Associations with the BRAF(T1799A) mutation (P&lt;0.05) were as follows: low tum... BeFree 17159915 Detail
0.002 neuroblastoma To explore the mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus o... BeFree 21430505 Detail
0.004 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
0.020 melanoma In this study, we utilised genetically engineered melanoma cell lines and xenogr... BeFree 25117819 Detail
0.325 Papillary thyroid carcinoma Three of the lines carried a heterozygous BRAF mutation V600E, which is in line ... BeFree 17465858 Detail
0.132 hairy cell leukemia Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grad... BeFree 22246856 Detail
0.080 Colorectal cancer metastatic In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is ... BeFree 20857202 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.015 Malignant neoplasm of lung Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are... BeFree 23825589 Detail
0.325 Papillary thyroid carcinoma In five thyroglossal carcinomas, mutated BRAF (V600E) was found, three in PTC an... BeFree 24777145 Detail
0.055 Neoplasm Metastasis BRAF(V600E) mutation is not a positive predictor for distant metastasis in spora... BeFree 23981603 Detail
0.032 Malignant neoplasm of thyroid The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid ca... BeFree 18202121 Detail
0.002 follicular adenoma The BRAF(V600E) mutation was absent in tumor DNA samples obtained from patients ... BeFree 25837167 Detail
0.055 adenocarcinoma Somatic BRAF mutations have been reported in 1-4% of non-small cell lung cancer ... BeFree 24888229 Detail
0.431 melanoma Next, of the 15 archived melanoma FNAs tested, BRAF mutations were observed in 8... BeFree 21793228 Detail
<0.001 multiple myeloma While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM ... BeFree 14616967 Detail
0.014 colorectal carcinoma KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 met... BeFree 21457162 Detail
0.001 childhood brain tumor Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors. BeFree 25484091 Detail
0.007 colon carcinoma In particular, gene instability caused by decreased expression of the hMLH1 gene... BeFree 19424571 Detail
0.060 Thyroid carcinoma BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) o... BeFree 22012135 Detail
0.002 Malignant neoplasm of thyroid Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-... BeFree 21795305 Detail
0.032 Malignant neoplasm of thyroid The effect of activating somatic mutations in the KRAS and BRAF genes on the res... BeFree 22442268 Detail
0.082 colorectal carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.032 Malignant neoplasm of thyroid In this article, we will summarize results on preclinical testing of selective a... BeFree 24362526 Detail
0.028 melanoma This tumour-specific inhibition of ERK signalling results in a broad therapeutic... BeFree 22113612 Detail
0.049 Metastatic melanoma Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032)... BeFree 21639808 Detail
<0.001 colorectal cancer Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2... BeFree 18806830 Detail
0.431 melanoma Both melanomas carried the V600E BRAF mutation. BeFree 24942556 Detail
0.127 uveal melanoma We wanted to gain an understanding of the role of GNAQ, GNA11 and BRAF V600E in ... BeFree 23685997 Detail
0.240 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.036 Colonic Neoplasms The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. BeFree 24244575 Detail
<0.001 high-grade childhood cerebral astrocytoma Here, ten PAs with atypical clinicoradiologic and histologic features and six pe... BeFree 24057326 Detail
0.055 Neoplasm Metastasis In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.144 Carcinogenesis Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi... BeFree 18032947 Detail
0.109 Thyroid carcinoma PTC, the most frequent thyroid carcinoma histotype, is associated with gene rear... BeFree 23132790 Detail
0.032 Malignant neoplasm of thyroid It is evident that the detection of the BRAF V600E mutation is crucial in order ... BeFree 22858857 Detail
0.032 Malignant neoplasm of thyroid This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patie... BeFree 22105775 Detail
0.017 Nevus Human naevi (moles) are benign tumours of melanocytes that frequently harbour on... BeFree 16079850 Detail
0.016 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
0.004 colorectal carcinoma Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for... BeFree 18428050 Detail
0.049 Metastatic melanoma Dabrafenib has been approved to treat patients with BRAF(V600E)-positive unresec... BeFree 24259661 Detail
0.027 Thyroid Nodule Surgical results of thyroid nodules according to a management guideline based on... BeFree 21239517 Detail
0.431 melanoma Several transcription factors and signaling pathways involved in the regulation ... BeFree 25433395 Detail
0.325 Papillary thyroid carcinoma BRAF V600E mutation in papillary thyroid carcinoma: significant association with... BeFree 22105775 Detail
0.325 Papillary thyroid carcinoma Among the 779 cases, 150 cases were positive for BRAF (V600E) staining, includin... BeFree 25784606 Detail
0.125 Carcinoma of lung BRAF V600E is an emerging drug target in lung cancer, but the clinical significa... BeFree 24035431 Detail
0.016 Colorectal cancer metastatic BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patient... BeFree 20857202 Detail
0.002 Malignant neoplasm of thyroid They also potently blocked MEK phosphorylation in human thyroid cancer cell line... BeFree 16551863 Detail
0.055 Neoplasm Metastasis We also observed a positive association between BRAF V600E and TERT C228T mutati... BeFree 25583906 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immu... BeFree 25602793 Detail
0.023 Melanocytic nevus Human naevi (moles) are benign tumours of melanocytes that frequently harbour on... BeFree 16079850 Detail
0.144 Carcinogenesis Although BRAF(V600E) is well known to play an important role in the tumorigenesi... BeFree 22189819 Detail
0.074 colorectal carcinoma BRAF V600E mutation in colorectal cancer is associated with right-sided tumours ... BeFree 25862899 Detail
0.023 Melanocytic nevus Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 ... BeFree 15373778 Detail
0.001 Multiple polyps Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for... BeFree 18428050 Detail
0.023 Melanocytic nevus Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E)... BeFree 24614711 Detail
0.055 Neoplasm Metastasis However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors... BeFree 25097033 Detail
0.055 Neoplasm Metastasis BRAF(T1799A) can be detected in the blood of PTC patients with residual or metas... BeFree 19850689 Detail
0.144 colorectal cancer BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers... BeFree 15342696 Detail
0.003 glioblastoma BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRA... BeFree 25581727 Detail
0.431 melanoma Peripheral blood DNA from two of these tumor-positive cases of sporadic melanoma... BeFree 12619120 Detail
0.431 melanoma The second is vemurafenib, an inhibitor that blocks the abnormal signaling for m... BeFree 23082737 Detail
<0.001 biliary tract cancer The V599E BRAF mutation is uncommon in biliary tract cancers. BeFree 15181454 Detail
0.016 melanoma We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 g... BeFree 25073704 Detail
0.003 Neoplasm Metastasis The activating mutation BRAF(V600E) is a frequent genetic event in papillary thy... BeFree 19861538 Detail
0.032 Malignant neoplasm of thyroid We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in the... BeFree 22090271 Detail
0.018 Malignant tumor of colon Prognostic significance of defective mismatch repair and BRAF V600E in patients ... BeFree 18519771 Detail
0.074 colorectal carcinoma Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and sp... BeFree 24085553 Detail
0.009 Glioma BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phos... BeFree 24721513 Detail
0.055 Neoplasm Metastasis In malignant FNABs, BRAF(V600E) mutation was significantly associated with prese... BeFree 21948220 Detail
0.082 colorectal carcinoma The aim of this study is to compare the utility of methylation analysis of MLH1 ... BeFree 20489114 Detail
0.216 Colorectal Neoplasms To verify the technical characteristics of the microarray system for the correct... BeFree 23536897 Detail
<0.001 Lymphoproliferative Disorders Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferativ... BeFree 23161722 Detail
0.431 melanoma Comparison of testing methods for the detection of BRAF V600E mutations in malig... BeFree 23326492 Detail
0.017 Cutaneous Melanoma Around 50% of cutaneous melanomas harbor the BRAF(V600E) mutation and can be tre... BeFree 25411185 Detail
0.049 Metastatic melanoma Targeting MEK1/2 is proving to be an important therapeutic strategy, given that ... BeFree 24717435 Detail
0.020 melanoma Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V6... BeFree 24970815 Detail
0.055 Neoplasm Metastasis This study correlates histological features, immunoreactivity for CK19, HBME, an... BeFree 25702102 Detail
0.086 Carcinoma, Papillary The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of p... BeFree 17714762 Detail
0.135 colon carcinoma NA CLINVAR Detail
0.125 Carcinoma of lung Uncommon V599E BRAF mutations in Japanese patients with lung cancer. BeFree 16376942 Detail
0.017 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation analysis is a highly sensitive diagnostic tool in the diagn... BeFree 25616949 Detail
0.014 melanoma These results provide a conceptual framework for the combined deployment of BRAF... BeFree 25472943 Detail
0.017 Cutaneous Melanoma We obtained blood and tissue samples from a patient diagnosed with a BRAF(V600E)... BeFree 23948972 Detail
0.086 Carcinoma, Papillary Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of... BeFree 17520704 Detail
0.055 Neoplasm Metastasis Here, we show intralesional molecular heterogeneity in a progressing V600E BRAF-... BeFree 22962325 Detail
0.274 colorectal cancer Detection of the BRAF V600E mutation in colorectal cancer by immunohistochemistr... BeFree 23650027 Detail
0.431 melanoma Based on in silico screening results, a series of novel pyrazole derivatives has... BeFree 25641840 Detail
0.325 Papillary thyroid carcinoma Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in p... BeFree 25837167 Detail
0.055 Neoplasm Metastasis BRAF(V600E) significantly correlated with absence of node metastasis. BeFree 16452550 Detail
<0.001 Mastocytosis, Systemic Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis. BeFree 25034364 Detail
0.236 melanoma We investigated the associations between BRAF(V600E) and NRAS(Q61R) mutations an... BeFree 25048604 Detail
0.014 melanoma The reactivation of senescence features and elimination of cells refractory to B... BeFree 22549727 Detail
0.055 Neoplasm Metastasis Dual abnormalities of INI-1 loss and V600E BRAF mutation were identified in a ce... BeFree 22082607 Detail
0.129 Glioma A BRAF p.Thr599dup or p.V600E mutation was identified by Sanger sequencing in on... BeFree 24767714 Detail
0.325 Papillary thyroid carcinoma Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive ... BeFree 25353071 Detail
0.431 melanoma RAF inhibitors such as vemurafenib and dabrafenib block BRAF-mediated cell proli... BeFree 23288408 Detail
0.325 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.055 Neoplasm Metastasis There were significant differences in clinicopathological parameters, such as ex... BeFree 23528368 Detail
0.003 Prostatic Neoplasms Importantly, genetic extinction of BRAF(V600E) in established prostate tumors di... BeFree 19079609 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.002 Thyroid Gland Follicular Adenoma BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along wi... BeFree 19269016 Detail
0.121 Kidney Neoplasm These data support a role for BRAF V600E IHC in diagnostically challenging cases... BeFree 25602792 Detail
0.008 Anaplastic thyroid carcinoma BRAF(V600E) mutation was detected in 20 of 43 PTCs and all three anaplastic thyr... BeFree 19156774 Detail
<0.001 melanoma HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma ... BeFree 26145173 Detail
0.020 Papillary thyroid carcinoma The two groups did not show significant differences in clinical and prognostic f... BeFree 20447069 Detail
<0.001 Thyroid carcinoma Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V60... BeFree 19207009 Detail
0.006 Metastatic melanoma NFAT2 and 4 are expressed in human metastatic melanoma cell lines and are activa... BeFree 19724275 Detail
0.082 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
<0.001 high-grade childhood cerebral astrocytoma Here, ten PAs with atypical clinicoradiologic and histologic features and six pe... BeFree 24057326 Detail
<0.001 Adenocarcinoma of the gastroesophageal junction To summarize the usefulness of several recently discovered immunohistochemical m... BeFree 25549141 Detail
0.009 pancreatic ductal adenocarcinoma Moreover, concomitant expression of BRAF(V600E) and TP53(R270H) result in lethal... BeFree 22628411 Detail
0.049 Metastatic melanoma This article summarises the milestones in the development of dabrafenib leading ... BeFree 23881668 Detail
0.431 melanoma We investigated the hypothesis that this common somatic BRAF mutation (V599E) wo... BeFree 12794760 Detail
0.049 Metastatic melanoma Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significan... BeFree 25399551 Detail
<0.001 Thyroid carcinoma Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24... BeFree 24382015 Detail
0.049 Metastatic melanoma This study investigated the sensitivity and specificity of immunohistochemical (... BeFree 23026937 Detail
0.074 colorectal carcinoma Since RAC1b has been associated with the BRAF(V600E) mutation, associated with p... BeFree 24833563 Detail
0.144 Carcinogenesis We have identified an alternative pathway of tumorigenesis in sporadic colon can... BeFree 18718023 Detail
0.132 hairy cell leukemia The high prevalence of BRAF(V600E) activating mutation in papillary thyroid carc... BeFree 22369373 Detail
0.160 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.055 Neoplasm Metastasis On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroi... BeFree 21803329 Detail
0.021 Thyroid carcinoma Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.160 colorectal cancer A correlation between MLH1 promoter methylation, specifically the 'C' region, an... BeFree 23880961 Detail
<0.001 malignant peripheral nerve sheath tumor Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tu... BeFree 24335681 Detail
0.049 Metastatic melanoma Control of BRAF(V600E) metastatic melanoma by BRAF inhibitor (BRAF-I) is limited... BeFree 24732172 Detail
0.060 Thyroid carcinoma Orthotopic mouse models for the preclinical and translational study of targeted ... BeFree 24362526 Detail
0.431 melanoma Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF ... BeFree 24422853 Detail
0.027 Thyroid Nodule Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation eva... BeFree 22535974 Detail
0.055 Neoplasm Metastasis BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding t... BeFree 24888229 Detail
0.431 melanoma Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. BeFree 25319388 Detail
0.002 colorectal cancer Promoter methylation of Wnt5a is associated with microsatellite instability and ... BeFree 21587258 Detail
0.049 Metastatic melanoma Results from a phase 3 trial (N=675) comparing vemurafenib 960 mg twice daily (t... BeFree 23481513 Detail
0.060 Thyroid carcinoma Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V6... BeFree 25262966 Detail
0.325 Papillary thyroid carcinoma Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid ... BeFree 24301760 Detail
0.001 Anaplastic carcinoma In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinom... BeFree 17453004 Detail
<0.001 melanoma Here, CDK2/4 inhibition statistically significantly augmented the effects of BRA... BeFree 22997239 Detail
0.431 melanoma The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the eme... BeFree 23341544 Detail
0.001 uterine corpus cancer This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
<0.001 Carcinogenesis Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in M... BeFree 24717435 Detail
0.016 melanoma Our data show for the first time that BRAF(V600E) mutation increases HIF-1alpha ... BeFree 17409425 Detail
0.060 Thyroid carcinoma The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers. BeFree 17054470 Detail
0.431 melanoma 29 (39·2%, 95% CI 28·0-51·2) of 74 patients with Val600Glu BRAF-mutant melanoma ... BeFree 23051966 Detail
0.135 colon carcinoma In microsatellite stable tumors, homozygous carriers of the G39E polymorphism ha... BeFree 19582761 Detail
<0.001 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
0.325 Papillary thyroid carcinoma BRAF V600E mutation and its association with clinicopathological features of pap... BeFree 23055546 Detail
0.002 Thyroid carcinoma We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl... BeFree 16533790 Detail
0.049 Metastatic melanoma Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-... BeFree 22535154 Detail
0.007 Histiocytosis, Langerhans-Cell Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Ch... BeFree 23258922 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) mutation is an independent, poor prognostic factor for the outco... BeFree 23066120 Detail
0.060 Thyroid carcinoma Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide sym... BeFree 23163107 Detail
0.060 Thyroid carcinoma Overall, BRAF(V600E) PTC tumors display a broadly immunosuppressive profile and ... BeFree 24955518 Detail
0.003 T-cell large granular lymphocyte leukemia They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mut... BeFree 24689848 Detail
0.431 melanoma When used alone or in combination with a specific inhibitor of the BRAF(V600E) o... BeFree 21430780 Detail
0.017 Cutaneous Melanoma We propose an assay based on the use of a locked nucleic acid probe and an allel... BeFree 20576522 Detail
0.274 colorectal cancer Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.049 Metastatic melanoma Vemurafenib is an oral agent licensed for patients with BRAF V600E mutation-posi... BeFree 23094782 Detail
0.049 Metastatic melanoma We studied the efficacy of dabrafenib in patients with BRAF(V600E)-mutated metas... BeFree 22735384 Detail
0.431 melanoma Detection of BRAF p.V600E mutations in melanomas: comparison of four methods arg... BeFree 23159108 Detail
0.325 Papillary thyroid carcinoma Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with ... BeFree 18470905 Detail
0.030 adenoma Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. BeFree 23825589 Detail
0.024 Malignant tumor of colon In particular, gene instability caused by decreased expression of the hMLH1 gene... BeFree 19424571 Detail
0.325 Papillary thyroid carcinoma In contrast, the frequency of PTC cases with point mutations (mainly BRAF(V600E)... BeFree 23050789 Detail
<0.001 Thyroid carcinoma The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid ca... BeFree 18202121 Detail
0.329 Glioma These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with at... BeFree 24057326 Detail
0.325 Papillary thyroid carcinoma The prognostic significance of the BRAF V600E mutation in papillary thyroid carc... BeFree 24247620 Detail
0.274 colorectal cancer Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability spor... BeFree 19190129 Detail
0.074 colorectal carcinoma High-frequency microsatellite instability and BRAF mutation (V600E) in unselecte... BeFree 22210186 Detail
0.020 melanoma Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy,... BeFree 23802768 Detail
0.431 melanoma The BRAF inhibitor vemurafenib has become an important treatment option for mela... BeFree 23074264 Detail
0.049 Metastatic melanoma Mutationally activated BRAF(V600E) cooperates with PTEN silencing in the convers... BeFree 24425783 Detail
0.001 B-Cell Lymphomas Here, we confirm the specificity of BRAF V600E for HCL among low and intermediat... BeFree 22246856 Detail
0.005 Neoplasm Metastasis However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors... BeFree 25097033 Detail
0.001 melanoma Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inh... BeFree 24884503 Detail
0.025 Malignant tumor of colon BRAF(V600E) efficient transformation and induction of microsatellite instability... BeFree 19881948 Detail
0.012 Malignant neoplasm of ovary We also found no BRAF V599E mutation in 101 normal healthy women and 10 well-est... BeFree 17309670 Detail
0.325 Papillary thyroid carcinoma Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. BeFree 17542667 Detail
0.002 thyroiditis BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nod... BeFree 23775008 Detail
0.226 melanoma Furthermore, we identify TP53/Trp53 as a UVR-target gene that cooperates with BR... BeFree 24919155 Detail
0.002 Follicular neoplasm BRAF(V599E) mutations were unique to PTCs, and not found in any of the other typ... BeFree 12670889 Detail
0.049 Metastatic melanoma Vemurafenib is a new-targeted therapy approved for the treatment of patients wit... BeFree 23528218 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.135 colon carcinoma Sorafenib and cetuximab therapy led to a mixed radiographic response with some a... BeFree 23792568 Detail
0.431 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.274 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.004 sarcoma To explore the mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus o... BeFree 21430505 Detail
0.001 Serous cystadenoma, borderline malignancy Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation ... BeFree 25174456 Detail
0.003 Papillary thyroid carcinoma PTC, the most frequent thyroid carcinoma histotype, is associated with gene rear... BeFree 23132790 Detail
0.074 colorectal carcinoma The aim of our study was to test sebaceous neoplasms for V600E BRAF or KRAS muta... BeFree 24767862 Detail
0.431 melanoma BRAF(V600E) mutation may be associated with an unfavorable prognosis among melan... BeFree 25048604 Detail
0.005 Neoplasm Metastasis In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.431 melanoma V600E point mutation was identified in the BRAF gene in 3 intramucosal nevi and ... BeFree 23159116 Detail
0.004 Traditional Serrated Adenoma Both the HP and TSA exhibited the V600E BRAF mutation without MSI or MMR deficie... BeFree 17914558 Detail
0.004 Traditional Serrated Adenoma V600E BRAF mutations occur in 29% of cases, all of them classified as serrated a... BeFree 18782444 Detail
0.074 colorectal carcinoma When subclassified by combined BRAF V600E mutation and MMR status, loss of ARID1... BeFree 24925223 Detail
0.121 Angioimmunoblastic Lymphadenopathy They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mut... BeFree 24689848 Detail
0.017 Cutaneous Melanoma The effect of NRAS mutations on the pathological features and clinical outcomes ... BeFree 21615881 Detail
<0.001 Non-small cell lung carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.003 oxyphilic adenoma A previous study identified BRAF V600E mutations in approximately 90% of MA and ... BeFree 25602792 Detail
0.060 Thyroid carcinoma Immunohistochemical detection of mutated BRAF V600E supports the clonal origin o... BeFree 23775351 Detail
0.325 Papillary thyroid carcinoma Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and l... BeFree 26120069 Detail
0.028 melanoma Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to bot... BeFree 24077403 Detail
<0.001 Adenocarcinoma, Endometrioid This study hypothesized that the BRAF V600E mutation may be associated with muci... BeFree 23370429 Detail
0.001 Splenic Marginal Zone B-Cell Lymphoma In this study we investigated the application of a BRAF V600E mutation-specific ... BeFree 22531170 Detail
0.074 colorectal carcinoma The association of BRAF V600E mutation and the presence of the CpG island methyl... BeFree 22314188 Detail
0.002 Superficial spreading malignant melanoma of skin Associations with the BRAF(T1799A) mutation (P&lt;0.05) were as follows: low tum... BeFree 17159915 Detail
0.001 metanephric adenoma A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutat... BeFree 24432405 Detail
0.274 colorectal cancer In conclusion, miR-145 might be used as a therapeutic target in the treatment of... BeFree 24248543 Detail
0.060 Thyroid carcinoma Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cel... BeFree 21185263 Detail
<0.001 Papillary thyroid carcinoma The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways c... BeFree 21249150 Detail
<0.001 panniculitis We report the clinical course and management in 2 women with metastatic melanoma... BeFree 22250191 Detail
0.002 Stage IV Skin Melanoma We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutat... BeFree 26037941 Detail
0.007 Tumor Progression Beyond development, we can look into the effectiveness of already approved targe... BeFree 25347569 Detail
0.005 Benign melanocytic nevus All neoplastic melanocytes within such a nevus would be expected to carry the BR... BeFree 23690527 Detail
0.002 Recurrent tumor The proportion of BRAF(V600E) mutation was significantly associated with the num... BeFree 22190222 Detail
0.029 melanoma We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors spec... BeFree 15208655 Detail
0.325 Papillary thyroid carcinoma BRAF V600E in papillary thyroid carcinoma is associated with increased programme... BeFree 24955518 Detail
0.325 Papillary thyroid carcinoma Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papi... BeFree 26232865 Detail
<0.001 plasma cell neoplasm We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chron... BeFree 26071465 Detail
0.017 Cutaneous Melanoma The most common recurring mutation in cutaneous melanoma is the prooncogenic BRA... BeFree 23174497 Detail
0.002 Recurrent tumor In addition to the diagnostic use, BRAF V600E mutation can also be used for tumo... BeFree 21526955 Detail
0.005 endometrial carcinoma This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
0.274 colorectal cancer High-frequency microsatellite instability and BRAF mutation (V600E) in unselecte... BeFree 22210186 Detail
0.385 Non-small cell lung carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.274 colorectal cancer Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and py... BeFree 25280751 Detail
0.431 melanoma The V600E mutation in the kinase BRAF is frequently detected in melanomas and re... BeFree 23362240 Detail
0.015 Malignant neoplasm of lung The three most common BRAF mutations in lung cancers accounted for only 41% of t... BeFree 26386083 Detail
0.134 pilocytic astrocytoma Different types of aberrations of the BRAF gene in the classic and oligodendrogl... BeFree 23082883 Detail
0.029 melanoma In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ER... BeFree 23349307 Detail
0.055 Neoplasm Metastasis We also studied the role of BRAF V600E mutation in a set of melanoma patients wh... BeFree 25442222 Detail
0.074 colorectal carcinoma We demonstrate that SSA-associated synchronous colorectal carcinomas have a stri... BeFree 23887157 Detail
0.431 melanoma BRAF is the most mutated gene in melanoma, with approximately 50% of patients co... BeFree 23416158 Detail
0.028 melanoma To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, ... BeFree 23948972 Detail
0.134 pilocytic astrocytoma Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600... BeFree 23196000 Detail
0.325 Papillary thyroid carcinoma The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucos... BeFree 22376167 Detail
0.001 Carcinogenesis We propose that continuously activated BRAF(V600E) signaling may be a possible m... BeFree 22430208 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) mutation is the most common diagnostic/prognostic marker in papi... BeFree 25156883 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.134 pilocytic astrocytoma A single BRAF V600E mutation was identified in the fusion-negative extracerebell... BeFree 24057326 Detail
0.004 colorectal cancer Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for... BeFree 18428050 Detail
0.431 melanoma The loss of the (V599E)BRAF genotype during progression from primary to metastat... BeFree 15289355 Detail
0.002 mucinous adenocarcinoma BRAF V600E mutation and CpG island methylation phenotype-positive status are sim... BeFree 22522845 Detail
0.132 hairy cell leukemia HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma ... BeFree 26145173 Detail
0.055 adenocarcinoma In exon 15, one BRAF mutation (1796 thymine to adenine; V599E) was found in nons... BeFree 16376942 Detail
0.060 Thyroid carcinoma they were normally maintained hypomethylated and over-expressed by BRAF V600E in... BeFree 21937738 Detail
<0.001 pleomorphic xanthoastrocytoma These tumors showed a markedly better prognosis, with molecularly PXA-like tumor... BeFree 25752754 Detail
0.001 Papillary thyroid carcinoma The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways c... BeFree 21249150 Detail
0.001 Papillary thyroid carcinoma Association between expression of X-linked inhibitor of apoptosis protein and th... BeFree 24124924 Detail
0.431 melanoma BRAF(V600E) mutations are frequent in melanomas originating from intermittently ... BeFree 23690527 Detail
0.236 melanoma To determine whether specific mutations are clinically important to differentiat... BeFree 23922205 Detail
0.321 Non-small cell lung carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.325 Papillary thyroid carcinoma Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mu... BeFree 24417277 Detail
0.431 melanoma NA CLINVAR Detail
0.016 ovarian neoplasm Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative ana... BeFree 23089489 Detail
0.082 colorectal carcinoma Thus, large-scale KRAS mutation screening is needed for efficient patient manage... BeFree 21516079 Detail
<0.001 Benign thyroid nodule We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7... BeFree 25121551 Detail
0.431 melanoma With the discovery of (V600E)BRAF in about 50% of cutaneous melanomas, there was... BeFree 23489578 Detail
0.160 colorectal cancer Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability spor... BeFree 19190129 Detail
0.001 Anaplastic carcinoma The molecular genetic study of the BRAF gene showed the presence of a missense t... BeFree 15126572 Detail
0.005 Colorectal cancer metastatic Inadequate evidence was found regarding association of BRAF V600E mutation testi... BeFree 23429431 Detail
0.431 melanoma Recombinant insulin attenuated dacarbazine-induced cytotoxicity in both wild-typ... BeFree 24600206 Detail
0.074 colorectal carcinoma 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted th... BeFree 23341544 Detail
0.003 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
0.003 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
0.049 Metastatic melanoma Studies presented or published during the European Society for Medical Oncology ... BeFree 25477091 Detail
<0.001 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
0.016 Colorectal cancer metastatic Thus, large-scale KRAS mutation screening is needed for efficient patient manage... BeFree 21516079 Detail
0.325 Papillary thyroid carcinoma Associations of the BRAF(V600E) mutation with sonographic features and clinicopa... BeFree 25337709 Detail
0.160 adenoma Contrary to KRAS mutant tumors, BRAF(V600E)-induced tumors are benign adenomas t... BeFree 23825589 Detail
0.060 Thyroid carcinoma Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A n... BeFree 23931930 Detail
0.003 Erdheim-Chester disease Our findings indicate that the association of LCH and ECD is not fortuitous and ... BeFree 24894769 Detail
0.003 Erdheim-Chester disease Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester dis... BeFree 25735579 Detail
0.004 uveal melanoma We wanted to gain an understanding of the role of GNAQ, GNA11 and BRAF V600E in ... BeFree 23685997 Detail
0.001 B-Cell Lymphomas BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-c... BeFree 25480661 Detail
0.027 Thyroid Nodule Detection of BRAF(V600E) in cytology specimens by pyrosequencing is a useful dia... BeFree 24267957 Detail
<0.001 Anaplasia This last observation led us to investigate the role of BRAF(V600E) and the MEK-... BeFree 16601293 Detail
<0.001 Neurofibromatoses Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS muta... BeFree 23190154 Detail
0.431 melanoma In conclusion, we used highly sensitive BRAF mutation detection methods and obse... BeFree 22235286 Detail
<0.001 Malignant melanoma of iris The T1799A BRAF mutation is present in iris melanoma. BeFree 17962436 Detail
0.002 leukemia We identified a novel breakpoint region at 14q32.13 that was rearranged together... BeFree 22553924 Detail
0.027 Thyroid Nodule BRAF V600E mutation, common in papillary thyroid carcinoma (PTC), is helpful in ... BeFree 24746198 Detail
0.060 Thyroid carcinoma Papillary thyroid carcinomas with and without BRAF V600E mutations are morpholog... BeFree 22335197 Detail
0.325 Papillary thyroid carcinoma DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mut... BeFree 22691412 Detail
0.431 melanoma Assessment of V600E mutation of BRAF gene and rate of cell proliferation using f... BeFree 20944096 Detail
0.325 Papillary thyroid carcinoma Targeted expression of rearranged during transfection (RET)/papillary thyroid ca... BeFree 17210745 Detail
0.032 Malignant neoplasm of thyroid Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cel... BeFree 21185263 Detail
<0.001 Malignant neoplasm of thyroid The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid ca... BeFree 18202121 Detail
0.007 leukemia We assessed phospho-ERK expression in 37 patients with hairy cell leukemia and 4... BeFree 23349307 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong c... BeFree 22426956 Detail
0.001 keratoacanthoma RAF inhibitors are effective against melanomas with BRAF V600E mutations but may... BeFree 22067401 Detail
0.004 Solid tumour The primary endpoint was the proportion of patients with Val600Glu BRAF-mutant m... BeFree 23051966 Detail
0.325 Papillary thyroid carcinoma Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polis... BeFree 17693984 Detail
0.002 Adenocarcinoma of large intestine Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody ... BeFree 23763264 Detail
0.431 melanoma Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. BeFree 21635872 Detail
0.431 melanoma Besides confirming the presence of known melanoma driver mutations (BRAF(V600E),... BeFree 23704925 Detail
0.055 Neoplasm Metastasis Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the m... BeFree 20635392 Detail
0.018 Thyroid carcinoma Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide sym... BeFree 23163107 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.325 Papillary thyroid carcinoma BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid... BeFree 22190222 Detail
0.001 influenza However, a subset of AUS/FLUS cases with the V600E BRAF mutation appeared to rep... BeFree 22887810 Detail
<0.001 renal carcinoma Thus, BRAF V600E immunostaining is a helpful marker for pediatric metanephric ad... BeFree 26014474 Detail
0.001 influenza We also investigated the value of ultrasound features that predict malignancy an... BeFree 24261392 Detail
0.274 colorectal cancer miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regul... BeFree 24242331 Detail
0.060 Thyroid carcinoma Epidermal growth factor receptor (EGFR) overexpression (EGFR-H) is implicated in... BeFree 23746767 Detail
<0.001 Adenomatous goiter The BRAF(V600E) mutation was absent in tumor DNA samples obtained from patients ... BeFree 25837167 Detail
0.002 Adenomatous Polyposis Coli Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mut... BeFree 17293392 Detail
0.019 polyps BRAF (V600E) mutation assay was performed to explore its value in the differenti... BeFree 23069257 Detail
<0.001 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.144 Carcinogenesis Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mut... BeFree 21185263 Detail
0.325 Papillary thyroid carcinoma A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detectio... BeFree 19534623 Detail
0.274 colorectal cancer Promoter methylation of Wnt5a is associated with microsatellite instability and ... BeFree 21587258 Detail
<0.001 endocrine carcinoma We found a high rate of V559E mutations in papillary thyroid carcinomas (47%), o... BeFree 15613458 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) mutation, which accounts for about 60-80% papillary thyroid carc... BeFree 24228637 Detail
0.325 Papillary thyroid carcinoma BRAF (V600E) might provide prognostic and diagnostic information for papillary t... BeFree 24389984 Detail
0.001 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.160 colorectal cancer Specific KRAS mutation is an informative prognostic factor in both sporadic and ... BeFree 20162668 Detail
0.431 melanoma Absence of V599E BRAF mutations in desmoplastic melanomas. BeFree 15641040 Detail
0.274 colorectal cancer BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRA... BeFree 19213871 Detail
0.086 Carcinoma, Papillary In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinom... BeFree 17453004 Detail
0.019 polyps Colorectal cancers arising from serrated polyps are characterized by the CpG isl... BeFree 18628431 Detail
0.325 Papillary thyroid carcinoma The authors' data suggested that BRAF(V600E) mutation and p27(Kip1) down-regulat... BeFree 17685465 Detail
0.325 Papillary thyroid carcinoma PCCL3 rat thyroid cells that conditionally overexpress either BRAF(V600E) or RET... BeFree 20470206 Detail
0.325 Papillary thyroid carcinoma Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-... BeFree 24039206 Detail
0.074 colorectal carcinoma In this review, clinicopathologic characteristics associated with BRAF-mutant tu... BeFree 25744437 Detail
<0.001 iron deficiency anemia BRAF V600E mutation in colorectal cancer is associated with right-sided tumours ... BeFree 25862899 Detail
0.008 HIV Infections We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors spec... BeFree 15208655 Detail
0.017 Secondary malignant neoplasm of lymph node The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients ... BeFree 23253715 Detail
<0.001 Papillary thyroid carcinoma Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advance... BeFree 24382015 Detail
0.431 melanoma Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-posit... BeFree 24508103 Detail
0.007 Tumor Progression Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and... BeFree 23533235 Detail
<0.001 Central Nervous System Neoplasms We evaluated CNS tumor cells with BRAF(V600E) and found that mutant (but not wil... BeFree 24823863 Detail
0.055 Neoplasm Metastasis Multivariate logistic regression analysis confirmed that BRAF((V600E)) was an in... BeFree 18310287 Detail
0.135 colon carcinoma Herein, we present the case of a patient with bulky V600E-mutant BRAF hepatic fl... BeFree 23792567 Detail
0.144 Carcinogenesis The prevalence (90%) of the BRAF (V600E) mutation in this study is the highest e... BeFree 23179992 Detail
<0.001 Recurrent tumor Decreased CPSF2 gene expression was associated with shorter disease-free surviva... BeFree 24654752 Detail
<0.001 Odontogenic Tumors BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in a... BeFree 24993163 Detail
0.002 Recurrent tumor Genetic analyses revealed amplification of the BRAF gene in both the primary cer... BeFree 23082883 Detail
0.274 colorectal cancer These results seem to indicate that Cdx2 may play a role in the serrated pathway... BeFree 24166180 Detail
0.431 melanoma This combinatorial effect was recapitulated in human melanoma-derived cell lines... BeFree 25358764 Detail
0.002 Recurrent tumor Decreased CPSF2 gene expression was associated with shorter disease-free surviva... BeFree 24654752 Detail
0.431 melanoma One melanoma carried a BRAF point mutation that is frequently found in cutaneous... BeFree 19936769 Detail
0.060 Thyroid carcinoma Although BRAF(V600E) represents 95% of all BRAF mutations, uncommon BRAF mutatio... BeFree 26230187 Detail
0.017 Secondary malignant neoplasm of lymph node The percentage of BRAF(V600E) alleles (P = 0.014), tumor volume (P = 0.012), and... BeFree 22508706 Detail
0.160 colorectal cancer BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers... BeFree 15342696 Detail
0.288 Thyroid Neoplasm To investigate the alternative methods like immunohistochemistry and exon 15 in ... BeFree 24947099 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer The BRAF-V600E hotspot mutation was found in 40% (82/206) of the sporadic MSI-H ... BeFree 15342696 Detail
0.032 Malignant neoplasm of thyroid Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V6... BeFree 25262966 Detail
<0.001 Malignant neoplasm of thyroid The negative regulators of the cell cycle, p21 and p27, are strongly induced by ... BeFree 21249150 Detail
0.347 acute promyelocytic leukemia Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.144 Carcinogenesis This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
0.325 Papillary thyroid carcinoma The recognition of this functional trilogy provides insight on how BRAF(V600E) d... BeFree 21903858 Detail
0.008 Anaplastic thyroid carcinoma Additionally, preclinical and clinical studies investigating combination therapy... BeFree 21900390 Detail
0.004 Metastatic malignant neoplasm to brain Dabrafenib has activity and an acceptable safety profile in patients with Val600... BeFree 23051966 Detail
0.020 Papillary thyroid carcinoma After surgery, 115 nodules were confirmed as conventional papillary thyroid carc... BeFree 25111330 Detail
0.144 Carcinogenesis The BRAF V600E mutation plays an important role in the tumorigenesis of papillar... BeFree 21937738 Detail
0.032 Malignant neoplasm of thyroid The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF... BeFree 22535974 Detail
0.004 Metastatic malignant neoplasm to brain MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplific... BeFree 25073704 Detail
0.274 colorectal cancer The aim of this study is to compare the utility of methylation analysis of MLH1 ... BeFree 20489114 Detail
0.012 colorectal cancer We show that activation of the PI3K/AKT pathway is a mechanism of both innate an... BeFree 23251002 Detail
0.004 Metastatic malignant neoplasm to brain Metastatic melanoma has a high prevalence of V600-mutant BRAF, and clinical tria... BeFree 24756796 Detail
<0.001 Secondary malignant neoplasm of lymph node We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases ... BeFree 25755776 Detail
0.325 Papillary thyroid carcinoma Approximately 45% of papillary thyroid carcinomas harbor BRAF p.V600E mutations ... BeFree 24897065 Detail
0.132 hairy cell leukemia They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mut... BeFree 24689848 Detail
0.125 Carcinoma of lung The three most common BRAF mutations in lung cancers accounted for only 41% of t... BeFree 26386083 Detail
0.001 Malignant neoplasm of thyroid BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.001 Carcinogenesis We propose that continuously activated BRAF(V600E) signaling may be a possible m... BeFree 22430208 Detail
0.027 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
0.274 colorectal cancer The aim of this study was to relate the CpG island methylator phenotype (CIMP; c... BeFree 20197478 Detail
0.004 Turcot syndrome (disorder) Both the HP and TSA exhibited the V600E BRAF mutation without MSI or MMR deficie... BeFree 17914558 Detail
<0.001 Myopericytoma Patients with BRAF(WT/V600E)-MPC should be closely followed because of the risk ... BeFree 25063326 Detail
0.431 melanoma Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF ... BeFree 24071017 Detail
0.055 Neoplasm Metastasis BRAF V600E was associated with extrathyroidal invasion (P &lt; 0.0001), multicen... BeFree 17785355 Detail
0.027 Thyroid Nodule Clinical implication of highly sensitive detection of the BRAF V600E mutation in... BeFree 22500044 Detail
0.032 melanoma In this study, we utilised genetically engineered melanoma cell lines and xenogr... BeFree 25117819 Detail
0.055 Neoplasm Metastasis The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanc... BeFree 19034577 Detail
0.325 Papillary thyroid carcinoma Analysis of differential BRAF(V600E) mutational status in multifocal papillary t... BeFree 16983703 Detail
0.060 Thyroid carcinoma BRAF(V600E) mutation and p27(kip1) expression have been introduced as novel indi... BeFree 17685465 Detail
0.027 Thyroid Nodule We strongly recommend preoperative evaluation of the BRAF V600E mutation in inde... BeFree 26020381 Detail
0.055 Neoplasm Metastasis In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the rel... BeFree 17972530 Detail
0.431 melanoma The prevalence of the BRAF(V599E) mutation in PTC is the highest reported to dat... BeFree 12881714 Detail
<0.001 Adenomatous Polyps BRAF V600E mutation analysis was performed in 148 selected cases; mutations were... BeFree 19126563 Detail
0.004 melanoma Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. BeFree 23802768 Detail
0.002 Carcinogenesis We propose that continuously activated BRAF(V600E) signaling may be a possible m... BeFree 22430208 Detail
0.049 Metastatic melanoma We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom trea... BeFree 23036672 Detail
0.431 melanoma In the dose-escalation cohort, among the 16 patients with melanoma whose tumors ... BeFree 20818844 Detail
0.085 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.028 melanoma The development of RAF inhibitors targeted against BRAF V600E mutant melanoma ce... BeFree 23174497 Detail
0.001 Liver neoplasms To summarize the usefulness of several recently discovered immunohistochemical m... BeFree 25549141 Detail
0.027 Thyroid Nodule What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation... BeFree 25616949 Detail
0.001 hairy cell leukemia Advanced molecular techniques have identified distinct molecular aberrations in ... BeFree 24652320 Detail
0.431 melanoma The T1799A BRAF mutation was identified in two of the five (40%) conjunctival me... BeFree 16123397 Detail
0.032 Malignant neoplasm of thyroid BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) o... BeFree 22012135 Detail
0.001 Primary Lesion We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases ... BeFree 25755776 Detail
0.431 melanoma Among the 20 melanomas with completed BRAF-sequencing analysis, 6 (30%) harbored... BeFree 22809251 Detail
0.027 Thyroid Nodule We recommend that patients with a thyroid nodule with any suspicious sonographic... BeFree 25337709 Detail
0.002 Anaplasia This last observation led us to investigate the role of BRAF(V600E) and the MEK-... BeFree 16601293 Detail
0.431 melanoma The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma ... BeFree 23463675 Detail
0.017 Nevus Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 ... BeFree 15373778 Detail
0.027 Thyroid Nodule Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according t... BeFree 20945104 Detail
0.030 adenoma These findings indicate that adenomas might be less important in the cancer deve... BeFree 17119056 Detail
0.325 Papillary thyroid carcinoma The lesions were screened for the BRAF(V600E) and NRAS mutations and for RET/PTC... BeFree 23966419 Detail
0.325 Papillary thyroid carcinoma We consider that BRAF(V600E) mutation does not possess prognostic value in Korea... BeFree 21862261 Detail
0.049 Metastatic melanoma BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF... BeFree 23403819 Detail
0.055 Neoplasm Metastasis In 42 cases with LN metastases, 23 harbored the BRAF(V600E) mutation in the meta... BeFree 17685465 Detail
0.032 Malignant neoplasm of thyroid The influence of the BRAF V600E mutation in thyroid cancer cell lines on the ant... BeFree 21795305 Detail
0.002 Malignant neoplasm of thyroid Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-... BeFree 21795305 Detail
0.002 multiple myeloma While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM ... BeFree 14616967 Detail
0.001 Congenital melanocytic nevus Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese ... BeFree 21430505 Detail
0.001 Glioma These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with at... BeFree 24057326 Detail
0.027 Thyroid Nodule Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis... BeFree 23505540 Detail
0.431 melanoma Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma ... BeFree 19659611 Detail
0.032 Malignant neoplasm of thyroid BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.028 melanoma The activating BRAF mutation V600E and related mutations in this codon are most ... BeFree 24756795 Detail
0.012 colorectal carcinoma Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.431 melanoma Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Go... BeFree 23651150 Detail
0.029 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
0.236 melanoma Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed... BeFree 20149136 Detail
0.010 adenoma KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 met... BeFree 21457162 Detail
0.325 Papillary thyroid carcinoma BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in... BeFree 12881714 Detail
0.431 melanoma Dual targeting of BRAF(V600E) and Hdm2 with vemurafenib and Nt-3, respectively, ... BeFree 23812671 Detail
0.325 Papillary thyroid carcinoma After surgery, 115 nodules were confirmed as conventional papillary thyroid carc... BeFree 25111330 Detail
0.032 Malignant neoplasm of thyroid BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyr... BeFree 18310287 Detail
<0.001 Seizures The expression of both BRAF V600E and pS6 was associated with a worse postoperat... BeFree 23941441 Detail
0.060 Thyroid carcinoma They also potently blocked MEK phosphorylation in human thyroid cancer cell line... BeFree 16551863 Detail
0.002 Papillary thyroid carcinoma BRAF V600E and TERT promoter mutations cooperatively identify the most aggressiv... BeFree 25024077 Detail
0.325 Papillary thyroid carcinoma In particular, V600E mutation is highly prevalent in papillary thyroid carcinoma... BeFree 17972530 Detail
<0.001 Congenital chromosomal disease However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/... BeFree 22558328 Detail
0.003 melanoma In a Phase I study (BRIM-1), a 960-mg BID dose achieved an objective response ra... BeFree 22742884 Detail
0.029 melanoma RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma... BeFree 24185007 Detail
0.006 Neoplasm Metastasis However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors... BeFree 25097033 Detail
0.431 melanoma In contrast to previous work with BRAF(V600E) in melanoma cells, feedback inhibi... BeFree 24362263 Detail
0.002 leukemia The BRAF kinase is mutated, typically Val 600→Glu (V600E), to induce an active o... BeFree 24717435 Detail
0.023 Melanocytic nevus Melanocytic naevi with globular and reticular dermoscopic patterns display disti... BeFree 25039578 Detail
0.015 melanoma The activating BRAF mutation V600E and related mutations in this codon are most ... BeFree 24756795 Detail
0.086 Carcinoma, Papillary The T1799A BRAF mutation is absent in cribriform-morular variant of papillary ca... BeFree 19415957 Detail
<0.001 Papillary thyroid carcinoma BRAF (V600E) mutation was more common in the conventional PTC (38 out of 62; 61%... BeFree 22105775 Detail
0.001 chronic lymphocytic leukemia Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolym... BeFree 22230299 Detail
0.004 sarcoma BRAF (v-raf murine sarcoma viral oncogene homologue B) V600E mutations have been... BeFree 25039578 Detail
0.004 colorectal carcinoma In conclusion, miR-145 might be used as a therapeutic target in the treatment of... BeFree 24248543 Detail
<0.001 Carcinoma, Signet Ring Cell BRAF V600E mutation and CpG island methylation phenotype-positive status are sim... BeFree 22522845 Detail
0.005 Epithelial ovarian cancer A patient with V600E BRAF-mutant melanoma and another with platinum-refractory e... BeFree 25370471 Detail
0.325 Papillary thyroid carcinoma Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurre... BeFree 23806056 Detail
0.019 polyps BRAF V600E mutation was found in 74% of serrated polyps in MUTYH-negative patien... BeFree 24470512 Detail
0.086 Carcinoma, Papillary These findings indicate that, although BRAF(V600E) mutation may play some roles ... BeFree 18840924 Detail
0.005 melanoma One such target is the V600E gain-of-function BRAF mutation found in 60% of mela... BeFree 19679016 Detail
0.244 Adenocarcinoma of lung (disorder) Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation ... BeFree 23927882 Detail
0.018 Malignant tumor of colon Colon cancers from 2008 to 2012 tested by pyrosequencing for BRAF V600E mutation... BeFree 23650027 Detail
0.086 Carcinoma, Papillary Cells derived from papillary carcinoma harboring the mutant BRAF (V600E) allele ... BeFree 25879531 Detail
0.325 Papillary thyroid carcinoma Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using... BeFree 17298986 Detail
0.431 melanoma Activating mutations in the BRAF serine/threonine kinase are found in more than ... BeFree 22361686 Detail
<0.001 Lentigo maligna melanoma Compared to tumors without the mutation, the P131L mutant positive tumors were a... BeFree 25544760 Detail
0.126 Papillary thyroid carcinoma PTC, the most frequent thyroid carcinoma histotype, is associated with gene rear... BeFree 23132790 Detail
<0.001 Terminal illness However, as in humans, BRAF(V600E)-induced mouse PTC is indolent and does not le... BeFree 24770869 Detail
0.008 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.431 melanoma At clinically informative sites, we identified seven low-frequency point mutatio... BeFree 23382536 Detail
<0.001 Colorectal Serrated Adenocarcinoma VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal c... BeFree 24722974 Detail
0.325 Papillary thyroid carcinoma BRAF V600E status adds incremental value to current risk classification systems ... BeFree 23158172 Detail
0.015 Malignant neoplasm of lung Uncommon V599E BRAF mutations in Japanese patients with lung cancer. BeFree 16376942 Detail
0.002 Thyroid Gland Follicular Adenoma The BRAF(V600E) mutation was absent in tumor DNA samples obtained from patients ... BeFree 25837167 Detail
0.074 colorectal carcinoma BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in ... BeFree 23553055 Detail
0.001 melanoma Finally, we conclude that inhibition of SHH-GLI signaling pathway in human melan... BeFree 23935925 Detail
0.136 melanoma Here, CDK2/4 inhibition statistically significantly augmented the effects of BRA... BeFree 22997239 Detail
0.431 melanoma In this issue of Cancer Discovery, Shi and colleagues add further insight into t... BeFree 22588873 Detail
<0.001 melanoma Expression of AID in malignant melanoma with BRAF(V600E) mutation. BeFree 24684646 Detail
0.055 Neoplasm Metastasis It has a higher rate of central nodal metastasis and BRAF V600E mutation in comp... BeFree 22431868 Detail
<0.001 diffuse large B-cell lymphoma Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... BeFree 22575864 Detail
0.002 Thyroid carcinoma Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-... BeFree 21795305 Detail
0.008 Anaplastic thyroid carcinoma BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying diff... BeFree 17453004 Detail
0.002 Thyroid carcinoma In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.229 Neoplasm Metastasis BRAF V600E also predicts poor prognosis in microsatellite stable colorectal canc... BeFree 23650027 Detail
0.023 Thyroid carcinoma Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.049 Metastatic melanoma Assessment of BRAF p.V600E mutational status has become necessary for treatment ... BeFree 23651150 Detail
<0.001 high-grade childhood cerebral astrocytoma Here, ten PAs with atypical clinicoradiologic and histologic features and six pe... BeFree 24057326 Detail
<0.001 adult glioblastoma Moreover, to our knowledge, there is no detailed report of the BRAF V600E mutati... BeFree 25885250 Detail
0.001 Anaplastic thyroid carcinoma Combined, these data demonstrate that the BRAF(V600E) cooperates with either PIK... BeFree 24770869 Detail
0.074 colorectal carcinoma Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer ca... BeFree 23462926 Detail
0.274 colorectal cancer Thus, large-scale KRAS mutation screening is needed for efficient patient manage... BeFree 21516079 Detail
0.008 Anaplastic thyroid carcinoma BRAF(V600E) mutations were identified in 22.2% of the carcinoma cases (n = 18, 1... BeFree 23746767 Detail
0.074 colorectal carcinoma The aim of this study is to compare the utility of methylation analysis of MLH1 ... BeFree 20489114 Detail
0.431 melanoma Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. BeFree 22742884 Detail
0.002 Anaplastic thyroid carcinoma Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation,... BeFree 25584719 Detail
0.431 melanoma In this review, clinicopathologic characteristics associated with BRAF-mutant tu... BeFree 25744437 Detail
0.431 melanoma Here, CDK2/4 inhibition statistically significantly augmented the effects of BRA... BeFree 22997239 Detail
0.431 melanoma AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in mel... BeFree 24201813 Detail
0.002 leukemia BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-c... BeFree 25480661 Detail
0.274 colorectal cancer Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or... BeFree 18628431 Detail
0.002 leukemia All 12 cases of HCL showed cytoplasmic BRAF V600E protein expression in leukemia... BeFree 25120816 Detail
0.060 Thyroid carcinoma It is evident that the detection of the BRAF V600E mutation is crucial in order ... BeFree 22858857 Detail
0.060 Thyroid carcinoma PTC, the most frequent thyroid carcinoma histotype, is associated with gene rear... BeFree 23132790 Detail
0.272 melanoma Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed... BeFree 20149136 Detail
0.015 melanoma We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors spec... BeFree 15208655 Detail
0.325 Papillary thyroid carcinoma Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-su... BeFree 23157614 Detail
0.049 Metastatic melanoma A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of... BeFree 24178368 Detail
0.001 Secondary malignant neoplasm of lung NK cell frequencies were significantly enhanced by PLX4720 specifically in the l... BeFree 25351955 Detail
0.049 Metastatic melanoma The loss of the (V599E)BRAF genotype during progression from primary to metastat... BeFree 15289355 Detail
0.236 melanoma Our data suggest that one of the major functions of C-MYC overexpression in mela... BeFree 18679422 Detail
0.049 Metastatic melanoma Array comparative genomic hybridization analysis showed that CCND1 was amplified... BeFree 18790768 Detail
0.009 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.032 Malignant neoplasm of thyroid While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangeme... BeFree 21048359 Detail
0.049 Metastatic melanoma Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) i... BeFree 23329082 Detail
0.002 lymphoma BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-c... BeFree 25480661 Detail
0.325 Papillary thyroid carcinoma We believe that our findings will help to decide the realistic usefulness of BRA... BeFree 26338373 Detail
0.030 adenoma We investigated 194 serrated lesions of the colon, comprising 42 sessile serrate... BeFree 23887306 Detail
0.007 melanoma Several transcription factors and signaling pathways involved in the regulation ... BeFree 25433395 Detail
0.003 Erdheim-Chester disease Reproducible and sustained efficacy of targeted therapy with vemurafenib in pati... BeFree 25422482 Detail
0.001 Anaplastic carcinoma The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cas... BeFree 25894433 Detail
0.049 Metastatic melanoma An international, multicenter, randomized, open-label trial in 675 previously un... BeFree 25096067 Detail
0.060 Thyroid carcinoma While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangeme... BeFree 21048359 Detail
0.004 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
0.001 uterine corpus cancer Analysis of a correlation between the BRAF V600E mutation and abnormal DNA misma... BeFree 19424571 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer In addition, the combination of microsatellite instability testing, MLH1 promote... BeFree 18556776 Detail
0.002 Undifferentiated carcinoma In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinom... BeFree 17453004 Detail
0.004 uveal melanoma Others have demonstrated a BRAF T1799A-activating mutation in cutaneous but not ... BeFree 15277467 Detail
0.325 Papillary thyroid carcinoma Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. BeFree 22997209 Detail
<0.001 Thyroid carcinoma We assessed the utility of immunohistochemistry to detect BRAF p.V600E mutations... BeFree 24897065 Detail
0.049 Metastatic melanoma Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop i... BeFree 24345644 Detail
0.002 Malignant neoplasm of thyroid The effect of activating somatic mutations in the KRAS and BRAF genes on the res... BeFree 22442268 Detail
0.002 lymphoma The BRAF-V600E mutation defines genetically hairy cell leukemia among B-cell leu... BeFree 23349307 Detail
0.431 melanoma We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma con... BeFree 24448821 Detail
<0.001 T-cell large granular lymphocyte leukemia They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mut... BeFree 24689848 Detail
0.001 Colorectal cancer metastatic These data suggest that combined therapy with RAF and EGFR inhibitors could be a... BeFree 25589621 Detail
0.003 glioblastoma We tested our originally reported cohort of 8 E-GBMs and 2 rhabdoid GBMs (R-GBM)... BeFree 23552385 Detail
0.342 melanoma In the course of modeling malignant melanoma in a tyrosinase promoter transgenic... BeFree 19079609 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation status was assessed in thyroid fine-needle aspiration (FNA)... BeFree 22488961 Detail
0.274 colorectal cancer Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for... BeFree 18428050 Detail
0.431 melanoma Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRA... BeFree 23134356 Detail
0.014 melanoma Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, a... BeFree 19233913 Detail
0.325 Papillary thyroid carcinoma V600E BRAF gene mutation was demonstrated in 19/43 malignant nodules, in 0/56 be... BeFree 25194426 Detail
0.055 Neoplasm Metastasis Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E... BeFree 23416953 Detail
<0.001 melanoma We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 g... BeFree 25073704 Detail
0.023 Malignant tumor of colon Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback acti... BeFree 22281684 Detail
0.431 melanoma Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. BeFree 24917033 Detail
0.001 B-Cell Lymphomas Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lym... BeFree 22575864 Detail
0.431 melanoma Here, we show a role for FOXO4 in mediating senescence by the human BRAF(V600E) ... BeFree 20959475 Detail
0.002 Metastatic melanoma The development of RAF inhibitors targeted against BRAF V600E mutant melanoma ce... BeFree 23174497 Detail
0.431 melanoma Further analyses suggested a complex mechanism driven by mutation BRAF (V600E) o... BeFree 25890285 Detail
0.431 melanoma Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E... BeFree 18462259 Detail
0.010 melanoma Significantly, SAHA and the clinically available BRAF inhibitor vemurafenib coop... BeFree 23744355 Detail
0.325 Papillary thyroid carcinoma Clinicopathological characteristics were evaluated according to the Notch1/Notch... BeFree 22118425 Detail
0.008 Rectal Carcinoma Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall ... BeFree 25973534 Detail
0.325 Papillary thyroid carcinoma 80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a ... BeFree 25400776 Detail
0.020 melanoma RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma... BeFree 24185007 Detail
0.014 melanoma These results provide a conceptual framework for the combined deployment of BRAF... BeFree 25472943 Detail
<0.001 Familial Nonmedullary Thyroid Cancer The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thy... BeFree 16117812 Detail
<0.001 Multiple polyps Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for... BeFree 18428050 Detail
0.325 Papillary thyroid carcinoma WRO cells (a BRAF(V600E)-mutant follicular-derived papillary thyroid carcinoma c... BeFree 22998776 Detail
0.329 Hereditary Nonpolyposis Colorectal Cancer MSI-H colorectal carcinomas were divided into sporadic (112/1292, 8.7%) and LS/p... BeFree 24034859 Detail
0.074 colorectal carcinoma VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal c... BeFree 24722974 Detail
0.431 melanoma The BRAF(V600E) melanoma mutation, like the KIT exon 11 mutation in GIST, has th... BeFree 24531699 Detail
0.130 endometrial carcinoma This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
<0.001 inflammatory myofibroblastic tumor In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a p... BeFree 20393746 Detail
0.015 melanoma Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy,... BeFree 23802768 Detail
0.431 melanoma Overall, this study supports the idea that additional NK cell-based immunotherap... BeFree 25351955 Detail
0.431 melanoma reveal in vivo proof of MITF directly regulating tumor development in BRAF(V600E... BeFree 24352080 Detail
0.431 melanoma In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ER... BeFree 23349307 Detail
<0.001 melanoma CAST-PCR gave rapid and accurate results for the common V600E and V600K mutation... BeFree 23584600 Detail
0.086 Carcinoma, Papillary PTC with any RET/PTC rearrangements had more aggressive behavior than BRAF(V600E... BeFree 21403618 Detail
0.076 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.002 lymphoma The detection of BRAF V600E by IHC is useful in the distinction of HCLs from oth... BeFree 26071465 Detail
<0.001 Invasive Skin Melanoma Somatic BRAF(V600E) and NRAS(Q61R) mutations of 127 primary invasive melanomas f... BeFree 25048604 Detail
0.431 melanoma SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms d... BeFree 25848750 Detail
0.325 Papillary thyroid carcinoma Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer... BeFree 23969188 Detail
0.131 Non-small cell lung carcinoma NA CLINVAR Detail
<0.001 Hurthle Cell Tumor A previous study identified BRAF V600E mutations in approximately 90% of MA and ... BeFree 25602792 Detail
0.431 melanoma The BRAF V600E genotype and an absence of primary melanoma ulceration were also ... BeFree 26218930 Detail
0.004 sarcoma In many ERK1/2-dependent tumour cell lines, inhibition of BRAF(V600E) (v-raf mur... BeFree 24527759 Detail
0.002 Thyroid carcinoma In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.020 Thyroid Neoplasm Treatment of the most resistant cell line, 8505c, using lexatumumab in combinati... BeFree 24603332 Detail
0.002 Superficial spreading malignant melanoma of skin We further showed that BRAF, a downstream signaling molecule of ARMS in ERK path... BeFree 18089783 Detail
0.007 Tumor Progression Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. BeFree 23825589 Detail
0.325 Papillary thyroid carcinoma Furthermore, high Mig-6 expression was independently predictive of greater disea... BeFree 19040996 Detail
0.121 ameloblastoma That this therapy was not effective in another primary cell culture led to the d... BeFree 24749150 Detail
<0.001 Ameloblastic fibroma BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in a... BeFree 24993163 Detail
<0.001 Struma ovarii, malignant BRAF T1799A mutation occurring in a case of malignant struma ovarii. BeFree 17478764 Detail
0.431 melanoma In this review, the current state of targeted therapy for melanoma is discussed,... BeFree 21962474 Detail
0.431 melanoma Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resista... BeFree 22588879 Detail
0.020 colon carcinoma In particular, gene instability caused by decreased expression of the hMLH1 gene... BeFree 19424571 Detail
0.080 colorectal carcinoma A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may ... BeFree 23657789 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation and the biology of papillary thyroid cancer. BeFree 18310287 Detail
0.005 Benign melanocytic nevus However, using immunomagnetic separation or laser-capture microdissection, we ex... BeFree 19752400 Detail
0.074 colorectal carcinoma We show MCC expression is dramatically decreased in many CRC cell lines and the ... BeFree 18591935 Detail
0.431 melanoma Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E m... BeFree 24879157 Detail
0.001 Cutaneous Melanoma To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, ... BeFree 23948972 Detail
0.020 Papillary thyroid carcinoma To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (F... BeFree 17727338 Detail
0.060 Thyroid carcinoma Immunohistochemical Investigation of BRAF p.V600E mutations in thyroid carcinoma... BeFree 24897065 Detail
<0.001 IMMUNE SUPPRESSION Evidence suggesting that mitogen-activated protein kinase pathway activation in ... BeFree 22355009 Detail
0.002 Thyroid Neoplasm Treatment of the most resistant cell line, 8505c, using lexatumumab in combinati... BeFree 24603332 Detail
0.431 melanoma The detection of V600E BRAF mutation in melanoma is fundamental since here BRAF ... BeFree 23579220 Detail
0.192 colorectal cancer We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell... BeFree 23251002 Detail
0.001 dysembryoplastic neuroepithelial tumor BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and... BeFree 25346165 Detail
<0.001 pilocytic astrocytoma This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E... BeFree 24532263 Detail
0.017 Cutaneous Melanoma Analysis of the BRAF V600E mutation in primary cutaneous melanoma. BeFree 24535907 Detail
0.134 pilocytic astrocytoma The high mutation frequencies in pleomorphic xanthoastrocytomas, gangliogliomas ... BeFree 21274720 Detail
0.029 melanoma Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromi... BeFree 23306863 Detail
0.012 Gastrointestinal Stromal Tumors Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointest... BeFree 18615679 Detail
0.025 colon carcinoma Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback acti... BeFree 22281684 Detail
0.037 adenocarcinoma KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 met... BeFree 21457162 Detail
0.160 colorectal cancer The aim of this study is to compare the utility of methylation analysis of MLH1 ... BeFree 20489114 Detail
0.431 melanoma Moreover, in BRAF(V600E) melanoma cell lines, vemurafenib inhibits 4E-BP1 phosph... BeFree 25615552 Detail
0.001 Lymphocytic infiltration The diagnostic value of BRAF(V600E) in inconclusive FNAs was not hampered by thy... BeFree 23775008 Detail
0.003 ganglioglioma Pediatric posterior fossa ganglioglioma: unique MRI features and correlation wit... BeFree 24792487 Detail
0.431 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
0.020 melanoma Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to bot... BeFree 24077403 Detail
<0.001 Papillary thyroid carcinoma BRAF V600E in papillary thyroid carcinoma is associated with increased programme... BeFree 24955518 Detail
0.003 ganglioglioma The highest frequencies of BRAF (V600E) mutations were found in WHO grade II ple... BeFree 21274720 Detail
0.002 multiple myeloma Targeting the BRAF V600E mutation in multiple myeloma. BeFree 23612012 Detail
0.060 Thyroid carcinoma BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nuclei... BeFree 23179992 Detail
<0.001 melanoma In this study, we show that the expression of LAT1 and ASCT2 is significantly in... BeFree 24531984 Detail
0.002 pleomorphic xanthoastrocytoma The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomo... BeFree 25885250 Detail
0.012 Gastrointestinal Stromal Tumors We constructed tissue microarrays of formalin-fixed and paraffin-embedded specim... BeFree 23343956 Detail
0.002 pleomorphic xanthoastrocytoma Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoas... BeFree 24857351 Detail
<0.001 Papillary thyroid carcinoma Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with ... BeFree 18470905 Detail
<0.001 melanoma AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in mel... BeFree 24201813 Detail
0.002 pleomorphic xanthoastrocytoma BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and... BeFree 21479234 Detail
0.236 melanoma They also suggest that targeting the MAPKs and/or NRAS may provide a strategy to... BeFree 25063807 Detail
0.029 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
0.325 Papillary thyroid carcinoma Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid... BeFree 24612623 Detail
<0.001 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
0.002 Thyroid carcinoma Fourteen tumours (52%) had somatic mutations: BRAF-V600E mutation was observed i... BeFree 18310288 Detail
<0.001 hairy cell leukemia RAF is among the most frequently mutated kinases, where BRAF V600E mutation occu... BeFree 25034364 Detail
0.020 melanoma This tumour-specific inhibition of ERK signalling results in a broad therapeutic... BeFree 22113612 Detail
0.325 Papillary thyroid carcinoma We identified two miRNAs that are differentially expressed in PTC tissues with B... BeFree 23416953 Detail
0.018 Malignant tumor of colon BRAF V600E was associated with advanced TNM (P &lt; 0.001), more distant metasta... BeFree 25367198 Detail
<0.001 leukemia We assessed phospho-ERK expression in 37 patients with hairy cell leukemia and 4... BeFree 23349307 Detail
0.060 Thyroid carcinoma The aim of this study was to determine whether combined detection of BRAF(V600E)... BeFree 24588959 Detail
<0.001 hairy cell leukemia RAF is among the most frequently mutated kinases, where BRAF V600E mutation occu... BeFree 25034364 Detail
0.132 hairy cell leukemia We conclude that the presence of pERK as detected by immunohistochemical stainin... BeFree 23211289 Detail
0.032 Malignant neoplasm of thyroid BRAF(T1799A) mutation is the most prevalent genetic alteration in thyroid cancer... BeFree 22504197 Detail
0.431 melanoma RAF is among the most frequently mutated kinases, where BRAF V600E mutation occu... BeFree 25034364 Detail
0.049 Metastatic melanoma A 75-year-old woman was diagnosed with a BRAF V600E mutated metastatic melanoma. BeFree 25185693 Detail
0.322 Colorectal Neoplasms To verify the technical characteristics of the microarray system for the correct... BeFree 23536897 Detail
0.060 Thyroid carcinoma Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papil... BeFree 17972530 Detail
<0.001 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
<0.001 melanoma CAST-PCR gave rapid and accurate results for the common V600E and V600K mutation... BeFree 23584600 Detail
0.032 Malignant neoplasm of thyroid The Korean population has a high iodine intake, high prevalence of BRAF V600E mu... BeFree 23427907 Detail
0.016 Colorectal cancer metastatic Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E... BeFree 20485284 Detail
0.274 colorectal cancer BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers... BeFree 15342696 Detail
0.274 colorectal cancer The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests ... BeFree 15782118 Detail
<0.001 Neurofibromatoses Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS muta... BeFree 23190154 Detail
0.004 colorectal carcinoma Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in... BeFree 17065421 Detail
<0.001 Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse The performance of the BRAF V600E-specific VE1 antibody was compared with that o... BeFree 25511147 Detail
0.104 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.431 melanoma These results suggest that combination of selective BRAF inhibitors with ABT-737... BeFree 23087082 Detail
<0.001 Papillary thyroid carcinoma We found that BRAF(V600E) mutation occurs selectively in PTC nodules and is asso... BeFree 21903858 Detail
<0.001 Thyroid carcinoma The negative regulators of the cell cycle, p21 and p27, are strongly induced by ... BeFree 21249150 Detail
0.325 Papillary thyroid carcinoma Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurren... BeFree 21594703 Detail
0.015 melanoma In this study, we utilised genetically engineered melanoma cell lines and xenogr... BeFree 25117819 Detail
0.012 Papillary thyroid carcinoma Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurre... BeFree 23806056 Detail
0.002 Metastatic melanoma The development of RAF inhibitors targeted against BRAF V600E mutant melanoma ce... BeFree 23174497 Detail
0.017 Cutaneous Melanoma BRAF(V600E) mutations in primary cutaneous melanomas were associated with reside... BeFree 25048604 Detail
0.431 melanoma Cell sensitivity to PLX4032 was dependent on BRAF(V600E) and independent from ot... BeFree 22241959 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
<0.001 keratoacanthoma RAF inhibitors are effective against melanomas with BRAF V600E mutations but may... BeFree 22067401 Detail
0.325 Papillary thyroid carcinoma The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients ... BeFree 23253715 Detail
0.325 Papillary thyroid carcinoma The results of the present study provide encouraging data supporting the possibi... BeFree 23788690 Detail
0.029 melanoma MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased product... BeFree 16801397 Detail
0.001 adenoma Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. BeFree 23825589 Detail
0.018 melanoma Our findings highlight the role of BRAF(V600E) in activating the stroma and sugg... BeFree 25117819 Detail
0.431 melanoma In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four paren... BeFree 25300205 Detail
0.014 melanoma The reactivation of senescence features and elimination of cells refractory to B... BeFree 22549727 Detail
<0.001 tuberous sclerosis The diagnostic subgroups of tuberous sclerosis complex were not correlated with ... BeFree 25346165 Detail
0.431 melanoma To examine the association between level and patterns of baseline intra-tumoural... BeFree 23403819 Detail
0.002 Thyroid carcinoma BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.015 melanoma Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. BeFree 18715233 Detail
0.005 Epithelial ovarian cancer A patient with V600E BRAF-mutant melanoma and another with platinum-refractory e... BeFree 25370471 Detail
0.244 Adenocarcinoma of lung (disorder) The histopathology of BRAF-V600E-mutated lung adenocarcinoma. BeFree 18636014 Detail
0.023 Melanocytic nevus The absence of the BRAF V600E mutation within a changing naevus supports the the... BeFree 25380183 Detail
0.001 Malignant neoplasm of endometrium Analysis of a correlation between the BRAF V600E mutation and abnormal DNA misma... BeFree 19424571 Detail
0.023 Melanocytic nevus To investigate whether the frequency of the BRAF(V600E) (V-raf murine sarcoma vi... BeFree 16691193 Detail
0.431 melanoma In order to better understand the mechanistic basis for this resistance, we cond... BeFree 21527556 Detail
0.082 colorectal carcinoma Specific KRAS mutation is an informative prognostic factor in both sporadic and ... BeFree 20162668 Detail
0.003 glioblastoma These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V60... BeFree 24894018 Detail
<0.001 Colonic Neoplasms The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. BeFree 24244575 Detail
0.252 Papillary thyroid carcinoma Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurre... BeFree 23806056 Detail
0.325 Papillary thyroid carcinoma Surgery was recommended to all 45 patients with BRAF(V600E) mutation-positive AC... BeFree 21239517 Detail
0.325 Papillary thyroid carcinoma BRAF V600E does not predict aggressive features of pediatric papillary thyroid c... BeFree 24604709 Detail
0.012 colorectal cancer We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell... BeFree 23251002 Detail
0.274 colorectal cancer High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutati... BeFree 25176643 Detail
<0.001 Invasive Skin Melanoma Somatic BRAF(V600E) and NRAS(Q61R) mutations of 127 primary invasive melanomas f... BeFree 25048604 Detail
0.281 Mastocytosis, Systemic Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis. BeFree 25034364 Detail
0.002 colorectal carcinoma Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in... BeFree 17065421 Detail
0.431 melanoma Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V60... BeFree 18790768 Detail
<0.001 Carcinoma, Papillary BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.021 Thyroid carcinoma Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
<0.001 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.003 Thyroid Diseases The incidence of BRAF(V600E) was studied in 85 microdissected cases of IM detect... BeFree 17542667 Detail
0.001 Astrocytoma The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF... BeFree 24132923 Detail
0.001 Secondary malignant neoplasm of lymph node Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p &lt; 0.01), ... BeFree 21879273 Detail
<0.001 Pancreatic intraepithelial neoplasia Here, we show that expression of BRAF(V600E), but not PIK3CA(H1047R), in the mou... BeFree 22628411 Detail
0.002 melanoma We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; ... BeFree 22791410 Detail
0.274 colorectal cancer Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2... BeFree 18806830 Detail
0.431 melanoma Assessment of association between BRAF-V600E mutation status in melanomas and cl... BeFree 22382362 Detail
0.325 Papillary thyroid carcinoma In conclusion, the present study on the first Italian series of thyroid cancers ... BeFree 15272920 Detail
0.325 Papillary thyroid carcinoma The two groups did not show significant differences in clinical and prognostic f... BeFree 20447069 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression level... BeFree 20473281 Detail
0.288 Thyroid Neoplasm The aim of the study was to explore TERT promoter mutations in various thyroid t... BeFree 24617711 Detail
0.329 Hereditary Nonpolyposis Colorectal Cancer The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CR... BeFree 17942460 Detail
0.001 Central Nervous System Neoplasms These findings suggest that CNS tumors with BRAF(V600E) are autophagy-dependent ... BeFree 24823863 Detail
<0.001 Central Nervous System Neoplasms We evaluated CNS tumor cells with BRAF(V600E) and found that mutant (but not wil... BeFree 24823863 Detail
<0.001 prolymphocytic leukemia Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolym... BeFree 22230299 Detail
0.004 Secondary malignant neoplasm of lymph node Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with ... BeFree 18470905 Detail
0.020 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
0.017 Secondary malignant neoplasm of lymph node Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with ... BeFree 18470905 Detail
0.002 Neoplasm Metastasis In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.003 differentiated thyroid gland carcinoma We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7... BeFree 25121551 Detail
0.126 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.431 melanoma The V600E mutation of BRAF was initially described in 2002 and has been found at... BeFree 23406774 Detail
<0.001 dysembryoplastic neuroepithelial tumor In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expr... BeFree 23442159 Detail
<0.001 Brain Neoplasms The two most commonly observed alterations in BRAF in patients with brain tumor ... BeFree 24857135 Detail
0.160 colorectal cancer Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.125 Carcinoma of lung The incidence of BRAF mutations other than V600E is significantly higher in lung... BeFree 21483012 Detail
0.001 acute promyelocytic leukemia Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.325 Papillary thyroid carcinoma Diagnostically, the BRAF(V600E) mutation is a powerful molecular marker for papi... BeFree 22369373 Detail
<0.001 Metastatic malignant neoplasm to brain MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplific... BeFree 25073704 Detail
<0.001 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.027 Thyroid Nodule To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (F... BeFree 17727338 Detail
0.004 Turcot syndrome (disorder) All patients underwent tumor microsatellite instability analysis and immunostain... BeFree 18061181 Detail
<0.001 Leukemoid reaction Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastati... BeFree 25576527 Detail
0.015 Malignant neoplasm of lung BRAF V600E is an emerging drug target in lung cancer, but the clinical significa... BeFree 24035431 Detail
0.018 Malignant tumor of colon Sorafenib and cetuximab therapy led to a mixed radiographic response with some a... BeFree 23792568 Detail
0.240 Malignant neoplasm of breast Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.055 Neoplasm Metastasis In this study, the occurrence and percentage of the BRAF V600E mutated allele wa... BeFree 23533235 Detail
0.001 diffuse astrocytoma A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A5... BeFree 22568401 Detail
<0.001 juvenile pilocytic astrocytoma AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-... BeFree 20806365 Detail
0.017 Secondary malignant neoplasm of lymph node We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of t... BeFree 18360353 Detail
0.325 Papillary thyroid carcinoma Among these, the recently identified BRAF(V600E) mutation has been found at high... BeFree 17186541 Detail
0.060 Thyroid carcinoma Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS... BeFree 24243688 Detail
<0.001 Hereditary Melanoma We therefore conclude that the common somatic BRAF mutation V599E does not contr... BeFree 12794760 Detail
0.032 Malignant neoplasm of thyroid These data clearly confirm that BRAF(V599E) is the more common genetic alteratio... BeFree 15126572 Detail
0.132 hairy cell leukemia We investigated BRAF mutations in 36 subjects with different forms of SM, but co... BeFree 25034364 Detail
0.002 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.132 hairy cell leukemia Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, ... BeFree 22313586 Detail
0.144 Carcinogenesis The presence of BRAF V600E and mitogen-activated protein kinase activation in a ... BeFree 22727996 Detail
0.017 Secondary malignant neoplasm of lymph node The BRAF(V600E) mutation, BRAF V600E IHC, low ΔCt, and high BRAF RNA ISH were si... BeFree 25468810 Detail
0.001 benign neoplasm Human naevi (moles) are benign tumours of melanocytes that frequently harbour on... BeFree 16079850 Detail
0.132 hairy cell leukemia Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell ... BeFree 26071465 Detail
0.074 colorectal carcinoma This improved classification of serrated lesions including immunohistochemical e... BeFree 23887306 Detail
0.060 Thyroid carcinoma Fourteen tumours (52%) had somatic mutations: BRAF-V600E mutation was observed i... BeFree 18310288 Detail
0.049 Metastatic melanoma In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRA... BeFree 22037033 Detail
0.431 melanoma In conclusion, the T1799A BRAF mutation is present in a proportion of posterior ... BeFree 18985043 Detail
0.074 colorectal carcinoma Promoter methylation of Wnt5a is associated with microsatellite instability and ... BeFree 21587258 Detail
0.274 colorectal cancer The reference tumor group contained 28 HNPCC with proven germ-line mutations or ... BeFree 17545526 Detail
<0.001 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
0.049 Metastatic melanoma Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic... BeFree 23211290 Detail
0.006 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.325 Papillary thyroid carcinoma In monoclonal BRAF V600E-positive mPTCs, BRAF V600E is not always present in all... BeFree 18393366 Detail
0.074 colorectal carcinoma In addition, the combination of microsatellite instability testing, MLH1 promote... BeFree 18556776 Detail
0.082 colorectal carcinoma Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) pati... BeFree 23792567 Detail
0.074 colorectal carcinoma BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. BeFree 23650027 Detail
0.049 Metastatic melanoma Recent breakthroughs in the treatment of metastatic melanoma have arisen as a re... BeFree 22723080 Detail
0.017 Secondary malignant neoplasm of lymph node The results showed that the BRAF (V600E) mutation was associated with extra-thyr... BeFree 24389984 Detail
0.016 Colorectal cancer metastatic BRAF V600E mutation is a poor prognostic factor in MSI-H metastatic CRC. BeFree 24585723 Detail
0.016 melanoma Apollon modulation and melanoma apoptosis were evaluated by Western blot and/or ... BeFree 22553342 Detail
0.002 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
<0.001 Metastatic melanoma NFAT2 and 4 are expressed in human metastatic melanoma cell lines and are activa... BeFree 19724275 Detail
0.015 melanoma These results provide a conceptual framework for the combined deployment of BRAF... BeFree 25472943 Detail
0.329 Glioma In this study a retrospective cohort of 198 pediatric low-grade gliomas (includi... BeFree 22492957 Detail
0.001 melanoma Pharmacologic inhibition of BRAF(V600E) in human melanoma cell lines resulted in... BeFree 23935925 Detail
0.006 Thyroid carcinoma We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines ... BeFree 19880792 Detail
0.004 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
0.001 Malignant melanoma of conjunctiva To gain a better understanding of the molecular events leading to the developmen... BeFree 16123397 Detail
0.216 Colorectal Neoplasms Evaluation of high-resolution melting analysis as a diagnostic tool to detect th... BeFree 19213871 Detail
0.325 Papillary thyroid carcinoma Incorporating the use of the recently identified BRAF V600E point mutation, a hi... BeFree 17159251 Detail
0.003 melanoma SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway i... BeFree 15313890 Detail
<0.001 glioblastoma A valine-to-glutamic acid substitution at position 600 of the serine/threonine-p... BeFree 24894018 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
<0.001 Primary Lesion We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases ... BeFree 25755776 Detail
0.036 Colonic Neoplasms A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors. BeFree 24503755 Detail
0.018 Malignant tumor of colon Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mut... BeFree 17293392 Detail
0.252 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.057 Colorectal cancer metastatic Here we report the first clinical evidence that the combination of an anti-EGFR ... BeFree 24755613 Detail
<0.001 Thyroid Nodule To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (F... BeFree 17727338 Detail
<0.001 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
0.431 melanoma Furthermore, we identify TP53/Trp53 as a UVR-target gene that cooperates with BR... BeFree 24919155 Detail
0.060 Thyroid carcinoma We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in the... BeFree 22090271 Detail
0.431 melanoma Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Pat... BeFree 25980594 Detail
0.325 Papillary thyroid carcinoma Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papill... BeFree 21803329 Detail
0.274 colorectal cancer BRAF mutation (V600E) is found in MSI colorectal cancers. BeFree 19289622 Detail
0.029 melanoma This focus has been justified by the recent success of BRAF and MEK inhibitors i... BeFree 24352648 Detail
0.002 Malignant neoplasm of thyroid PCCL3 cells conditionally expressing RET/PTC3, HRAS(G12V), or BRAF(V600E) and hu... BeFree 25029414 Detail
0.060 Thyroid carcinoma Notch functions as an oncogene or tumor suppressor according to the type of mali... BeFree 22118425 Detail
0.132 Astrocytoma Our findings indicate a rational therapeutic strategy for treating a subset of p... BeFree 22586120 Detail
<0.001 IMMUNE SUPPRESSION This study evaluated the relationship between BRAF(V600E) status and known strat... BeFree 24955518 Detail
0.431 melanoma Both conventional melanomas had the exon 15 T1796A (V599E) mutation, but none of... BeFree 15588860 Detail
0.001 Malignant neoplasm of thyroid This study investigated the therapeutic potential of a BRAF(V600E)-selective inh... BeFree 21185263 Detail
0.055 adenocarcinoma We analyzed 29 gallbladder carcinomas (9 papillary and 20 nonpapillary adenocarc... BeFree 21307665 Detail
0.032 Malignant neoplasm of thyroid They also potently blocked MEK phosphorylation in human thyroid cancer cell line... BeFree 16551863 Detail
0.144 Carcinogenesis Conclusions.-The T1799A BRAF mutation does not appear to play a role in the tumo... BeFree 19415957 Detail
0.021 melanoma Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V60... BeFree 18790768 Detail
<0.001 hypothyroidism One month following BRAF(V600E) expression, mice displayed increased thyroid siz... BeFree 21512141 Detail
0.015 adenocarcinoma KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 met... BeFree 21457162 Detail
<0.001 inflammatory myofibroblastic tumor In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a p... BeFree 20393746 Detail
0.001 Malignant neoplasm of thyroid Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A n... BeFree 23931930 Detail
0.032 Malignant neoplasm of thyroid (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadher... BeFree 23435375 Detail
0.431 melanoma Immunohistochemical detection of the BRAF V600E mutation in melanoma patients wi... BeFree 25359093 Detail
0.325 Papillary thyroid carcinoma The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of pa... BeFree 24721322 Detail
<0.001 Thyroid carcinoma Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A n... BeFree 23931930 Detail
0.431 melanoma RAF inhibitors are effective against melanomas with BRAF V600E mutations but may... BeFree 22067401 Detail
0.012 melanoma In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four paren... BeFree 25300205 Detail
<0.001 melanoma BRAF(V600E) mutation confers constitutive BRAK kinase activation in melanoma cel... BeFree 24259661 Detail
0.001 Serrated polyp The absence of the BRAF(V600E) mutation does not support a role for the serrated... BeFree 24894811 Detail
<0.001 Papillary thyroid carcinoma Additionally, preclinical and clinical studies investigating combination therapy... BeFree 21900390 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.001 Carcinoma, Endometrioid This study hypothesized that the BRAF V600E mutation may be associated with muci... BeFree 23370429 Detail
0.004 sarcoma To investigate whether the frequency of the BRAF(V600E) (V-raf murine sarcoma vi... BeFree 16691193 Detail
0.055 Neoplasm Metastasis Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation,... BeFree 25584719 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) mutation is a useful diagnostic marker for differentiating papil... BeFree 21707687 Detail
0.060 Thyroid carcinoma Histopathological analysis ascertained that all BRAF(V600E)-positive cases were ... BeFree 18462259 Detail
<0.001 Hurthle Cell Tumor We investigated 7 spindle cell oncocytomas, 4 pituicytomas, and 3 granular cell ... BeFree 23887161 Detail
0.325 Papillary thyroid carcinoma Activating mutations in the BRAF gene, primarily at V600E, are associated with p... BeFree 17878251 Detail
0.001 Central Nervous System Neoplasms These findings suggest CNS tumors with BRAF(V600E) are autophagy-dependent and t... BeFree 25484091 Detail
0.074 colorectal carcinoma High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutati... BeFree 25176643 Detail
0.160 colorectal cancer Through an RNAi screen, here we identify the transcriptional repressor MAFG as t... BeFree 25219500 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
<0.001 Non-Neoplastic Disorder One-hundred and twenty-nine papillary thyroid microcarcinomas were tested for BR... BeFree 22918165 Detail
<0.001 Papillary Thyroid Microcarcinoma BRAF V600E and decreased NIS and TPO expression are associated with aggressivene... BeFree 26338373 Detail
0.020 Papillary thyroid carcinoma The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%... BeFree 21498916 Detail
0.325 Papillary thyroid carcinoma Unlike the most common BRAF mutation seen in PTC carcinoma (BRAF(V600E)), this p... BeFree 22136270 Detail
0.002 Progressive Neoplastic Disease Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for resp... BeFree 16880785 Detail
0.431 melanoma Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. BeFree 18715233 Detail
0.192 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.055 Neoplasm Metastasis All patients with lateral cervical node metastasis (n=9), and all but one tumor ... BeFree 22918165 Detail
0.027 Thyroid Nodule The molecular tests on the thyroid nodule revealed the presence of BRAF-V600E mu... BeFree 23200790 Detail
0.325 Papillary thyroid carcinoma Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult... BeFree 21512141 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle ... BeFree 21774961 Detail
<0.001 IMMUNE SUPPRESSION This study reveals a novel mechanism of immune suppression sensitive to BRAF(V60... BeFree 22850568 Detail
<0.001 melanoma MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplific... BeFree 25073704 Detail
0.060 Thyroid carcinoma The BRAF V600E mutation is the most common genetic alteration in thyroid cancer. BeFree 25266729 Detail
0.431 melanoma Of the drugs tested to date in patients with metastatic melanoma, those that hav... BeFree 22261672 Detail
0.012 melanoma Effective inhibition of cell growth and invasion of melanoma by combined suppres... BeFree 16052531 Detail
0.325 Papillary thyroid carcinoma We used pyrosequencing, peptide nucleic acid (PNA)-clamping polymerase chain rea... BeFree 23690118 Detail
0.431 melanoma Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is ... BeFree 22355009 Detail
0.008 Anaplastic thyroid carcinoma First, absent/faint staining for BRAF V600E correlates perfectly with the lack o... BeFree 23775351 Detail
0.325 Papillary thyroid carcinoma NA CLINVAR Detail
0.055 Neoplasm Metastasis BRAF V600E mutation in papillary thyroid carcinoma: significant association with... BeFree 22105775 Detail
0.274 colorectal cancer We show that activation of the PI3K/AKT pathway is a mechanism of both innate an... BeFree 23251002 Detail
0.060 Thyroid carcinoma This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patie... BeFree 22105775 Detail
0.325 Papillary thyroid carcinoma Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyr... BeFree 22524468 Detail
0.616 Gastrointestinal Stromal Tumors V600E BRAF mutations are alternative early molecular events in a subset of KIT/P... BeFree 19561230 Detail
0.431 melanoma Here we have used a zebrafish melanoma model to test genes in a recurrently ampl... BeFree 21430779 Detail
0.060 Thyroid carcinoma Our results suggest that hypoxia-inducible factor-1alpha is expressed in papilla... BeFree 20473281 Detail
0.002 melanoma Analysis of frozen and fixed material from 21 CCS and 21 MM showed the presence ... BeFree 22045652 Detail
0.060 Thyroid carcinoma The inability of MEK and RAF inhibitors, U0126 and sorafenib, respectively, to b... BeFree 20926530 Detail
0.082 colorectal carcinoma The current data showed instead that the BRAF V599E mutation was associated only... BeFree 16015629 Detail
0.049 Metastatic melanoma The US Food and Drug Administration (FDA) approved vemurafenib to treat patients... BeFree 23273605 Detail
0.001 ganglioglioma In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expr... BeFree 23442159 Detail
<0.001 melanoma Preclinical studies revealed that GLV-1h68 combined with radiotherapy significan... BeFree 23624923 Detail
0.003 nodular goiter BRAF(V600E) allele was detected and quantified by an allele-specific real-time q... BeFree 23788690 Detail
0.325 Papillary thyroid carcinoma Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, high... BeFree 18310286 Detail
<0.001 melanoma BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. BeFree 24858900 Detail
0.009 Hashimoto Disease Screening for activating BRAF mutations in a series of 83 PTCs identified the mo... BeFree 18426810 Detail
0.160 colorectal cancer Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) pati... BeFree 23792567 Detail
<0.001 pleomorphic xanthoastrocytoma Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoas... BeFree 24857351 Detail
0.027 Thyroid Nodule To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the F... BeFree 17054470 Detail
0.002 Central neuroblastoma To explore the mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus o... BeFree 21430505 Detail
0.129 Glioma However, a previous study on BRAF V600E mutation in paediatric glioma revealed a... BeFree 23822828 Detail
0.431 melanoma Analysis of the BRAF V600E mutation in primary cutaneous melanoma. BeFree 24535907 Detail
0.001 Secondary malignant neoplasm of lung Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in p... BeFree 25837167 Detail
0.002 Thyroid carcinoma We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl... BeFree 16533790 Detail
0.325 Papillary thyroid carcinoma The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as... BeFree 23533235 Detail
0.027 Thyroid Nodule The BRAF(V600E) mutation is associated with malignant ultrasonographic features ... BeFree 21707687 Detail
0.431 melanoma The BRAF(V600E) causes widespread alterations in gene methylation in the genome ... BeFree 22189819 Detail
0.057 Colorectal cancer metastatic Recent studies in metastatic colorectal cancer found that an oncogenic activatio... BeFree 19547661 Detail
0.049 Metastatic melanoma A combination of dabrafenib and trametinib, as compared with dabrafenib alone, i... BeFree 25265492 Detail
0.132 hairy cell leukemia The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms... BeFree 22072557 Detail
0.032 Malignant neoplasm of thyroid Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.179 Papillary thyroid carcinoma Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirate... BeFree 15859312 Detail
0.431 melanoma In the current review, we discuss how knowledge about these new melanoma subgrou... BeFree 19351826 Detail
<0.001 Benign thyroid nodule We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7... BeFree 25121551 Detail
0.004 melanoma Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. BeFree 23802768 Detail
0.005 melanoma MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplific... BeFree 25073704 Detail
0.017 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.011 melanoma In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase ... BeFree 20425073 Detail
0.216 Colorectal Neoplasms Recently, a V599E hotspot mutation within the BRAF gene was reported in a high p... BeFree 14668801 Detail
0.055 Neoplasm Metastasis BRAF V600E also predicts poor prognosis in microsatellite stable colorectal canc... BeFree 23650027 Detail
0.135 colon carcinoma These data suggest that the BRAF V600E mutation is not the target gene for abnor... BeFree 19424571 Detail
0.325 Papillary thyroid carcinoma It has been suggested that patients with papillary thyroid cancer (PTC) harbouri... BeFree 22702340 Detail
0.012 Papillary thyroid carcinoma After surgery, 115 nodules were confirmed as conventional papillary thyroid carc... BeFree 25111330 Detail
0.325 Papillary thyroid carcinoma The large BRAF V600E neoplastic cell subpopulations found in mutated cases is co... BeFree 24780046 Detail
0.131 Non-small cell lung carcinoma BRAF V600E mutations: a series of case reports in patients with non-small cell l... BeFree 26066373 Detail
0.431 melanoma In a patient (whose melanoma showed to bear the BRAF V600E mutation in blood, bu... BeFree 21570823 Detail
0.049 Metastatic melanoma While dabrafenib has demonstrated comparable efficacy to vemurafenib in BRAF V60... BeFree 23621583 Detail
0.003 Erdheim-Chester disease BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdhei... BeFree 25003820 Detail
0.014 melanoma Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma pro... BeFree 24425783 Detail
0.135 colon carcinoma Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of ... BeFree 24832158 Detail
0.016 Colorectal cancer metastatic Recent studies in metastatic colorectal cancer found that an oncogenic activatio... BeFree 19547661 Detail
0.431 melanoma Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromi... BeFree 23306863 Detail
0.002 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.015 colorectal cancer Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.004 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
0.003 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
0.017 melanoma We applied human immunodeficiency virus (HIV) lentivirus-mediated RNA interferen... BeFree 16052531 Detail
0.074 colorectal carcinoma A correlation between MLH1 promoter methylation, specifically the 'C' region, an... BeFree 23880961 Detail
0.002 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.027 Thyroid Nodule BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to ... BeFree 20187782 Detail
0.032 Malignant neoplasm of thyroid The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers. BeFree 17054470 Detail
<0.001 papillary craniopharyngioma Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngi... BeFree 24413733 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a... BeFree 18682506 Detail
0.049 Metastatic melanoma Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastat... BeFree 23051966 Detail
0.032 Malignant neoplasm of thyroid they were normally maintained hypomethylated and over-expressed by BRAF V600E in... BeFree 21937738 Detail
0.431 melanoma Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expres... BeFree 25063807 Detail
0.060 Thyroid carcinoma The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF... BeFree 22535974 Detail
0.020 melanoma To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, ... BeFree 23948972 Detail
0.002 Papillary microcarcinoma BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along wi... BeFree 19269016 Detail
0.431 melanoma BRAF V600E mutations are the most common found in melanoma; specific inhibitors ... BeFree 20412787 Detail
0.060 Thyroid carcinoma From September 2008 to December 2009, we performed routine analysis of the BRAF(... BeFree 21803329 Detail
0.431 melanoma BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and... BeFree 25117819 Detail
<0.001 Oncocytic Neoplasm A previous study identified BRAF V600E mutations in approximately 90% of MA and ... BeFree 25602792 Detail
0.002 Progressive cGVHD Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for resp... BeFree 16880785 Detail
0.002 Thyroid carcinoma PTC, the most frequent thyroid carcinoma histotype, is associated with gene rear... BeFree 23132790 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer To evaluate the role of oncogenic BRAF mutations in non-hereditary nonpolyposis ... BeFree 17119056 Detail
0.002 Sessile Serrated Adenoma/Polyp The BRAF V600E mutation is one of the most frequent molecular abnormalities iden... BeFree 26030242 Detail
0.121 peripheral T-cell lymphoma They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mut... BeFree 24689848 Detail
0.004 colorectal cancer In conclusion, miR-145 might be used as a therapeutic target in the treatment of... BeFree 24248543 Detail
0.431 melanoma Here, we show intralesional molecular heterogeneity in a progressing V600E BRAF-... BeFree 22962325 Detail
0.055 Neoplasm Metastasis BRAF(V600E) was characterized in 113 PTC patients diagnosed with pT1aNo-x (one P... BeFree 24354346 Detail
0.131 melanoma Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resista... BeFree 22588879 Detail
0.001 Papillary thyroid carcinoma We found that BRAF(V600E) mutation occurs selectively in PTC nodules and is asso... BeFree 21903858 Detail
0.179 Papillary thyroid carcinoma After surgery, 115 nodules were confirmed as conventional papillary thyroid carc... BeFree 25111330 Detail
0.129 Glioma Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF ... BeFree 24071017 Detail
0.018 Malignant tumor of colon The BRAF V600E mutation is reportedly associated with inferior survival among co... BeFree 25636897 Detail
0.015 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
0.086 Carcinoma, Papillary In our series, BRAF mutation was detected exclusively in papillary carcinoma (54... BeFree 16555627 Detail
0.567 Cardio-facio-cutaneous syndrome Germline mutation in BRAF codon 600 is compatible with human development: de nov... BeFree 20735442 Detail
0.274 colorectal cancer This improved classification of serrated lesions including immunohistochemical e... BeFree 23887306 Detail
0.325 Papillary thyroid carcinoma Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in pa... BeFree 21249150 Detail
0.001 Splenic Marginal Zone B-Cell Lymphoma BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-c... BeFree 25480661 Detail
0.135 colon carcinoma The BRAF V600E mutation is reportedly associated with inferior survival among co... BeFree 25636897 Detail
<0.001 Pancreatic intraepithelial neoplasia Here, we show that expression of BRAF(V600E), but not PIK3CA(H1047R), in the mou... BeFree 22628411 Detail
0.015 Astrocytoma Our findings indicate a rational therapeutic strategy for treating a subset of p... BeFree 22586120 Detail
0.134 pilocytic astrocytoma BRAF(V600E) was also seen in five of 11 (45%) non-brainstem GGs and one of eight... BeFree 24238153 Detail
0.017 Secondary malignant neoplasm of lymph node Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and... BeFree 23533235 Detail
0.020 melanoma RAF inhibitors are effective against melanomas with BRAF V600E mutations but may... BeFree 22067401 Detail
0.274 colorectal cancer BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in ... BeFree 23553055 Detail
0.005 Hereditary Nonpolyposis Colorectal Cancer HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of... BeFree 24196786 Detail
0.272 melanoma Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence ... BeFree 21725359 Detail
<0.001 colorectal carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.004 Papillary Thyroid Microcarcinoma Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E... BeFree 23370668 Detail
0.005 Benign melanocytic nevus Human naevi (moles) are benign tumours of melanocytes that frequently harbour on... BeFree 16079850 Detail
0.001 Cutaneous Melanoma To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, ... BeFree 23948972 Detail
0.012 Gastrointestinal Stromal Tumors Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V... BeFree 26486743 Detail
0.431 melanoma Our data indicate that the C57BL/6J Tyr::CreER(T2);PTEN(F-/-);BRAF(F-V600E/+) me... BeFree 22796458 Detail
0.325 Papillary thyroid carcinoma Quantification of BRAF V600E alleles predicts papillary thyroid cancer progressi... BeFree 25266729 Detail
0.016 Colorectal cancer metastatic Inadequate evidence was found regarding association of BRAF V600E mutation testi... BeFree 23429431 Detail
0.003 differentiated thyroid gland carcinoma These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FD... BeFree 25814520 Detail
<0.001 colorectal cancer Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
<0.001 Papillary Thyroid Microcarcinoma BRAF V600E and decreased NIS and TPO expression are associated with aggressivene... BeFree 26338373 Detail
0.060 Thyroid carcinoma Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24... BeFree 24382015 Detail
0.060 Thyroid carcinoma TERT promoter mutations and their association with BRAF V600E mutation and aggre... BeFree 24617711 Detail
0.020 Papillary thyroid carcinoma Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurre... BeFree 23806056 Detail
0.019 Neoplasm Metastasis Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E... BeFree 23416953 Detail
0.274 colorectal cancer The patient with SSL as index lesions who developed CRC harbored V600E BRAF muta... BeFree 25708741 Detail
0.325 Papillary thyroid carcinoma Of ten cases with diagnostic concomitant or incidental papillary carcinoma, thre... BeFree 20012784 Detail
0.024 colon carcinoma BRAF(V600E) efficient transformation and induction of microsatellite instability... BeFree 19881948 Detail
0.325 Papillary thyroid carcinoma Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid canc... BeFree 22435913 Detail
0.074 colorectal carcinoma Optimizing targeted therapeutic development: analysis of a colorectal cancer pat... BeFree 20635392 Detail
0.325 Papillary thyroid carcinoma Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advance... BeFree 24382015 Detail
0.003 differentiated thyroid gland carcinoma BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had ide... BeFree 17989125 Detail
0.244 Adenocarcinoma of lung (disorder) BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding t... BeFree 24888229 Detail
0.032 Malignant neoplasm of thyroid Overall, BRAF(V600E) PTC tumors display a broadly immunosuppressive profile and ... BeFree 24955518 Detail
0.325 Papillary thyroid carcinoma The association of the BRAF(V600E) mutation with prognostic factors and poor cli... BeFree 21882184 Detail
0.160 colorectal cancer Thus, large-scale KRAS mutation screening is needed for efficient patient manage... BeFree 21516079 Detail
0.002 colorectal carcinoma Promoter methylation of Wnt5a is associated with microsatellite instability and ... BeFree 21587258 Detail
0.431 melanoma We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; ... BeFree 22791410 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation has emerged as a marker of aggressive behavior in papillary... BeFree 22918165 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) mutation, the most common genetic alteration reported in papilla... BeFree 16268813 Detail
0.325 Papillary thyroid carcinoma Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohisto... BeFree 25468810 Detail
0.003 ganglioglioma BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/gan... BeFree 23822828 Detail
0.012 colorectal carcinoma Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
0.049 Metastatic melanoma Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. BeFree 25257244 Detail
0.060 Thyroid carcinoma Reduction of false-negative papillary thyroid carcinomas by the routine analysis... BeFree 22504197 Detail
0.274 colorectal cancer We show MCC expression is dramatically decreased in many CRC cell lines and the ... BeFree 18591935 Detail
0.027 Thyroid Nodule We calculated and compared the diagnostic performances of DPO-PCR and real-time ... BeFree 22964613 Detail
0.032 Malignant neoplasm of thyroid Immunohistochemical detection of mutated BRAF V600E supports the clonal origin o... BeFree 23775351 Detail
0.325 Papillary thyroid carcinoma Clinical and pathological features and the BRAF(V600E) mutation in patients with... BeFree 19014278 Detail
0.431 melanoma The v-raf murine sarcoma viral oncogene homolog B1 V600E mutant melanoma cell li... BeFree 26124322 Detail
0.325 Papillary thyroid carcinoma Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma i... BeFree 19475551 Detail
0.017 Secondary malignant neoplasm of lymph node Only one BRAF(V600E) negative case has shown extrathyroidal extension and lymph ... BeFree 22767446 Detail
0.431 melanoma PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and... BeFree 20149136 Detail
0.001 benign neoplasm The presence of BRAF V600E and mitogen-activated protein kinase activation in a ... BeFree 22727996 Detail
0.007 Neoplasm Metastasis Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation,... BeFree 25584719 Detail
0.002 Metastatic melanoma B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progres... BeFree 22726224 Detail
0.029 melanoma These data suggest that regulation of BIM expression by BRAF--&gt;MEK--&gt;ERK s... BeFree 18715233 Detail
0.012 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.132 hairy cell leukemia Discovery of the BRAF V600E mutation as a disease-defining genetic event in hair... BeFree 24789721 Detail
0.055 Neoplasm Metastasis They include BRAF(V600E) and AKT that affect tumor initiation, progression and m... BeFree 24362526 Detail
0.144 Carcinogenesis The high frequency of methylation and BRAF V600E mutation suggests that many sig... BeFree 22522845 Detail
0.132 hairy cell leukemia The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of ha... BeFree 25511150 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroi... BeFree 24267957 Detail
0.431 melanoma CAST-PCR gave rapid and accurate results for the common V600E and V600K mutation... BeFree 23584600 Detail
0.017 melanoma These results provide a conceptual framework for the combined deployment of BRAF... BeFree 25472943 Detail
0.325 Papillary thyroid carcinoma An association between a BRAF(V600E) mutation and upregulation of mitogen-activa... BeFree 23544999 Detail
0.018 Malignant tumor of colon In microsatellite stable tumors, homozygous carriers of the G39E polymorphism ha... BeFree 19582761 Detail
0.001 Thyroid carcinoma BRAF(V600E) mutation and p27(kip1) expression have been introduced as novel indi... BeFree 17685465 Detail
0.060 Thyroid carcinoma The relationship of the BRAF(V600E) mutation and the established prognostic fact... BeFree 22767446 Detail
0.002 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.017 Secondary malignant neoplasm of lymph node Of the patients with diffuse FVPTC, all had central lymph node metastasis (P &lt... BeFree 22431868 Detail
0.002 Papillary thyroid carcinoma The T1799A missense mutation in exon 15 of the BRAF gene and RET/PTC rearrangeme... BeFree 17464312 Detail
0.236 melanoma Mutation in BRAF and NRAS was present in 43% (88% V600E, 10% V600K) and 30% (48%... BeFree 23855428 Detail
0.002 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.017 Secondary malignant neoplasm of lymph node Mutational patterns identical to those in the primary tumors were found in 11/12... BeFree 17044028 Detail
0.036 Colonic Neoplasms To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V6... BeFree 22281684 Detail
<0.001 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.017 Secondary malignant neoplasm of lymph node Multivariate analysis showed that BRAF V600E mutation [OR (95% CI) = 4.2 (1.2-14... BeFree 17717450 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%... BeFree 21498916 Detail
0.001 Malignant melanoma of conjunctiva Multiplex ligation-dependent probe amplification of conjunctival melanoma reveal... BeFree 21693616 Detail
<0.001 fibrosarcoma Similar targeting of BRAF(V599E) or wild-type BRAF in human fibrosarcoma cells t... BeFree 14500344 Detail
0.017 Secondary malignant neoplasm of lymph node BRAF(V600E) mutation-positive cancers (55.3%) were more frequently associated wi... BeFree 24787545 Detail
0.431 melanoma A patient with V600E BRAF-mutant melanoma and another with platinum-refractory e... BeFree 25370471 Detail
0.109 Thyroid carcinoma Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.032 Malignant neoplasm of thyroid Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A n... BeFree 23931930 Detail
0.325 Papillary thyroid carcinoma The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid ca... BeFree 18202121 Detail
0.004 Carcinogenesis Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mut... BeFree 21185263 Detail
0.060 Thyroid carcinoma Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V60... BeFree 19207009 Detail
0.325 Papillary thyroid carcinoma BRAF V600E and TERT promoter mutations cooperatively identify the most aggressiv... BeFree 25024077 Detail
<0.001 Congenital chromosomal disease However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/... BeFree 22558328 Detail
0.055 Neoplasm Metastasis In contrast, age- and size-matched classic papillary microcarcinomas (n=26) show... BeFree 23682579 Detail
0.074 melanoma Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma ... BeFree 19659611 Detail
0.055 Neoplasm Metastasis The utility of immunohistochemistry (IHC) as an alternative approach for detecti... BeFree 24798160 Detail
0.001 Colorectal cancer metastatic These data suggest that combined therapy with RAF and EGFR inhibitors could be a... BeFree 25589621 Detail
0.001 Congenital chromosomal disease However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/... BeFree 22558328 Detail
0.029 Colonic Neoplasms A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors. BeFree 24503755 Detail
0.132 hairy cell leukemia The thymidine kinase inhibitor vemurafenib, which inhibits the V600E mutant of B... BeFree 23892906 Detail
<0.001 rhabdoid meningioma Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to per... BeFree 25116269 Detail
0.431 melanoma The discovery of activating BRAF V600E mutations in 50% of all melanoma patients... BeFree 21505227 Detail
0.074 colorectal carcinoma The V600E mutation of BRAF was initially described in 2002 and has been found at... BeFree 23406774 Detail
0.325 Papillary thyroid carcinoma Taken together, BRAF V600E is common in Finnish patients with low-risk PTC but d... BeFree 22515292 Detail
0.002 Thyroid carcinoma BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
<0.001 Papillary thyroid carcinoma miR-21* and 203 were significantly dysregulated (P&lt;0.05) in PTC tissues with ... BeFree 23416953 Detail
0.060 Thyroid carcinoma The Korean population has a high iodine intake, high prevalence of BRAF V600E mu... BeFree 23427907 Detail
0.431 melanoma In this study, sensitive and quantitative BRAF V600E and V600K mutation-specific... BeFree 23499336 Detail
0.028 melanoma Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed... BeFree 20149136 Detail
0.049 Metastatic melanoma Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and met... BeFree 22235286 Detail
0.025 Malignant tumor of colon A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails ... BeFree 22393095 Detail
<0.001 Congenital chromosomal disease However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/... BeFree 22558328 Detail
<0.001 Papillary thyroid carcinoma BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cy... BeFree 23203004 Detail
0.179 Papillary thyroid carcinoma Similarly to the results obtained by others, there was no coexistence of BRAF (V... BeFree 17693984 Detail
0.011 Malignant neoplasm of thyroid Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.252 Papillary thyroid carcinoma After surgery, 115 nodules were confirmed as conventional papillary thyroid carc... BeFree 25111330 Detail
0.055 Neoplasm Metastasis We present a case of a 56-year old woman with a history of stage IIIA malignant ... BeFree 25576527 Detail
<0.001 subependymal giant cell astrocytoma BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and... BeFree 25346165 Detail
0.001 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.325 Papillary thyroid carcinoma Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyro... BeFree 23534744 Detail
0.055 adenocarcinoma BRAF V600E mutation and CpG island methylation phenotype-positive status are sim... BeFree 22522845 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation is not a positive predictor for distant metastasis in spora... BeFree 23981603 Detail
0.002 leukemia None of the 195 patients with other peripheral B-cell lymphomas or leukemias who... BeFree 21663470 Detail
0.074 colorectal carcinoma We hypothesized it would be more commonly methylated and inactivated in serrated... BeFree 25613750 Detail
0.060 Thyroid carcinoma BRAF V600E mutational status in pediatric thyroid cancer. BeFree 24677749 Detail
0.018 Malignant tumor of colon Poor survival associated with the BRAF V600E mutation in microsatellite-stable c... BeFree 16024606 Detail
0.325 Papillary thyroid carcinoma The BRAF(V600E) mutation influences the short- and medium-term outcomes of class... BeFree 24787545 Detail
0.074 colorectal carcinoma A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may ... BeFree 23657789 Detail
<0.001 Serrated adenocarcinoma In this study, we conducted immunohistochemical determination of BRAF V600E muta... BeFree 24722974 Detail
0.008 Anaplastic thyroid carcinoma Combined, these data demonstrate that the BRAF(V600E) cooperates with either PIK... BeFree 24770869 Detail
0.001 Central Nervous System Neoplasms BRAF V600E-mutations have been described in a modest 6% to 7% of primary central... BeFree 24725538 Detail
0.144 Carcinogenesis We propose that continuously activated BRAF(V600E) signaling may be a possible m... BeFree 22430208 Detail
0.074 melanoma Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, a... BeFree 19233913 Detail
<0.001 Giant Cell Tumors Histiocytic sarcoma exhibited the highest rate of BRAF(V600E) (62.5%, five of ei... BeFree 24720374 Detail
<0.001 Superficial spreading malignant melanoma of skin We further showed that BRAF, a downstream signaling molecule of ARMS in ERK path... BeFree 18089783 Detail
<0.001 Glioma Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoas... BeFree 24857351 Detail
0.017 Secondary malignant neoplasm of lymph node Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p &lt; 0.01), ... BeFree 21879273 Detail
0.431 melanoma Molecular studies demonstrated that the melanoma was positive for the 1799T&gt;A... BeFree 24220097 Detail
0.431 melanoma Immunohistochemistry is highly sensitive and specific for the detection of V600E... BeFree 23026937 Detail
0.017 Nevus All neoplastic melanocytes within such a nevus would be expected to carry the BR... BeFree 23690527 Detail
0.060 Thyroid carcinoma ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V... BeFree 23544999 Detail
0.023 Malignant tumor of colon The results of these studies suggest that combined treatment of BRAF(V600E)-driv... BeFree 23074264 Detail
<0.001 hairy cell leukemia Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mut... BeFree 22210875 Detail
0.004 Papillary Thyroid Microcarcinoma Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic feature... BeFree 23682579 Detail
<0.001 Multiple tumors We sought to examine the extent of intrapatient heterogeneity of BRAF(V600E) pro... BeFree 24335665 Detail
0.074 colorectal carcinoma BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRA... BeFree 19213871 Detail
0.027 Thyroid Nodule Outcome of thyroid nodules characterized as atypia of undetermined significance ... BeFree 24261392 Detail
0.431 melanoma The DDFI was significantly shorter in patients with BRAF(V600K/R) versus BRAF(V6... BeFree 24918823 Detail
0.431 melanoma We also report the X-ray crystal structure of a BRAF/quinolol complex revealing ... BeFree 22537109 Detail
0.020 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.006 Neoplasm Metastasis In this study we compared drug responses to RAF and MEK inhibitors on tumor cell... BeFree 26384551 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer The detection of a BRAF V600E mutation further supports the exclusion of HNPCC. BeFree 17545526 Detail
0.005 Brain Neoplasms Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. BeFree 24823863 Detail
0.001 Papillary thyroid carcinoma However, the expressions of c-Fos and PCNA were elevated in BRAF(V600E)-positive... BeFree 22535643 Detail
0.274 colorectal cancer Somatic BRAF-V600E mutations in familial colorectal cancer. BeFree 17119056 Detail
0.288 Thyroid Neoplasm These results reveal a novel (V600E)BRAF-induced mechanism in thyroid tumours pr... BeFree 23435375 Detail
0.008 Anaplastic thyroid carcinoma Molecular studies have shown that the BRAF V600E mutation is found mainly in pap... BeFree 21221869 Detail
0.126 pilocytic astrocytoma The data further support previous observations that these two alterations of the... BeFree 21884820 Detail
0.017 Secondary malignant neoplasm of lymph node The patients with BRAF p.Val600Glu mutation of primary tumour had only non-signi... BeFree 24839220 Detail
0.236 melanoma Besides confirming the presence of known melanoma driver mutations (BRAF(V600E),... BeFree 23704925 Detail
0.131 melanoma In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been ... BeFree 25654738 Detail
0.123 Papillary thyroid carcinoma The five conventional PTC cell lines carry the BRAF V600E mutation and the folli... BeFree 25427145 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of... BeFree 24196786 Detail
0.055 Neoplasm Metastasis The BRAF (V600E) mutation was associated with aggressive clinical behaviors incl... BeFree 23179992 Detail
0.129 Glioma Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF... BeFree 22038996 Detail
0.028 melanoma Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the d... BeFree 24710085 Detail
0.325 Papillary thyroid carcinoma Association of high iodine intake with the T1799A BRAF mutation in papillary thy... BeFree 19190105 Detail
0.274 colorectal cancer 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted th... BeFree 23341544 Detail
<0.001 Thyroid carcinoma Furthermore, ICAM-1 upregulation correlated with aggressive tumor features such ... BeFree 21879273 Detail
0.012 Papillary thyroid carcinoma Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurre... BeFree 23806056 Detail
0.029 melanoma MEK inhibitors are clinically active in BRAF(V600E) melanomas but only marginall... BeFree 24746704 Detail
0.003 ganglioglioma Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytoma... BeFree 23442159 Detail
0.325 Papillary thyroid carcinoma BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cy... BeFree 23203004 Detail
0.017 Secondary malignant neoplasm of lymph node The presence of PB was significantly correlated with tumor multifocality, extrat... BeFree 23716027 Detail
0.055 Neoplasm Metastasis We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom trea... BeFree 23036672 Detail
0.049 Metastatic melanoma Due to the BRAF (V600E) mutation in her tumor and her poor functional status, we... BeFree 24888229 Detail
0.431 melanoma The activating BRAF mutation V600E and related mutations in this codon are most ... BeFree 24756795 Detail
0.060 Thyroid carcinoma Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metast... BeFree 17387744 Detail
0.060 Thyroid carcinoma We developed an allele-specific real-time PCR method for the detection of BRAF(T... BeFree 19850689 Detail
<0.001 Congenital chromosomal disease However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/... BeFree 22558328 Detail
0.002 Papillary microcarcinoma Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma i... BeFree 19475551 Detail
0.060 Thyroid carcinoma Correlation between the BRAF V600E mutation and tumor invasiveness in papillary ... BeFree 20631031 Detail
0.074 colorectal carcinoma Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic s... BeFree 17065421 Detail
0.003 Thyroid Nodule Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; g... BeFree 23668556 Detail
0.146 Non-small cell lung carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.274 colorectal cancer In addition, the combination of microsatellite instability testing, MLH1 promote... BeFree 18556776 Detail
0.325 Papillary thyroid carcinoma Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirate... BeFree 15859312 Detail
0.020 melanoma Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence ... BeFree 21725359 Detail
0.006 Colorectal cancer metastatic It has been reported that KRAS mutations (and to a lesser extent KRAS mutations ... BeFree 18669866 Detail
0.216 Colorectal Neoplasms Secondly, considering the alternative possibility, we identified genes whose DNA... BeFree 20027224 Detail
<0.001 anaplastic oligodendroglioma A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A5... BeFree 22568401 Detail
0.016 Colorectal cancer metastatic High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic col... BeFree 24500755 Detail
<0.001 Papillary thyroid carcinoma Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in pa... BeFree 21249150 Detail
0.017 Secondary malignant neoplasm of lymph node The BRAF(V600E) mutation was significantly associated with age (≥ 45 years), tum... BeFree 22190222 Detail
0.132 hairy cell leukemia In 2011, the V600E mutation of the BRAF gene in exon 15 was identified in HCL; b... BeFree 24994538 Detail
0.431 melanoma Taken together, our study demonstrates that ASCT2-mediated glutamine transport i... BeFree 24531984 Detail
0.060 Thyroid carcinoma BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive c... BeFree 21447745 Detail
0.325 Papillary thyroid carcinoma Although BRAF(V600E) and XIAP expression are commonly seen in PTC, their presenc... BeFree 19355825 Detail
0.060 Thyroid carcinoma PCCl3 rat thyroid cells, PCCl3 cells overexpressing BRAF(V600E), or primary cult... BeFree 24400871 Detail
0.016 Colorectal cancer metastatic Since RAC1b has been associated with the BRAF(V600E) mutation, associated with p... BeFree 24833563 Detail
0.015 melanoma The reactivation of senescence features and elimination of cells refractory to B... BeFree 22549727 Detail
0.132 hairy cell leukemia Recently, the BRAF V600E mutation was uniformly identified in one HCL series, wh... BeFree 22212971 Detail
0.001 hairy cell leukemia Advanced molecular techniques have identified distinct molecular aberrations in ... BeFree 24652320 Detail
<0.001 HIV Infections We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors spec... BeFree 15208655 Detail
0.057 Colorectal cancer metastatic BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patient... BeFree 20857202 Detail
0.325 Papillary thyroid carcinoma Association between BRAF V600E mutation and mortality in patients with papillary... BeFree 23571588 Detail
<0.001 Lymphoma, Follicular The performance of the BRAF V600E-specific VE1 antibody was compared with that o... BeFree 25511147 Detail
0.032 Malignant neoplasm of thyroid Transgenic induction of BRAF(V600E)in the thyroid gland results in cancers resem... BeFree 21249150 Detail
0.001 chronic lymphocytic leukemia The performance of the BRAF V600E-specific VE1 antibody was compared with that o... BeFree 25511147 Detail
0.431 melanoma BRAF is an oncogene that is commonly mutated in both melanomas and papillary thy... BeFree 17302867 Detail
0.008 Anaplastic thyroid carcinoma BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had ide... BeFree 17989125 Detail
0.002 pleomorphic xanthoastrocytoma Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRA... BeFree 24894018 Detail
0.003 melanoma Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence... BeFree 24703243 Detail
0.431 melanoma Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed tha... BeFree 24185007 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer Tumors were also screened for BRAF V600E mutations; patients with the mutation w... BeFree 17312306 Detail
0.086 Carcinoma, Papillary After molecular analysis, the BRAF V600E mutation was detected in 18/32 (56.2%) ... BeFree 19534623 Detail
0.004 ovarian carcinoma Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. BeFree 17309670 Detail
<0.001 autoimmune thyroiditis Screening for activating BRAF mutations in a series of 83 PTCs identified the mo... BeFree 18426810 Detail
0.272 melanoma Although BRAF(V600E)/PIK3CA(H1047R) melanomas were sensitive to the antiprolifer... BeFree 25472943 Detail
0.060 Thyroid carcinoma The effect of activating somatic mutations in the KRAS and BRAF genes on the res... BeFree 22442268 Detail
0.001 dysembryoplastic neuroepithelial tumor In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expr... BeFree 23442159 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.012 Papillary thyroid carcinoma After surgery, 115 nodules were confirmed as conventional papillary thyroid carc... BeFree 25111330 Detail
0.004 Papillary Thyroid Microcarcinoma Analysis of differential BRAF(V600E) mutational status in high aggressive papill... BeFree 19034577 Detail
0.003 Thyroid carcinoma They also potently blocked MEK phosphorylation in human thyroid cancer cell line... BeFree 16551863 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
<0.001 perineurioma Previous studies demonstrated a high prevalence of a BRAF p.V600E mutation in pe... BeFree 23588369 Detail
0.027 Thyroid Nodule Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgica... BeFree 23280049 Detail
0.431 melanoma The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatical... BeFree 19276360 Detail
0.002 Thyroid carcinoma ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V... BeFree 23544999 Detail
<0.001 melanoma Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threoni... BeFree 24185007 Detail
0.074 colorectal carcinoma Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of B... BeFree 23549875 Detail
<0.001 acute promyelocytic leukemia Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.431 melanoma The incidence of BRAF mutations other than V600E is significantly higher in lung... BeFree 21483012 Detail
0.431 melanoma Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to bot... BeFree 24077403 Detail
0.025 Rectal Neoplasms Our investigation evaluates associations between active and passive smoking and ... BeFree 19358278 Detail
0.010 Malignant tumor of colon In particular, gene instability caused by decreased expression of the hMLH1 gene... BeFree 19424571 Detail
0.003 glioblastoma We report here the detection of the BRAF V600E mutation in a patient with c-GBM ... BeFree 25885250 Detail
0.028 melanoma Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V6... BeFree 24970815 Detail
0.004 sarcoma Histiocytic sarcoma exhibited the highest rate of BRAF(V600E) (62.5%, five of ei... BeFree 24720374 Detail
0.086 Carcinoma, Papillary A high percentage of both melanomas and papillary carcinomas of the thyroid harb... BeFree 24574369 Detail
0.017 Secondary malignant neoplasm of lymph node The BRAF(V600E) mutation was associated with male sex (P = 0.028), large tumor s... BeFree 25337709 Detail
0.060 Thyroid carcinoma VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinom... BeFree 25894433 Detail
0.003 melanoma We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; ... BeFree 22791410 Detail
0.001 Carcinoma, Endometrioid BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33... BeFree 17309670 Detail
0.108 colorectal cancer Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.002 Papillary thyroid carcinoma The T1799A missense mutation in exon 15 of the BRAF gene and RET/PTC rearrangeme... BeFree 17464312 Detail
0.431 melanoma One such target is the V600E gain-of-function BRAF mutation found in 60% of mela... BeFree 19679016 Detail
0.325 Papillary thyroid carcinoma BRAF V600E mutation was found in 115 samples, 80 of which were also cytologicall... BeFree 22535974 Detail
0.082 colorectal carcinoma KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 met... BeFree 21457162 Detail
0.126 pilocytic astrocytoma This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E... BeFree 24532263 Detail
0.325 Papillary thyroid carcinoma However, these findings are not specific enough to predict the presence or absen... BeFree 20410389 Detail
0.132 melanoma Dual targeting of BRAF(V600E) and Hdm2 with vemurafenib and Nt-3, respectively, ... BeFree 23812671 Detail
0.288 Thyroid Neoplasm Treatment of the most resistant cell line, 8505c, using lexatumumab in combinati... BeFree 24603332 Detail
0.325 Papillary thyroid carcinoma As the somatic T1799A BRAF mutation is highly prevalent in papillary thyroid can... BeFree 16117812 Detail
0.325 Papillary thyroid carcinoma BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid... BeFree 19574281 Detail
0.010 Thyroid carcinoma We tested the combinations of the Akt inhibitors MK2206 or perifosine with the B... BeFree 22090271 Detail
0.002 Thyroid carcinoma The effect of activating somatic mutations in the KRAS and BRAF genes on the res... BeFree 22442268 Detail
0.325 Papillary thyroid carcinoma Lack of correlation between BRAF V600E mutational status and the expression prof... BeFree 19370505 Detail
<0.001 Metastatic malignant neoplasm to brain MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplific... BeFree 25073704 Detail
0.029 melanoma The activating BRAF mutation V600E and related mutations in this codon are most ... BeFree 24756795 Detail
<0.001 Papillary thyroid carcinoma CYP24A1 overexpression is a poor prognostic indicator for PTC and may reflect BR... BeFree 24382015 Detail
0.325 Papillary thyroid carcinoma Factors influencing the detection of the BRAF T1799A mutation in papillary thyro... BeFree 21431280 Detail
0.005 Brain Neoplasms Future clinical trials should address whether BRAF (V600E) mutant brain tumor pa... BeFree 21274720 Detail
0.131 melanoma In this issue of Cancer Discovery, Shi and colleagues add further insight into t... BeFree 22588873 Detail
0.004 Papillary Thyroid Microcarcinoma BRAF V600E and decreased NIS and TPO expression are associated with aggressivene... BeFree 26338373 Detail
0.017 Secondary malignant neoplasm of lymph node On the contrary, no link could be detected between expression of BRAF(V599E) and... BeFree 15126572 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for a... BeFree 24052184 Detail
0.025 Malignant tumor of colon The prevalence of BRAF(V600E) was considerably higher in older (age &gt; 70) fem... BeFree 20635392 Detail
0.325 Papillary thyroid carcinoma Forty-six cases of papillary thyroid carcinoma have been evaluated for the prese... BeFree 22767446 Detail
0.004 Thyroid Nodule To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (F... BeFree 17727338 Detail
0.144 Carcinogenesis The paradoxically higher incidence of BRAF(V600E) mutations in medium-sized comp... BeFree 21430505 Detail
0.325 Papillary thyroid carcinoma We were unable to identify peripheral BRAF(V600E) mutations in patients with pap... BeFree 23161556 Detail
0.325 Papillary thyroid carcinoma RNA sequencing identifies multiple fusion transcripts, differentially expressed ... BeFree 24297791 Detail
0.002 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.134 pilocytic astrocytoma Recent developments in v-raf murine sarcoma viral oncogene homolog B1 (BRAF)(V60... BeFree 23160425 Detail
0.003 Thyroid carcinoma ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V... BeFree 23544999 Detail
0.007 Tumor Progression BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive c... BeFree 21447745 Detail
0.017 Secondary malignant neoplasm of lymph node We previously described a patient with BRAF V600E mutation in primary tumor and ... BeFree 19169486 Detail
0.431 melanoma MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplific... BeFree 25073704 Detail
0.020 melanoma Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the d... BeFree 24710085 Detail
0.001 pilocytic astrocytoma For the first time, we report concomitant presence of a somatic BRAF(V600E) muta... BeFree 21190184 Detail
0.003 differentiated thyroid gland carcinoma The aims of this study were to evaluate the utility of US-guided FNAB in the dia... BeFree 22535974 Detail
0.008 Anaplastic thyroid carcinoma Beyond development, we can look into the effectiveness of already approved targe... BeFree 25347569 Detail
0.129 Waldenstrom Macroglobulinemia They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mut... BeFree 24689848 Detail
0.017 Secondary malignant neoplasm of lymph node While univariate analysis showed the BRAF(V600E) mutation was associated with tu... BeFree 16918957 Detail
0.017 Secondary malignant neoplasm of lymph node Moreover, BRAF(V600E) mutation was not correlated with any of the prognostic fac... BeFree 21862261 Detail
0.244 Adenocarcinoma of lung (disorder) This study compared the specificity and sensitivity of IHC with other methods fo... BeFree 23131393 Detail
0.001 pilocytic astrocytoma For the first time, we report concomitant presence of a somatic BRAF(V600E) muta... BeFree 21190184 Detail
0.019 polyps Our BRAF(V600E) GEMM presented with sessile serrated adenomas/polyps, as seen in... BeFree 23549875 Detail
0.325 Papillary thyroid carcinoma Activating point mutation of the BRAF gene resulting in V600E (previously design... BeFree 16299399 Detail
0.129 Glioma These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with at... BeFree 24057326 Detail
0.015 melanoma Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma pro... BeFree 24425783 Detail
0.144 Carcinogenesis Recently, an alternative pathway of tumorigenesis has been identified in the col... BeFree 15765445 Detail
0.003 ganglioglioma Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentag... BeFree 24238153 Detail
0.431 melanoma Ectopic MITF expression in conjunction with the BRAF(V600E) mutant transformed p... BeFree 16001072 Detail
0.004 Thyroid carcinoma TERT promoter mutations and their association with BRAF V600E mutation and aggre... BeFree 24617711 Detail
<0.001 Tumor of the Pineal Region The demonstration of the BRAF V600E mutation in the pineal tumor made the patien... BeFree 25976339 Detail
0.144 Carcinogenesis The increased incidence of cancer in FDRs of index CRC patients with the p.V600E... BeFree 20570909 Detail
0.055 Neoplasm Metastasis BRAF(V599E) tended to be associated, although not significantly, with a greater ... BeFree 15272920 Detail
0.017 Secondary malignant neoplasm of lymph node Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E... BeFree 23416953 Detail
0.055 Neoplasm Metastasis BRAF V600E was associated with advanced TNM (P &lt; 0.001), more distant metasta... BeFree 25367198 Detail
0.074 colorectal carcinoma BRAF provides proliferation and survival signals in MSI colorectal carcinoma cel... BeFree 18098337 Detail
0.002 Myeloid Leukemia, Chronic Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.018 Malignant tumor of colon We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal ... BeFree 17427169 Detail
0.236 melanoma CH5126766/RO5126766 induced G1 cell cycle arrest in two melanoma cell lines with... BeFree 25422890 Detail
0.005 colon carcinoma The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and ... BeFree 17096326 Detail
0.017 Secondary malignant neoplasm of lymph node Patients with micro-PTC were evaluated separately, it was found that BRAF(V600E)... BeFree 22426956 Detail
0.010 Carcinogenesis Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mut... BeFree 21185263 Detail
0.325 Papillary thyroid carcinoma Lack of association between BRAF V600E mutation and mitogen-activated protein ki... BeFree 17199737 Detail
0.179 Papillary thyroid carcinoma Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurre... BeFree 23806056 Detail
0.025 Thyroid carcinoma Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC... BeFree 25333496 Detail
0.003 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
<0.001 melanoma Taken together, our study demonstrates that ASCT2-mediated glutamine transport i... BeFree 24531984 Detail
0.431 melanoma Analysis of frozen and fixed material from 21 CCS and 21 MM showed the presence ... BeFree 22045652 Detail
0.431 melanoma The U.S. Food and Drug Administration approved the use of trametinib and dabrafe... BeFree 24596183 Detail
0.032 Malignant neoplasm of thyroid Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS... BeFree 24243688 Detail
0.003 Thyroid Nodule Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a dia... BeFree 17381488 Detail
0.002 Thyroid carcinoma PCCL3 cells conditionally expressing RET/PTC3, HRAS(G12V), or BRAF(V600E) and hu... BeFree 25029414 Detail
0.325 Papillary thyroid carcinoma Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma ... BeFree 19850689 Detail
0.001 Malignant neoplasm of thyroid BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.060 Thyroid carcinoma (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadher... BeFree 23435375 Detail
0.018 Malignant tumor of colon These data suggest that the BRAF V600E mutation is not the target gene for abnor... BeFree 19424571 Detail
<0.001 premalignant lesion Three (60%) of 5 PTCs and 1 out of 17 benign lesions had BRAF(V600E) mutation (o... BeFree 17054470 Detail
0.017 Cutaneous Melanoma The BRAF V600E mutation accounts for the majority of BRAF mutations found in cut... BeFree 25607474 Detail
0.431 melanoma Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of ... BeFree 26058727 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.002 Malignant neoplasm of thyroid TERT promoter mutations and their association with BRAF V600E mutation and aggre... BeFree 24617711 Detail
<0.001 Thyroid carcinoma BRAF(V600E) mutation and p27(kip1) expression have been introduced as novel indi... BeFree 17685465 Detail
0.325 Papillary thyroid carcinoma Impact of clinical risk scores and BRAF V600E mutation status on outcome in papi... BeFree 25482468 Detail
0.003 ganglioglioma Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neurona... BeFree 23435618 Detail
0.325 Papillary thyroid carcinoma Association of BRAF V600E mutation with poor clinicopathological outcomes in 500... BeFree 17785355 Detail
0.003 Thyroid carcinoma This study investigated the therapeutic potential of a BRAF(V600E)-selective inh... BeFree 21185263 Detail
0.060 Thyroid carcinoma BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyr... BeFree 18310287 Detail
0.055 Neoplasm Metastasis Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metast... BeFree 17387744 Detail
0.027 Thyroid Nodule BRAF(V600E) positivity was a useful marker at thyroid nodules with suspicious fo... BeFree 19672964 Detail
0.200 Non-small cell lung carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.132 hairy cell leukemia Besides confirming the constant presence of BRAF-V600E in all patients with hair... BeFree 23349307 Detail
0.017 Secondary malignant neoplasm of lymph node Association between BRAF V600E mutation and regional lymph node metastasis in pa... BeFree 25755776 Detail
0.431 melanoma Continuing vemurafenib or dabrafenib therapy despite hypersensitivity reaction i... BeFree 26056325 Detail
0.074 colorectal carcinoma Performance comparison of three BRAF V600E detection methods in malignant melano... BeFree 25318602 Detail
0.431 melanoma Remarkably, abrogating MITF activity in BRAF(V600E)mitf melanoma leads to dramat... BeFree 23831555 Detail
0.055 adenocarcinoma From our patients and literature search, we found that BRAF-V600E mutations occu... BeFree 26066373 Detail
0.143 Thyroid Neoplasm The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyro... BeFree 22998776 Detail
0.135 Thyroid Neoplasm In conclusion, our study showed a high implication of TSHR gene methylation and ... BeFree 24927793 Detail
0.325 Papillary thyroid carcinoma BRAF(V600E) mutation analysis using ethanol-fixed PTC cells from a patient demon... BeFree 23691506 Detail
0.004 Papillary Thyroid Microcarcinoma The relationship between the BRAF(V600E) mutation in papillary thyroid microcarc... BeFree 24228637 Detail
0.325 Papillary thyroid carcinoma The oncogene BRAF V600E is associated with a high risk of recurrence and less di... BeFree 16601293 Detail
0.325 Papillary thyroid carcinoma The role of BRAF V600E mutation as a potential marker for prognostic stratificat... BeFree 24679337 Detail
0.017 Secondary malignant neoplasm of lymph node On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroi... BeFree 21803329 Detail
0.431 melanoma Our data suggest that one of the major functions of C-MYC overexpression in mela... BeFree 18679422 Detail
0.132 hairy cell leukemia Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mut... BeFree 22210875 Detail
0.002 Carcinogenesis Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in M... BeFree 24717435 Detail
0.001 Serous cystadenoma, borderline malignancy We postulated that BRAF could be a SBT susceptibility gene, and investigated bot... BeFree 17309670 Detail
0.011 melanoma Activating mutations in the BRAF serine/threonine kinase are found in more than ... BeFree 22361686 Detail
0.060 Thyroid carcinoma Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biops... BeFree 24570209 Detail
0.325 Papillary thyroid carcinoma A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: in-house PCR... BeFree 20607744 Detail
0.032 Malignant neoplasm of thyroid Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E... BeFree 18462259 Detail
0.002 Papillary thyroid carcinoma Influence of the BRAF V600E mutation on expression of vascular endothelial growt... BeFree 16772349 Detail
0.060 Thyroid carcinoma High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tum... BeFree 24780046 Detail
0.007 Papillary thyroid carcinoma TPC-1/BRAF (WT) wild-type and BcPAP/BRAF (V600E) -mutated PTC cell lines were se... BeFree 23893334 Detail
0.004 sarcoma One melanoma-sarcoma pair showed identical BRAF V600E mutations. BeFree 24117833 Detail
0.005 Epithelial ovarian cancer Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. BeFree 17309670 Detail
0.325 Papillary thyroid carcinoma The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroi... BeFree 22170714 Detail
0.002 lymphoma The presence of the BRAF c.1799T&gt;A V600E mutation was recently described in c... BeFree 23161722 Detail
0.241 craniopharyngioma Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngi... BeFree 24413733 Detail
0.325 Papillary thyroid carcinoma V600E BRAF mutation is emerging as an independent marker of papillary thyroid ca... BeFree 19693938 Detail
0.135 colon carcinoma We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal ... BeFree 17427169 Detail
0.004 Metastatic malignant neoplasm to brain Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples o... BeFree 22012135 Detail
0.004 melanoma At clinically informative sites, we identified seven low-frequency point mutatio... BeFree 23382536 Detail
0.002 Papillary thyroid carcinoma The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways c... BeFree 21249150 Detail
0.007 Malignant neoplasm of thyroid We tested the combinations of the Akt inhibitors MK2206 or perifosine with the B... BeFree 22090271 Detail
0.431 melanoma About 40% to 60% of cutaneous melanomas have BRAF mutations, and 90% of the muta... BeFree 25046227 Detail
0.049 Metastatic melanoma Researchers retrospectively reviewed medical records of all patients at our inst... BeFree 25746037 Detail
0.005 Brain Neoplasms An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of mal... BeFree 24721513 Detail
0.032 Malignant neoplasm of thyroid BRAF provides signals crucial for proliferation of thyroid carcinoma cells spont... BeFree 16533790 Detail
0.325 Papillary thyroid carcinoma In our study, BRAF V600E mutation revealed a strong association with specific hi... BeFree 22732794 Detail
0.010 Hereditary Nonpolyposis Colorectal Cancer Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in... BeFree 17065421 Detail
0.074 colorectal carcinoma BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal... BeFree 24921639 Detail
0.365 Turcot syndrome (disorder) All patients underwent tumor microsatellite instability analysis and immunostain... BeFree 18061181 Detail
<0.001 high-grade childhood cerebral astrocytoma Here, ten PAs with atypical clinicoradiologic and histologic features and six pe... BeFree 24057326 Detail
0.009 Carcinogenesis Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mut... BeFree 21185263 Detail
0.325 Papillary thyroid carcinoma Immunohistochemical detection of the mutated V600E BRAF protein in PTC may facil... BeFree 22592144 Detail
0.018 Malignant tumor of colon Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback acti... BeFree 22281684 Detail
0.431 melanoma Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. BeFree 23802768 Detail
0.325 Papillary thyroid carcinoma RET/PTC rearrangement and BRAF(V600E) mutation are the two prevalent molecular a... BeFree 23722226 Detail
0.004 Papillary Thyroid Microcarcinoma BRAF(V600E) mutation was more frequent in classic (75%), tall cell (91%), and ot... BeFree 22918165 Detail
0.288 Thyroid Neoplasm Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) m... BeFree 22435913 Detail
0.032 Malignant neoplasm of thyroid TERT promoter mutations and their association with BRAF V600E mutation and aggre... BeFree 24617711 Detail
0.005 Brain Neoplasms The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomo... BeFree 25885250 Detail
0.002 Papillary thyroid carcinoma The objective of the study was to investigate the effects of the BRAF V600E muta... BeFree 16772349 Detail
<0.001 differentiated thyroid gland carcinoma These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FD... BeFree 25814520 Detail
0.132 hairy cell leukemia Immunohistochemical analysis using a BRAF V600E mutation specific antibody is hi... BeFree 25120816 Detail
0.002 Secondary malignant neoplasm of lymph node BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyro... BeFree 17685465 Detail
0.017 melanoma The reactivation of senescence features and elimination of cells refractory to B... BeFree 22549727 Detail
0.431 melanoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.134 pilocytic astrocytoma The data further support previous observations that these two alterations of the... BeFree 21884820 Detail
0.001 melanoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
0.274 colorectal cancer A correlation between MLH1 promoter methylation, specifically the 'C' region, an... BeFree 23880961 Detail
0.008 Anaplastic thyroid carcinoma Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation,... BeFree 25584719 Detail
0.025 Neoplasm Metastasis They include BRAF(V600E) and AKT that affect tumor initiation, progression and m... BeFree 24362526 Detail
0.003 ganglioglioma BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliom... BeFree 25937573 Detail
0.003 Thyroid carcinoma Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-... BeFree 21795305 Detail
0.431 melanoma The BRAF gene has been identified as an oncogene in human cancer and the V600E m... BeFree 21262211 Detail
<0.001 pilocytic astrocytoma Neither CD34 expression nor BRAF(V600E) status was predictive of prognosis, exce... BeFree 23442159 Detail
0.080 breast carcinoma Here, we discuss the current commonly used predictive pharmacogenetic biomarkers... BeFree 22845480 Detail
<0.001 Papillary thyroid carcinoma The authors' data suggested that BRAF(V600E) mutation and p27(Kip1) down-regulat... BeFree 17685465 Detail
0.240 craniopharyngioma Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngi... BeFree 24413733 Detail
0.032 Malignant neoplasm of thyroid The BRAF(V600E) mutation can be detected peripherally in the serum of patients w... BeFree 23161556 Detail
<0.001 Cutaneous Melanoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.325 Papillary thyroid carcinoma BRAF V600E mutation is primarily present in conventional papillary thyroid cance... BeFree 17717450 Detail
0.325 Papillary thyroid carcinoma To clarify which gene alteration, chromosome aberration, or point mutation prefe... BeFree 18757433 Detail
<0.001 pancreatic ductal adenocarcinoma Moreover, concomitant expression of BRAF(V600E) and TP53(R270H) result in lethal... BeFree 22628411 Detail
0.244 Papillary thyroid carcinoma The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%... BeFree 21498916 Detail
0.179 Papillary thyroid carcinoma The purpose of this study is to describe a case of concurrent medullary and papi... BeFree 24858900 Detail
0.132 hairy cell leukemia BRAF-V600E was detected at different time points during the disease course, even... BeFree 22028477 Detail
0.028 melanoma RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma... BeFree 24185007 Detail
0.060 Thyroid carcinoma BRAF is an oncogene that is commonly mutated in both melanomas and papillary thy... BeFree 17302867 Detail
0.006 Secondary malignant neoplasm of lymph node Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E... BeFree 23416953 Detail
0.431 melanoma We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell... BeFree 23251002 Detail
0.029 melanoma We identified concurrent mutational inactivation of the PTEN and RB1 tumor suppr... BeFree 21725359 Detail
0.002 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.431 melanoma The reactivation of senescence features and elimination of cells refractory to B... BeFree 22549727 Detail
0.018 Malignant tumor of colon Though such data suggest that BRAF mutation is likely an early initiating event ... BeFree 18473997 Detail
0.051 colorectal carcinoma Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
<0.001 Malignant neoplasm of colon stage IV Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to pe... BeFree 23792568 Detail
0.002 colorectal cancer Commonly observed alterations across sporadic CRCs have allowed classification i... BeFree 26216840 Detail
0.004 Metastatic malignant neoplasm to brain While dabrafenib has demonstrated comparable efficacy to vemurafenib in BRAF V60... BeFree 23621583 Detail
0.274 colorectal cancer Optimizing targeted therapeutic development: analysis of a colorectal cancer pat... BeFree 20635392 Detail
0.002 Sessile Serrated Adenoma/Polyp This improved classification of serrated lesions including immunohistochemical e... BeFree 23887306 Detail
0.179 Papillary thyroid carcinoma Targeted expression of rearranged during transfection (RET)/papillary thyroid ca... BeFree 17210745 Detail
0.060 Thyroid carcinoma BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associa... BeFree 17854396 Detail
0.132 hairy cell leukemia We therefore suggest screening of BRAF V600E-negative HCL for alternative exon 1... BeFree 24433452 Detail
0.004 uterine corpus cancer This is the first report of BRAF V600E mutation in endometrial cancer, indicatin... BeFree 23370429 Detail
0.018 Malignant tumor of colon The results of these studies suggest that combined treatment of BRAF(V600E)-driv... BeFree 23074264 Detail
0.492 Turcot syndrome (disorder) All patients underwent tumor microsatellite instability analysis and immunostain... BeFree 18061181 Detail
<0.001 Glioblastoma multiforme We tested our originally reported cohort of 8 E-GBMs and 2 rhabdoid GBMs (R-GBM)... BeFree 23552385 Detail
0.074 colorectal carcinoma Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2... BeFree 18806830 Detail
0.325 Papillary thyroid carcinoma The aim of this study was to evaluate the prevalence of both RET/PTC rearrangeme... BeFree 22745248 Detail
0.325 Papillary thyroid carcinoma This analysis suggests that differences in disease course of PTC in children ver... BeFree 24677749 Detail
0.431 melanoma This tumour-specific inhibition of ERK signalling results in a broad therapeutic... BeFree 22113612 Detail
<0.001 Stage III Colon Cancer The BRAF V600E mutation is an independent prognostic factor for survival in stag... BeFree 20501503 Detail
Annotation

Annotations

DescrptionSourceLinks
49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were an... CIViC Evidence Detail
Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated w... CIViC Evidence Detail
V600E is associated with adverse pathological features of colorectal cancer. This can be concluded a... CIViC Evidence Detail
BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melan... CIViC Evidence Detail
BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and ... CIViC Evidence Detail
BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients ... CIViC Evidence Detail
V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo). CIViC Evidence Detail
In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the seq... CIViC Evidence Detail
Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant canc... CIViC Evidence Detail
Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response ... CIViC Evidence Detail
The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598... CIViC Evidence Detail
In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic color... CIViC Evidence Detail
In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after... CIViC Evidence Detail
5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with ... CIViC Evidence Detail
Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previo... CIViC Evidence Detail
Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation. ... CIViC Evidence Detail
Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed i... CIViC Evidence Detail
A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroi... CIViC Evidence Detail
In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 344 had V600E mu... CIViC Evidence Detail
In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRA... CIViC Evidence Detail
BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80... CIViC Evidence Detail
In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 pati... CIViC Evidence Detail
Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive h... CIViC Evidence Detail
Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF... CIViC Evidence Detail
Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant p... CIViC Evidence Detail
A 65-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and h... CIViC Evidence Detail
A 54-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and r... CIViC Evidence Detail
Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melano... CIViC Evidence Detail
Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 wit... CIViC Evidence Detail
In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there w... CIViC Evidence Detail
In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation... CIViC Evidence Detail
Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the ... CIViC Evidence Detail
The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patie... CIViC Evidence Detail
In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and beva... CIViC Evidence Detail
In a study of 322 advanced melanoma patients with BRAF-V600E or BRAF-V600K mutations, treatment with... CIViC Evidence Detail
In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with... CIViC Evidence Detail
In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a hi... CIViC Evidence Detail
Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomis... CIViC Evidence Detail
In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with... CIViC Evidence Detail
In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients... CIViC Evidence Detail
In a clinical study of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BR... CIViC Evidence Detail
In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175... CIViC Evidence Detail
In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V60... CIViC Evidence Detail
In a case report, a cervicomedullary ganglioglioma patient harboring BRAF V600E mutation was associa... CIViC Evidence Detail
A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutati... CIViC Evidence Detail
In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type... CIViC Evidence Detail
Chemotherapy-refractory, metastatic cholangiocarcinoma with BRAF V600E showed dramatically response ... CIViC Evidence Detail
Two cases of patients with BRAF V600E positive cholangiocarcinoma showed excellent response for Dabr... CIViC Evidence Detail
Dabrafenib and trametinib combination showed durable response for patients with standard chemotherap... CIViC Evidence Detail
Patients with metastatic cholangiocarcinoma havoring with BRAF V600E was treated with vemurafenib, p... CIViC Evidence Detail
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... CIViC Evidence Detail
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... CIViC Evidence Detail
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... CIViC Evidence Detail
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... CIViC Evidence Detail
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... CIViC Evidence Detail
In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patient... CIViC Evidence Detail
In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to ... CIViC Evidence Detail
In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to ... CIViC Evidence Detail
Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered... CIViC Evidence Detail
In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C... CIViC Evidence Detail
In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage... CIViC Evidence Detail
In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib a... CIViC Evidence Detail
Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and tra... CIViC Evidence Detail
Patients with completely resected colorectal adenocarcinoma (Stage II-III) were treated with fluorou... CIViC Evidence Detail
The CRYSTAL Phase III Trial evaluated efficacy of irinotecan, fluorouracil, and leucovorin (FOLFIRI)... CIViC Evidence Detail
Using Sanger sequencing, BRAFV600E mutations were identified in 21 of 285 patients with PLGGs (7.4%)... CIViC Evidence Detail
One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a part... CIViC Evidence Detail
BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer. CIViC Evidence Detail
Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer. CIViC Evidence Detail
This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progressio... CIViC Evidence Detail
BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide. CIViC Evidence Detail
In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show... CIViC Evidence Detail
Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor suc... CIViC Evidence Detail
In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to... CIViC Evidence Detail
In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib. CIViC Evidence Detail
Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemothe... CIViC Evidence Detail
Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely... CIViC Evidence Detail
Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A... CIViC Evidence Detail
Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy... CIViC Evidence Detail
Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells w... CIViC Evidence Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Carcinoma of colon ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Papillary thyroid carcinoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Astrocytoma, low-grade, somatic ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Nongerminomatous germ cell tumor ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Non-small cell lung carcinoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Melanoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND not provided ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Cardio-facio-cutaneous syndrome ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Malignant melanoma of skin ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Colonic neoplasm ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Squamous cell carcinoma of the head and neck ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Brainstem glioma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Glioblastoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Lung adenocarcinoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Multiple myeloma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Neoplasm of ovary ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Lung carcinoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Neoplasm of brain ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Gastrointestinal stromal tumor ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Papillary renal cell carcinoma, sporadic ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Neoplasm ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Neoplasm of the large intestine ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Cystic epithelial invagination containing papillae lin... ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Cerebral arteriovenous malformation ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Nephroblastoma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Malignant neoplastic disease ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Lymphangioma ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Vascular malformation ClinVar Detail
NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) AND Cardiovascular phenotype ClinVar Detail
BRAF(V600E) mutation was detected in 50% of the acquired nevi and in 70% of the cutaneus melanomas i... DisGeNET Detail
Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration ... DisGeNET Detail
All neoplastic melanocytes within such a nevus would be expected to carry the BRAF mutation, and thu... DisGeNET Detail
BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25... DisGeNET Detail
We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leuke... DisGeNET Detail
In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 201... DisGeNET Detail
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cel... DisGeNET Detail
In this study, we show that the expression of LAT1 and ASCT2 is significantly increased in human mel... DisGeNET Detail
The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and hMLH1) were assessed... DisGeNET Detail
Reported herein is a case of LCH in non-twin siblings (younger sister and elder brother) who were di... DisGeNET Detail
Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .... DisGeNET Detail
Studies presented or published during the European Society for Medical Oncology conference demonstra... DisGeNET Detail
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neu... DisGeNET Detail
The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and hMLH1) were assessed... DisGeNET Detail
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and... DisGeNET Detail
Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma proliferation, whereas ... DisGeNET Detail
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high freq... DisGeNET Detail
The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D5... DisGeNET Detail
We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the der... DisGeNET Detail
Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival a... DisGeNET Detail
The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D5... DisGeNET Detail
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) i... DisGeNET Detail
The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocyt... DisGeNET Detail
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of he... DisGeNET Detail
The primary melanoma expressed mutant BRAF-V600E and possessed a homozygous deletion of CDKN2A. DisGeNET Detail
BRAF V600E mutation analysis was performed in 148 selected cases; mutations were found in 44/49 (90%... DisGeNET Detail
Of the drugs tested to date in patients with metastatic melanoma, those that have yielded the best r... DisGeNET Detail
The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of papillary carcinomas ... DisGeNET Detail
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu ... DisGeNET Detail
In this study a retrospective cohort of 198 pediatric low-grade gliomas (including 40 treated with a... DisGeNET Detail
Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 (3 melanomas and 1 n... DisGeNET Detail
Our data indicate that the C57BL/6J Tyr::CreER(T2);PTEN(F-/-);BRAF(F-V600E/+) melanoma model could b... DisGeNET Detail
These expression profiles were associated with V600E BRAF mutation, a progressive accumulation of pr... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans c... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent im... DisGeNET Detail
To summarize the usefulness of several recently discovered immunohistochemical markers in the study ... DisGeNET Detail
Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V600E)-mutated melanom... DisGeNET Detail
BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent... DisGeNET Detail
We further showed that BRAF, a downstream signaling molecule of ARMS in ERK pathway, is not mutated ... DisGeNET Detail
However, using immunomagnetic separation or laser-capture microdissection, we examined BRAF mutation... DisGeNET Detail
miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regulated miRNA in CRCs w... DisGeNET Detail
The prevalence (90%) of the BRAF (V600E) mutation in this study is the highest ever reported, confir... DisGeNET Detail
Consistent with our findings in humans, expression of BRAF-V600E in BM DC progenitors recapitulated ... DisGeNET Detail
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high freq... DisGeNET Detail
None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspicious for malignancy, ... DisGeNET Detail
BRAF V600E and RAS mutations were mutually exclusive; all ATC cell lines exhibited a combination of ... DisGeNET Detail
Colorectal and lung cancers associated with the BRAF V600E mutation often demonstrated mucinous morp... DisGeNET Detail
HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of p53 in 26 out of 62... DisGeNET Detail
Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an importan... DisGeNET Detail
The activating BRAF mutation V600E and related mutations in this codon are most important for the ac... DisGeNET Detail
Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence... DisGeNET Detail
Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies... DisGeNET Detail
Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E) status, which sugge... DisGeNET Detail
Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an importan... DisGeNET Detail
Differential gene expression in melanocytic nevi with the V600E BRAF mutation. DisGeNET Detail
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth ... DisGeNET Detail
Approximately 40-60% of melanomas from Caucasian populations carry activating mutations in the BRAF ... DisGeNET Detail
Screening for activating BRAF mutations in a series of 83 PTCs identified the most common V600E muta... DisGeNET Detail
BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1... DisGeNET Detail
Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF(V... DisGeNET Detail
The treatment of malignant melanoma with inhibitors targeting the BRAF V600E mutation has demonstrat... DisGeNET Detail
Molecular platforms utilized to detect BRAF V600E mutation in melanoma. DisGeNET Detail
Thus, Wnt/β-catenin signaling and AXIN1 may regulate the efficacy of inhibitors of BRAF(V600E), sugg... DisGeNET Detail
These data suggest that p16 deletion adversely impacts the outcomes of BRAF-driven gliomas, that hig... DisGeNET Detail
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and rest... DisGeNET Detail
In 137 specimens of FNAB (107 papillary thyroid carcinomas (PTC); 3 follicular thyroid carcinomas (F... DisGeNET Detail
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samp... DisGeNET Detail
We demonstrate that SSA-associated synchronous colorectal carcinomas have a striking predilection fo... DisGeNET Detail
Interestingly, PI3K inhibition forestalled the onset of MEK inhibitor resistance in two independent ... DisGeNET Detail
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry... DisGeNET Detail
The presence of BRAF V600E and mitogen-activated protein kinase activation in a largely benign tumor... DisGeNET Detail
The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CRCs) harboring hMLH1 ... DisGeNET Detail
We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chro... DisGeNET Detail
The V600E mutation of BRAF (BRAF(V600E)) was detected in 141 of 170 malignant thyroid nodules (82.9%... DisGeNET Detail
Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progr... DisGeNET Detail
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly... DisGeNET Detail
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recu... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
BRAF V600E mutations were seen in 83% of proximal and 74% of distal hyperplastic polyps. DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
The absence of the BRAF V600E mutation in Spitz's nevi may serve as a molecular signature to disting... DisGeNET Detail
BRAF V600E was associated with advanced TNM (P &lt; 0.001), more distant metastases (P = 0.025), and... DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of ... DisGeNET Detail
BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in... DisGeNET Detail
A substantial proportion of solid tumors carry the BRAF V600E mutation, which causes activation of t... DisGeNET Detail
We also observed that pharmacological inhibition of oncogenic BRAF(V600E) using PLX4720 did not infl... DisGeNET Detail
We have prospectively studied a series of 1624 consecutive colorectal carcinomas with an algorithm i... DisGeNET Detail
Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC... DisGeNET Detail
The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of... DisGeNET Detail
Vemurafenib, a selective BRAF (v-raf murine sarcoma viral oncogene homologue B1) kinase inhibitor, i... DisGeNET Detail
Knockdown of Apollon, by siRNA, triggered apoptosis and/or significantly enhanced melanoma cell deat... DisGeNET Detail
When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific BRAF inhibitor PLX40... DisGeNET Detail
Anecdotal responses have been reported in a few patients with LCH and Erdheim-Chester Disease to vem... DisGeNET Detail
Using a transgenic BRAF(V600E) mouse model previously generated in our laboratory, we report that lo... DisGeNET Detail
Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with i... DisGeNET Detail
In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer p... DisGeNET Detail
Frequent somatic mutations of BRAF (v-raf murine sarcoma viral oncogene homolog B) exon T1799A, whic... DisGeNET Detail
Additional analyses of multiple metastatic samples from individual patients using the highly sensiti... DisGeNET Detail
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. DisGeNET Detail
BRAF(V600E) is the most common mutation in cutaneous melanoma and has become the target of treatment... DisGeNET Detail
Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. DisGeNET Detail
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy... DisGeNET Detail
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis. DisGeNET Detail
Our findings indicate that the association of LCH and ECD is not fortuitous and suggest a link betwe... DisGeNET Detail
We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild... DisGeNET Detail
Caco-2 human colon adenocarcinoma cells were stably transfected with BRAF(V600E) (Caco-BR cells) or ... DisGeNET Detail
The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. DisGeNET Detail
In PTC specimens without a BRAF mutation, two CpGs were more heavily methylated than in PTC specimen... DisGeNET Detail
However, using immunomagnetic separation or laser-capture microdissection, we examined BRAF mutation... DisGeNET Detail
In addition, targeting components of the MAPK pathway have also demonstrated survival advantage in p... DisGeNET Detail
B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival i... DisGeNET Detail
To address this question, we developed a metastatic BRAF(V600E)-mutant melanoma cell line and demons... DisGeNET Detail
To determine the occurrence of BRAF V600E gene mutations and copy number changes of all autosome arm... DisGeNET Detail
The use of COLD-PCR in apparently wild-type samples allowed us to identify 15 newly mutated CRCs (10... DisGeNET Detail
In total, we found 21 (70%) out of 30 melanoma cell lines with BRAF mutations in exon 15: two of whi... DisGeNET Detail
In addition to metastatic lesions, we also examined 20 primary melanomas for the expression of BRAF(... DisGeNET Detail
Vemurafenib and dabrafenib, two potent tyrosine kinase inhibitors (TKIs) of the BRAF(V600E) kinase, ... DisGeNET Detail
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency ... DisGeNET Detail
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highl... DisGeNET Detail
All patients were refractory to first-line treatment and harbored a BRAF(V600E) mutation.Four patien... DisGeNET Detail
We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leuke... DisGeNET Detail
NA DisGeNET Detail
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract ... DisGeNET Detail
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth ... DisGeNET Detail
A BRAF p.Thr599dup or p.V600E mutation was identified by Sanger sequencing in one and five gliomas, ... DisGeNET Detail
The presence of BRAF V600E was only associated with extrathyroidal extension and the absence of thyr... DisGeNET Detail
The BRAF V600E mutation is the most common genetic alteration in thyroid cancer. DisGeNET Detail
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu ... DisGeNET Detail
The BRAF V600E mutant melanoma cell line, A375, was used as an in-vitro model system. DisGeNET Detail
SIRT1 inhibition decreases melanoma cell growth and rescues the sensibility to PLX4032 of PLX4032-re... DisGeNET Detail
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. DisGeNET Detail
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) i... DisGeNET Detail
We present a case of a 56-year old woman with a history of stage IIIA malignant melanoma resected in... DisGeNET Detail
The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1 nevus had a novel A1781G (D5... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regulated miRNA in CRCs w... DisGeNET Detail
BRAF V600E mutation analysis was performed in 148 selected cases; mutations were found in 44/49 (90%... DisGeNET Detail
The BRAF V600E mutation is one of the most frequent molecular abnormalities identified in hyperplast... DisGeNET Detail
We investigated the associations between BRAF(V600E) and NRAS(Q61R) mutations and known risk factors... DisGeNET Detail
Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E)... DisGeNET Detail
However, relatively little is known about the intracranial effectiveness of vemurafenib, the only US... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary t... DisGeNET Detail
The BRAF-V600E hotspot mutation was found in 40% (82/206) of the sporadic MSI-H tumours analysed but... DisGeNET Detail
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal ca... DisGeNET Detail
Incidence and predictive factors of inadequate fine-needle aspirates for BRAF(V600E) mutation analys... DisGeNET Detail
Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients ... DisGeNET Detail
Our BRAF(V600E) GEMM presented with sessile serrated adenomas/polyps, as seen in humans. DisGeNET Detail
To anticipate potential mechanisms of acquired resistance to RAF inhibitors during the course of tre... DisGeNET Detail
V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gast... DisGeNET Detail
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 s... DisGeNET Detail
In a BRAF(V600E)-containing xenograft model of human melanoma, orally administered dabrafenib inhibi... DisGeNET Detail
BRAF((V600E)) mutation is not a frequent event in right colon serrated polyps in a subset of the Chi... DisGeNET Detail
High frequency of BRAF V600E mutations in ameloblastoma. DisGeNET Detail
In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable s... DisGeNET Detail
To determine the prognostic significance of deficient mismatch repair (dMMR) and BRAF V600E in Thai ... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-... DisGeNET Detail
This focus has been justified by the recent success of BRAF and MEK inhibitors in prolonging the liv... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Genetic analyses have identified BRAF V600E mutations in a subset of ovarian carcinomas. DisGeNET Detail
Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carc... DisGeNET Detail
IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may ... DisGeNET Detail
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highl... DisGeNET Detail
Dabrafenib joins vemurafenib to confirm the superior clinical outcome of the BRAF inhibitors when co... DisGeNET Detail
In conclusion, our study showed a high implication of TSHR gene methylation and its significant asso... DisGeNET Detail
HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of p53 in 26 out of 62... DisGeNET Detail
The aim of our study was to test sebaceous neoplasms for V600E BRAF or KRAS mutations to determine i... DisGeNET Detail
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72... DisGeNET Detail
We detected a BRAF mutation (V600E) in only one papillary renal cell carcinoma case. DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
BRAF V600E detection in the tumor does not induce a higher expression of the B-raf protein or the pr... DisGeNET Detail
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patient... DisGeNET Detail
Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are found in 3% of huma... DisGeNET Detail
There was a significant size-dependent relationship between the presence of the BRAF(V600E) mutation... DisGeNET Detail
Three of the lines carried a heterozygous BRAF mutation V600E, which is in line with reports of BRAF... DisGeNET Detail
The highest frequencies of BRAF (V600E) mutations were found in WHO grade II pleomorphic xanthoastro... DisGeNET Detail
PCCl3 rat thyroid cells, PCCl3 cells overexpressing BRAF(V600E), or primary cultured tumor cells fro... DisGeNET Detail
Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed that, paradoxically... DisGeNET Detail
Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inh... DisGeNET Detail
HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma and hairy cell leuke... DisGeNET Detail
On ultrasound, papillary thyroid carcinomas with the BRAF(V600E) mutation tended to show a taller-th... DisGeNET Detail
In 26 studies, compared with the patients who had the wild-type BRAF genes, the PTC patients with th... DisGeNET Detail
MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosup... DisGeNET Detail
Despite its high specificity, our meta-analysis shows that BRAF(V600E) mutation analysis has a low s... DisGeNET Detail
Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carc... DisGeNET Detail
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cel... DisGeNET Detail
Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF V600E mutation. DisGeNET Detail
Before undergoing thyroidectomy, we performed molecular diagnostic tests that revealed the absence o... DisGeNET Detail
The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5... DisGeNET Detail
The aim of this study was to relate the CpG island methylator phenotype (CIMP; characterized by exte... DisGeNET Detail
Our studies indicate CNS tumor cells with BRAF(V600E) mutant cells (but not wild type) display high ... DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high f... DisGeNET Detail
The objective of the study was to investigate the effects of the BRAF V600E mutation on expression o... DisGeNET Detail
We further investigated the utility of combined BRAF V600E (VE1) and p16 analysis by immunohistochem... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
To summarize the usefulness of several recently discovered immunohistochemical markers in the study ... DisGeNET Detail
The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CRCs) harboring hMLH1 ... DisGeNET Detail
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with olde... DisGeNET Detail
Research has shown that a majority of melanomas and nevi exhibit an activating V600E (T1799A) mutati... DisGeNET Detail
The molecular genetic study of the BRAF gene showed the presence of a missense thymine to adenine tr... DisGeNET Detail
Interestingly, this combination was also effective against BRAF V600E-mutant melanoma cells that wer... DisGeNET Detail
About 40% to 60% of cutaneous melanomas have BRAF mutations, and 90% of the mutations involve a spec... DisGeNET Detail
Adult classical glioblastoma with a BRAF V600E mutation. DisGeNET Detail
Mutationally activated BRAF(V600E) cooperates with PTEN silencing in the conversion of normal melano... DisGeNET Detail
An occult micro-PTC with BRAF(V600E) mutation was also detected. DisGeNET Detail
Intratumoral heterogeneity of genomic imbalance in a case of epithelioid glioblastoma with BRAF V600... DisGeNET Detail
BRAF V600E mutational status in pediatric thyroid cancer. DisGeNET Detail
BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET/PT... DisGeNET Detail
Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that t... DisGeNET Detail
The presence of BRAF V600E and mitogen-activated protein kinase activation in a largely benign tumor... DisGeNET Detail
Advanced molecular techniques have identified distinct molecular aberrations in the Raf/MEK-ERK path... DisGeNET Detail
To summarize the usefulness of several recently discovered immunohistochemical markers in the study ... DisGeNET Detail
The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%) and RET/PTC in 55/... DisGeNET Detail
We found that the BRAF(V600E) mutation was significantly associated with the classic variant of papi... DisGeNET Detail
These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinoge... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
A significant difference between the control group and invasive melanomas (p&lt;0.01) was evidenced ... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
BRAF V600E mutation was analyzed in CRC patients with MMR deficiencies (microsatellite instability a... DisGeNET Detail
Thus, VE1 antibody can be used on thyroid microhistologic specimens to detect BRAF(V600E)-mutated PT... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
BRAF V600E appeared to be the most commonly mutated gene in both the melanocytic aggregate (seven of... DisGeNET Detail
Transgenic induction of BRAF(V600E)in the thyroid gland results in cancers resembling human papillar... DisGeNET Detail
Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and pyrosequencing used to... DisGeNET Detail
CIMP-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathways by IGFBP7 DNA hy... DisGeNET Detail
Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and pyrosequencing used to... DisGeNET Detail
The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CRCs) harboring hMLH1 ... DisGeNET Detail
BRAF(V600E) is the most common oncogenic lesion in melanoma and results in constitutive activation o... DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma... DisGeNET Detail
Suppression of BRAF(V599E) in human melanoma abrogates transformation. DisGeNET Detail
Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24A1 expression and en... DisGeNET Detail
The activating BRAF mutation V600E and related mutations in this codon are most important for the ac... DisGeNET Detail
Our investigation evaluates associations between active and passive smoking and TP53, KRAS2, and BRA... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
We analyzed 222 adenocarcinomas of lung lacking KRAS and EGFR mutations and identified 10 adenocarci... DisGeNET Detail
We used preclinical models of CRC to demonstrate (18)F-FLT PET as a sensitive predictor of response ... DisGeNET Detail
We have evaluated five different methods: the Cobas test, Sanger sequencing, pyrosequencing, TaqMan-... DisGeNET Detail
We have evaluated five different methods: the Cobas test, Sanger sequencing, pyrosequencing, TaqMan-... DisGeNET Detail
These results seem to indicate that Cdx2 may play a role in the serrated pathway to colorectal cance... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a... DisGeNET Detail
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and rest... DisGeNET Detail
The activating mutation BRAF(V600E) is a frequent genetic event in papillary thyroid carcinomas (PTC... DisGeNET Detail
BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting the importance of a... DisGeNET Detail
Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and pyrosequencing used to... DisGeNET Detail
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harbori... DisGeNET Detail
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in or... DisGeNET Detail
Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patien... DisGeNET Detail
Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mutations, and the CpG ... DisGeNET Detail
We conclude that a V600E BRAF mutation may not be helpful in distinguishing sporadic from MTS-associ... DisGeNET Detail
BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI stat... DisGeNET Detail
To summarize the usefulness of several recently discovered immunohistochemical markers in the study ... DisGeNET Detail
Activating point mutations of BRAF, such as BRAF (V600E), also lead to pilocytic astrocytoma. DisGeNET Detail
Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid c... DisGeNET Detail
Expression of BRAF V600E mutant protein in epithelial ovarian tumors. DisGeNET Detail
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E... DisGeNET Detail
BRAF(V600E) was not limited to LCH and was detected more frequently in histiocytic sarcoma. DisGeNET Detail
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanth... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph... DisGeNET Detail
MEK inhibitors are clinically active in BRAF(V600E) melanomas but only marginally so in KRAS mutant ... DisGeNET Detail
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. DisGeNET Detail
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colo... DisGeNET Detail
Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup a... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatm... DisGeNET Detail
Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy fo... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and inc... DisGeNET Detail
Combination of the BRAF(V600E) mutation and its splicing variants may contribute towards disease pro... DisGeNET Detail
Sodium arsenite- or statin-induced apoptosis was independent of BRAF status (wild type versus V600E)... DisGeNET Detail
IHC using the VE1 clone and FLEX linker is a specific method for the detection BRAF V600E and may be... DisGeNET Detail
Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E) status, which sugge... DisGeNET Detail
We demonstrate that SSA-associated synchronous colorectal carcinomas have a striking predilection fo... DisGeNET Detail
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyro... DisGeNET Detail
BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of ... DisGeNET Detail
The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyroid tumors and is ass... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and ... DisGeNET Detail
BRAF V600E and RAS mutations were mutually exclusive; all ATC cell lines exhibited a combination of ... DisGeNET Detail
This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and ... DisGeNET Detail
We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAF(V600E) inhibitor... DisGeNET Detail
Clinicopathological characteristics were evaluated according to the Notch1/Notch3 receptors and BRAF... DisGeNET Detail
A patient with sporadic metastatic MPNST and the BRAF V600E mutation was treated with standard doses... DisGeNET Detail
Mutations in the BRAF gene causing a V599E amino acid substitution that enhance the kinase activity ... DisGeNET Detail
Through an RNAi screen, here we identify the transcriptional repressor MAFG as the pivotal factor re... DisGeNET Detail
The BRAF mutant, BRAF(V600E), is expressed in nearly half of melanomas, and oral BRAF inhibitors ind... DisGeNET Detail
We analyzed the correlation between the presence/absence of the BRAF(V600E) mutation in the fine-nee... DisGeNET Detail
Absence of V599E BRAF mutations in desmoplastic melanomas. DisGeNET Detail
miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including... DisGeNET Detail
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inh... DisGeNET Detail
Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. DisGeNET Detail
Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy, in combination with... DisGeNET Detail
Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare ad... DisGeNET Detail
Neither CD34 expression nor BRAF(V600E) status was predictive of prognosis, except for PA tumors whe... DisGeNET Detail
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the smal... DisGeNET Detail
From September 2008 to December 2009, we performed routine analysis of the BRAF(V600E) mutation usin... DisGeNET Detail
We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immunostaining and BRAF ... DisGeNET Detail
The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of... DisGeNET Detail
Similarly, activation of Notch1 signaling promoted acquired resistance to MAPK inhibitors in BRAF(V6... DisGeNET Detail
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal canc... DisGeNET Detail
We aimed to analyze the expression of RAC1b in PTC and correlate its expression with BRAF V600E muta... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
BRAF(V600E) is present in PTC, both in the classic form and in follicular variant with similar preva... DisGeNET Detail
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal canc... DisGeNET Detail
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal ca... DisGeNET Detail
Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. DisGeNET Detail
Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations... DisGeNET Detail
We investigated 7 spindle cell oncocytomas, 4 pituicytomas, and 3 granular cell tumors for their gen... DisGeNET Detail
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool pan... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Somatic BRAF-V600E mutations in familial colorectal cancer. DisGeNET Detail
Cell sensitivity to PLX4032 was dependent on BRAF(V600E) and independent from other gene alterations... DisGeNET Detail
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that gene... DisGeNET Detail
BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along with p.G606G silent ch... DisGeNET Detail
To determine the prognostic significance of deficient mismatch repair (dMMR) and BRAF V600E in Thai ... DisGeNET Detail
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal ... DisGeNET Detail
The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of... DisGeNET Detail
Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant ... DisGeNET Detail
BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. DisGeNET Detail
Further supporting a crucial role of PDH in OIS, enforced normalization of either PDK1 or PDP2 expre... DisGeNET Detail
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans c... DisGeNET Detail
Advanced molecular techniques have identified distinct molecular aberrations in the Raf/MEK-ERK path... DisGeNET Detail
BRAF((V600E)) mutations were found in 14.3% of SSAs and 7.1% of RHPs. DisGeNET Detail
BRAF(V600E) was not limited to LCH and was detected more frequently in histiocytic sarcoma. DisGeNET Detail
Thus, BRAF V600E immunostaining is a helpful marker for pediatric metanephric adenoma, and additiona... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
BRAF mutations (V600E) were observed in 45.8% (11 of 24) of HPs, 60.9% (14 of 23) of SSAs, and 63.6%... DisGeNET Detail
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis. DisGeNET Detail
This last observation led us to investigate the role of BRAF(V600E) and the MEK-ERK pathway in thyro... DisGeNET Detail
Using pyrosequencing and quantitative methylation-specific PCR (Q-MSP) methods, FNABs from 79 and 38... DisGeNET Detail
Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
These results indicate that cfDNA BRAF(V600E) mutational analysis in plasma and urine provides a con... DisGeNET Detail
BRAF(V600E) allele was detected and quantified by an allele-specific real-time quantitative PCR assa... DisGeNET Detail
BRAF(V600E) mutation is an early event in thyroid carcinogenesis, and is associated with distinctive... DisGeNET Detail
To evaluate the latter possibility, a mutated NRAS(Q61R) oncogene was expressed, under a constitutiv... DisGeNET Detail
When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific BRAF inhibitor PLX40... DisGeNET Detail
This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E mutation, mutations... DisGeNET Detail
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
MEK inhibitors are clinically active in BRAF(V600E) melanomas but only marginally so in KRAS mutant ... DisGeNET Detail
Our data demonstrate that MEK inhibition of BRAF(V600E)-positive melanoma cells can protect from gen... DisGeNET Detail
Activating mutations in the BRAF serine/threonine kinase are found in &gt;70% of human melanomas, of... DisGeNET Detail
Before undergoing thyroidectomy, we performed molecular diagnostic tests that revealed the absence o... DisGeNET Detail
Furthermore, ICAM-1 upregulation correlated with aggressive tumor features such as BRAF V600E mutati... DisGeNET Detail
MSI-H colorectal carcinomas were divided into sporadic (112/1292, 8.7%) and LS/probable LS-associate... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we develope... DisGeNET Detail
Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. DisGeNET Detail
CH5126766/RO5126766 induced G1 cell cycle arrest in two melanoma cell lines with the BRAF V600E or N... DisGeNET Detail
To evaluate the latter possibility, a mutated NRAS(Q61R) oncogene was expressed, under a constitutiv... DisGeNET Detail
These tumors have been reported to show increased activity in the mitogen-activated protein kinase p... DisGeNET Detail
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 s... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
We previously reported the concurrent methylation of the mismatch repair gene MLH1 with a cluster of... DisGeNET Detail
With regard to implications for therapy, our results support evaluation of BRAF(V600E)-specific inhi... DisGeNET Detail
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. DisGeNET Detail
In clinical trials trametinib, a MEK inhibitor (MEKi) increases BRAFi therapy efficacy in BRAF(V600E... DisGeNET Detail
Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy in follicular neoplas... DisGeNET Detail
BRAF V600E mutation was not observed in any tubular adenoma or tubulovillous/villous adenoma. DisGeNET Detail
On PTC univariate analysis, EGFR-H correlated with increasing stage, extrathyroid extension, tumor c... DisGeNET Detail
In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a part of exon 15 BRAF ... DisGeNET Detail
Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Sp... DisGeNET Detail
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in mela... DisGeNET Detail
BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignan... DisGeNET Detail
Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma proliferation, whereas ... DisGeNET Detail
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. DisGeNET Detail
Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) mutation. DisGeNET Detail
Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in colorectal carcinom... DisGeNET Detail
The inability of MEK and RAF inhibitors, U0126 and sorafenib, respectively, to block the mitochondri... DisGeNET Detail
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... DisGeNET Detail
These findings indicate that adenomas might be less important in the cancer development in the group... DisGeNET Detail
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III c... DisGeNET Detail
Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and i... DisGeNET Detail
Cu chelators used in the treatment of Wilson disease decreased tumour growth of human or murine cell... DisGeNET Detail
We used RNA interference to evaluate the effect of BRAF knockdown in the human anaplastic thyroid ca... DisGeNET Detail
We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell lines, followed by ... DisGeNET Detail
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. DisGeNET Detail
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite ins... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in colorectal carcinom... DisGeNET Detail
Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant ... DisGeNET Detail
: The prevalence of BRAF V600E mutation was higher in conventional papillary thyroid cancer (51.0%) ... DisGeNET Detail
The increase in radioiodide accumulation by Apigenin with Akt inhibition was also observed in thyroi... DisGeNET Detail
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutioniz... DisGeNET Detail
Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 (3 melanomas and 1 n... DisGeNET Detail
The BRAF(V600E) mutation can be used as a potential prognostic factor in PTMC patients in a BRAF(V60... DisGeNET Detail
BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilat... DisGeNET Detail
Thus, BRAF V600E immunostaining is a helpful marker for pediatric metanephric adenoma, and additiona... DisGeNET Detail
Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E) status, which sugge... DisGeNET Detail
Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microc... DisGeNET Detail
Through an RNAi screen, here we identify the transcriptional repressor MAFG as the pivotal factor re... DisGeNET Detail
Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyroid tumor initiation... DisGeNET Detail
The increase in radioiodide accumulation by Apigenin with Akt inhibition was also observed in thyroi... DisGeNET Detail
The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of... DisGeNET Detail
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanth... DisGeNET Detail
BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. DisGeNET Detail
The classical V600E BRAF mutation was not found; instead a novel V600L was observed suggesting that ... DisGeNET Detail
The probability of PTC for thyroid nodules with intermediate-risk (IR) US and atypia of undetermined... DisGeNET Detail
Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas... DisGeNET Detail
We used RNA interference to evaluate the effect of BRAF knockdown in the human anaplastic thyroid ca... DisGeNET Detail
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harbori... DisGeNET Detail
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRA... DisGeNET Detail
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we develope... DisGeNET Detail
Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: c... DisGeNET Detail
These results clarify that the mutated BRAF (V599E) is essentially involved in malignant phenotype o... DisGeNET Detail
This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E mutation, mutations... DisGeNET Detail
Discoveries of frequent mutations involving BRAF(V600E), developmental and oncogenic roles for the m... DisGeNET Detail
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and me... DisGeNET Detail
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyro... DisGeNET Detail
We investigated 194 serrated lesions of the colon, comprising 42 sessile serrated adenomas/polyps, 1... DisGeNET Detail
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high freq... DisGeNET Detail
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic... DisGeNET Detail
Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in m... DisGeNET Detail
Combined, these data demonstrate that the BRAF(V600E) cooperates with either PIK3CA(H1074R) or with ... DisGeNET Detail
Anthrax lethal toxin (LT), a virulence factor secreted by Bacillus anthracis, is selectively toxic t... DisGeNET Detail
Assaying for BRAF V600E in tissue and blood in melanoma. DisGeNET Detail
The demonstration of the BRAF V600E mutation in the pineal tumor made the patient eligible for intra... DisGeNET Detail
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-t... DisGeNET Detail
In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four parental cell lines and t... DisGeNET Detail
However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less freque... DisGeNET Detail
Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules. DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRA... DisGeNET Detail
Additionally, preclinical and clinical studies investigating combination therapy with agents such as... DisGeNET Detail
In contrast, age- and size-matched classic papillary microcarcinomas (n=26) showed no extrathyroidal... DisGeNET Detail
Our findings offer evidence of the potent antitumor activity of RG7204 against melanomas harboring t... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 s... DisGeNET Detail
The low incidence of BRAF(V600E)(-) mutant melanoma among Irish patients was confirmed in five indep... DisGeNET Detail
Neither the presence of V600E BRAF mutations nor that of a well-differentiated thyroid carcinoma cha... DisGeNET Detail
CIMP-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathways by IGFBP7 DNA hy... DisGeNET Detail
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. DisGeNET Detail
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... DisGeNET Detail
Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 (3 melanomas and 1 n... DisGeNET Detail
We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell lines, followed by ... DisGeNET Detail
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-1... DisGeNET Detail
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. DisGeNET Detail
IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may ... DisGeNET Detail
We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAF(V600E) inhibitor... DisGeNET Detail
The molecular genetic study of the BRAF gene showed the presence of a missense thymine to adenine tr... DisGeNET Detail
In conclusion, we provide evidences that BRAF (V600E) is non-associated with Gal-3 expression, where... DisGeNET Detail
In line with the previous reports, NRAS/BRAF mutations were rare; only one metastatic tumor had an N... DisGeNET Detail
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. DisGeNET Detail
BRAF(T1799A) mutation improves the diagnosis of PTC on FNAB, mainly because of the detection of cyto... DisGeNET Detail
The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and hMLH1) were assessed... DisGeNET Detail
Accordingly, therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cell... DisGeNET Detail
These results indicate that cfDNA BRAF(V600E) mutational analysis in plasma and urine provides a con... DisGeNET Detail
Our results describe a lung cell population in neonates mice where expression of BRAF(V600E) leads t... DisGeNET Detail
The five conventional PTC cell lines carry the BRAF V600E mutation and the follicular variant of PTC... DisGeNET Detail
Treatment of patients with thyroid nodules is guided by FNA biopsy, which can be scantly cellular, n... DisGeNET Detail
Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independe... DisGeNET Detail
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal can... DisGeNET Detail
In vitro, we showed that ABCB5-expressing cells selectively survive when exposed to dacarbazine, the... DisGeNET Detail
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. DisGeNET Detail
BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. DisGeNET Detail
We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresec... DisGeNET Detail
However, as in humans, BRAF(V600E)-induced mouse PTC is indolent and does not lead to rapid developm... DisGeNET Detail
Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insufficient for tumorigen... DisGeNET Detail
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immunostaining and BRAF ... DisGeNET Detail
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-1... DisGeNET Detail
Further supporting a crucial role of PDH in OIS, enforced normalization of either PDK1 or PDP2 expre... DisGeNET Detail
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in ... DisGeNET Detail
Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line me... DisGeNET Detail
Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15-30% of patients... DisGeNET Detail
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite ins... DisGeNET Detail
We performed an integrative analysis of transcriptomic and epigenomic changes disturbed by BRAF (V60... DisGeNET Detail
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorecta... DisGeNET Detail
This study provides a foundation for future investigations designed to improve BRAF inhibitor effect... DisGeNET Detail
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 express... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immunostaining and BRAF ... DisGeNET Detail
KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 methylation and express... DisGeNET Detail
CAST-PCR gave rapid and accurate results for the common V600E and V600K mutations, however additiona... DisGeNET Detail
This review focuses on the recent progress in understanding the role of BRAF(V600E) in the regulatio... DisGeNET Detail
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through B... DisGeNET Detail
BRAF(V600E) mutation was detected in 50% of the acquired nevi and in 70% of the cutaneus melanomas i... DisGeNET Detail
The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung a... DisGeNET Detail
The prevalence of BRAF(V600E) was considerably higher in older (age &gt; 70) females with KRAS wild-... DisGeNET Detail
The BRAF kinase is mutated, typically Val 600→Glu (V600E), to induce an active oncogenic state in a ... DisGeNET Detail
BRAF(V600E) cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinas... DisGeNET Detail
Expression of AID in malignant melanoma with BRAF(V600E) mutation. DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
All polyps showed the BRAF-V600E mutation. DisGeNET Detail
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high freq... DisGeNET Detail
Discoveries of frequent mutations involving BRAF(V600E), developmental and oncogenic roles for the m... DisGeNET Detail
A correlation between MLH1 promoter methylation, specifically the 'C' region, and BRAF V600E status ... DisGeNET Detail
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF... DisGeNET Detail
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillar... DisGeNET Detail
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth ... DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
BRAF(V600E) mutation analysis from May-Grünwald Giemsa-stained cytological samples as an adjunct in ... DisGeNET Detail
Vemurafenib, a selective BRAF (v-raf murine sarcoma viral oncogene homologue B1) kinase inhibitor, i... DisGeNET Detail
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the futu... DisGeNET Detail
The absence of the BRAF V600E mutation within a changing naevus supports the theory that BRAFi stimu... DisGeNET Detail
Researchers retrospectively reviewed medical records of all patients at our institution with surgica... DisGeNET Detail
The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of... DisGeNET Detail
BRAF p.V600E mutation was present in all HCL cases and absent in all HCL-v. Our data support the rec... DisGeNET Detail
The BRAF V600E missense mutation is known to be present in a subset of central nervous system tumors... DisGeNET Detail
Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF(V60... DisGeNET Detail
Our studies indicate CNS tumor cells with BRAF(V600E) mutant cells (but not wild type) display high ... DisGeNET Detail
Significance of allelic percentage of BRAF c.1799T &gt; A (V600E) mutation in papillary thyroid carc... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Finally, we conclude that inhibition of SHH-GLI signaling pathway in human melanoma by the specific ... DisGeNET Detail
The absence of the BRAF V600E mutation within a changing naevus supports the theory that BRAFi stimu... DisGeNET Detail
We used preclinical models of CRC to demonstrate (18)F-FLT PET as a sensitive predictor of response ... DisGeNET Detail
Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer c... DisGeNET Detail
NRAS mutations were associated with thicker tumors and higher rates of mitosis when compared to BRAF... DisGeNET Detail
The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on cl... DisGeNET Detail
The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyroid tumors and is ass... DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four parental cell lines and t... DisGeNET Detail
Subtype stratification demonstrated that the BRAF V600E mutation was associated with tumor size, ext... DisGeNET Detail
Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome i... DisGeNET Detail
Additionally, preclinical and clinical studies investigating combination therapy with agents such as... DisGeNET Detail
Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical beha... DisGeNET Detail
We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immunostaining and BRAF ... DisGeNET Detail
A 49-year-old man initially diagnosed in 1995 with cutaneous melanoma presented to the authors' inst... DisGeNET Detail
Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF(V60... DisGeNET Detail
Though such data suggest that BRAF mutation is likely an early initiating event in tumors such as me... DisGeNET Detail
Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 l... DisGeNET Detail
Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24A1 expression and en... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
All four patients with distant metastasis had BRAF(V600E) mutation. DisGeNET Detail
We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investiga... DisGeNET Detail
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recu... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in or... DisGeNET Detail
Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant ... DisGeNET Detail
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
This study compared two biomarkers in tumours with mismatch repair deficiency; quantification of met... DisGeNET Detail
Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Ex... DisGeNET Detail
BRAF V600E mutations were not identified in the early-onset colorectal carcinoma group. DisGeNET Detail
We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer is associated with a ... DisGeNET Detail
Associations with the BRAF(T1799A) mutation (P&lt;0.05) were as follows: low tumor thickness (odds r... DisGeNET Detail
To explore the mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus oncogene homolog B1) ... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
In this study, we utilised genetically engineered melanoma cell lines and xenograft mouse models to ... DisGeNET Detail
Three of the lines carried a heterozygous BRAF mutation V600E, which is in line with reports of BRAF... DisGeNET Detail
Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms... DisGeNET Detail
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF(V600E)) are found in 3% of huma... DisGeNET Detail
In five thyroglossal carcinomas, mutated BRAF (V600E) was found, three in PTC and in thyroglossal as... DisGeNET Detail
BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroi... DisGeNET Detail
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-1... DisGeNET Detail
The BRAF(V600E) mutation was absent in tumor DNA samples obtained from patients with benign follicul... DisGeNET Detail
Somatic BRAF mutations have been reported in 1-4% of non-small cell lung cancer (NSCLC), primarily i... DisGeNET Detail
Next, of the 15 archived melanoma FNAs tested, BRAF mutations were observed in 8 (53%); 5 and 3 mela... DisGeNET Detail
While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM studied (n = 21), th... DisGeNET Detail
KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 methylation and express... DisGeNET Detail
Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors. DisGeNET Detail
In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch rep... DisGeNET Detail
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72... DisGeNET Detail
Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-mutant thyroid cance... DisGeNET Detail
The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunit... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
In this article, we will summarize results on preclinical testing of selective and nonselective sing... DisGeNET Detail
This tumour-specific inhibition of ERK signalling results in a broad therapeutic index and RAF inhib... DisGeNET Detail
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response... DisGeNET Detail
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth ... DisGeNET Detail
Both melanomas carried the V600E BRAF mutation. DisGeNET Detail
We wanted to gain an understanding of the role of GNAQ, GNA11 and BRAF V600E in the pathogenesis of ... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. DisGeNET Detail
Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma... DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for m... DisGeNET Detail
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that gene... DisGeNET Detail
It is evident that the detection of the BRAF V600E mutation is crucial in order to identify novel av... DisGeNET Detail
This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patients in Indian subcon... DisGeNET Detail
Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (p... DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of he... DisGeNET Detail
Dabrafenib has been approved to treat patients with BRAF(V600E)-positive unresectable or metastatic ... DisGeNET Detail
Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mut... DisGeNET Detail
Several transcription factors and signaling pathways involved in the regulation of MITF expression a... DisGeNET Detail
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and... DisGeNET Detail
Among the 779 cases, 150 cases were positive for BRAF (V600E) staining, including 38 (of 611, 6%) CR... DisGeNET Detail
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF... DisGeNET Detail
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic co... DisGeNET Detail
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PT... DisGeNET Detail
We also observed a positive association between BRAF V600E and TERT C228T mutations in the cohort of... DisGeNET Detail
We defined sporadic MSI-high carcinomas as those with loss of MLH1 and PMS2 immunostaining and BRAF ... DisGeNET Detail
Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (p... DisGeNET Detail
Although BRAF(V600E) is well known to play an important role in the tumorigenesis of melanoma, its m... DisGeNET Detail
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency ... DisGeNET Detail
Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 (3 melanomas and 1 n... DisGeNET Detail
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of he... DisGeNET Detail
Furthermore, melanomas and their associated naevi were concordant in BRAF(V600E) status, which sugge... DisGeNET Detail
However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors and become ineffect... DisGeNET Detail
BRAF(T1799A) can be detected in the blood of PTC patients with residual or metastatic disease and ma... DisGeNET Detail
BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers from 206 sporadic c... DisGeNET Detail
BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. DisGeNET Detail
Peripheral blood DNA from two of these tumor-positive cases of sporadic melanoma were negative for t... DisGeNET Detail
The second is vemurafenib, an inhibitor that blocks the abnormal signaling for melanoma cellular gro... DisGeNET Detail
The V599E BRAF mutation is uncommon in biliary tract cancers. DisGeNET Detail
We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chro... DisGeNET Detail
The activating mutation BRAF(V600E) is a frequent genetic event in papillary thyroid carcinomas (PTC... DisGeNET Detail
We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in their combinational tre... DisGeNET Detail
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. DisGeNET Detail
Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for de... DisGeNET Detail
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and inc... DisGeNET Detail
In malignant FNABs, BRAF(V600E) mutation was significantly associated with presence of extra-thyroid... DisGeNET Detail
The aim of this study is to compare the utility of methylation analysis of MLH1 and BRAF V600E mutat... DisGeNET Detail
To verify the technical characteristics of the microarray system for the correct identification of t... DisGeNET Detail
Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. DisGeNET Detail
Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-a... DisGeNET Detail
Around 50% of cutaneous melanomas harbor the BRAF(V600E) mutation and can be treated with BRAF inhib... DisGeNET Detail
Targeting MEK1/2 is proving to be an important therapeutic strategy, given that a MEK1/2 inhibitor p... DisGeNET Detail
Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V600E)-mutated melanom... DisGeNET Detail
This study correlates histological features, immunoreactivity for CK19, HBME, and Gal, and BRAF V600... DisGeNET Detail
The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of papillary carcinomas ... DisGeNET Detail
NA DisGeNET Detail
Uncommon V599E BRAF mutations in Japanese patients with lung cancer. DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
BRAF(V600E) mutation analysis is a highly sensitive diagnostic tool in the diagnosis of papillary th... DisGeNET Detail
These results provide a conceptual framework for the combined deployment of BRAF(V600E) plus PI3K pa... DisGeNET Detail
We obtained blood and tissue samples from a patient diagnosed with a BRAF(V600E)-mutant cutaneous me... DisGeNET Detail
Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta... DisGeNET Detail
Here, we show intralesional molecular heterogeneity in a progressing V600E BRAF-mutant melanoma meta... DisGeNET Detail
Detection of the BRAF V600E mutation in colorectal cancer by immunohistochemistry is a viable altern... DisGeNET Detail
Based on in silico screening results, a series of novel pyrazole derivatives has been designed, synt... DisGeNET Detail
Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid car... DisGeNET Detail
BRAF(V600E) significantly correlated with absence of node metastasis. DisGeNET Detail
Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis. DisGeNET Detail
We investigated the associations between BRAF(V600E) and NRAS(Q61R) mutations and known risk factors... DisGeNET Detail
The reactivation of senescence features and elimination of cells refractory to BRAF(V600E) inhibitio... DisGeNET Detail
Dual abnormalities of INI-1 loss and V600E BRAF mutation were identified in a cell culture line esta... DisGeNET Detail
A BRAF p.Thr599dup or p.V600E mutation was identified by Sanger sequencing in one and five gliomas, ... DisGeNET Detail
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid ca... DisGeNET Detail
RAF inhibitors such as vemurafenib and dabrafenib block BRAF-mediated cell proliferation and achieve... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
There were significant differences in clinicopathological parameters, such as extrathyroidal extensi... DisGeNET Detail
Importantly, genetic extinction of BRAF(V600E) in established prostate tumors did not lead to tumor ... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along with p.G606G silent ch... DisGeNET Detail
These data support a role for BRAF V600E IHC in diagnostically challenging cases of MA and expand th... DisGeNET Detail
BRAF(V600E) mutation was detected in 20 of 43 PTCs and all three anaplastic thyroid carcinomas (ATCs... DisGeNET Detail
HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma and hairy cell leuke... DisGeNET Detail
The two groups did not show significant differences in clinical and prognostic features, whereas the... DisGeNET Detail
Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. DisGeNET Detail
NFAT2 and 4 are expressed in human metastatic melanoma cell lines and are activated by oncogenic BRA... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma... DisGeNET Detail
To summarize the usefulness of several recently discovered immunohistochemical markers in the study ... DisGeNET Detail
Moreover, concomitant expression of BRAF(V600E) and TP53(R270H) result in lethal PDA. DisGeNET Detail
This article summarises the milestones in the development of dabrafenib leading to this first approv... DisGeNET Detail
We investigated the hypothesis that this common somatic BRAF mutation (V599E) would contribute to me... DisGeNET Detail
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall... DisGeNET Detail
Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24A1 expression and en... DisGeNET Detail
This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using ... DisGeNET Detail
Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC... DisGeNET Detail
We have identified an alternative pathway of tumorigenesis in sporadic colon cancer, involving micro... DisGeNET Detail
The high prevalence of BRAF(V600E) activating mutation in papillary thyroid carcinoma, cutaneous mal... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
A correlation between MLH1 promoter methylation, specifically the 'C' region, and BRAF V600E status ... DisGeNET Detail
Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor. DisGeNET Detail
Control of BRAF(V600E) metastatic melanoma by BRAF inhibitor (BRAF-I) is limited by intrinsic and ac... DisGeNET Detail
Orthotopic mouse models for the preclinical and translational study of targeted therapies against me... DisGeNET Detail
Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF signaling in BRAF(V6... DisGeNET Detail
Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid n... DisGeNET Detail
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vem... DisGeNET Detail
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. DisGeNET Detail
Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation ... DisGeNET Detail
Results from a phase 3 trial (N=675) comparing vemurafenib 960 mg twice daily (taken either with or ... DisGeNET Detail
Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in th... DisGeNET Detail
Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using mult... DisGeNET Detail
In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary ca... DisGeNET Detail
Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inh... DisGeNET Detail
The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired r... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu ... DisGeNET Detail
Our data show for the first time that BRAF(V600E) mutation increases HIF-1alpha expression and melan... DisGeNET Detail
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers. DisGeNET Detail
29 (39·2%, 95% CI 28·0-51·2) of 74 patients with Val600Glu BRAF-mutant melanoma in cohort A achieved... DisGeNET Detail
In microsatellite stable tumors, homozygous carriers of the G39E polymorphism had an increased risk ... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cance... DisGeNET Detail
We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcar... DisGeNET Detail
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic me... DisGeNET Detail
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and La... DisGeNET Detail
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with ... DisGeNET Detail
Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic va... DisGeNET Detail
Overall, BRAF(V600E) PTC tumors display a broadly immunosuppressive profile and evidence of disturbe... DisGeNET Detail
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström... DisGeNET Detail
When used alone or in combination with a specific inhibitor of the BRAF(V600E) oncogene, DHODH inhib... DisGeNET Detail
We propose an assay based on the use of a locked nucleic acid probe and an allele specific primer to... DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
Vemurafenib is an oral agent licensed for patients with BRAF V600E mutation-positive inoperable and ... DisGeNET Detail
We studied the efficacy of dabrafenib in patients with BRAF(V600E)-mutated metastatic melanoma. DisGeNET Detail
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential u... DisGeNET Detail
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasi... DisGeNET Detail
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. DisGeNET Detail
In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch rep... DisGeNET Detail
In contrast, the frequency of PTC cases with point mutations (mainly BRAF(V600E)) was significantly ... DisGeNET Detail
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-1... DisGeNET Detail
These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiol... DisGeNET Detail
The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mu... DisGeNET Detail
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal canc... DisGeNET Detail
High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients w... DisGeNET Detail
Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy, in combination with... DisGeNET Detail
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the m... DisGeNET Detail
Mutationally activated BRAF(V600E) cooperates with PTEN silencing in the conversion of normal melano... DisGeNET Detail
Here, we confirm the specificity of BRAF V600E for HCL among low and intermediate grade B-NHL and de... DisGeNET Detail
However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors and become ineffect... DisGeNET Detail
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the smal... DisGeNET Detail
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) i... DisGeNET Detail
We also found no BRAF V599E mutation in 101 normal healthy women and 10 well-established ovarian can... DisGeNET Detail
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. DisGeNET Detail
BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent... DisGeNET Detail
Furthermore, we identify TP53/Trp53 as a UVR-target gene that cooperates with BRAF(V600E) to induce ... DisGeNET Detail
BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated... DisGeNET Detail
Vemurafenib is a new-targeted therapy approved for the treatment of patients with V600E BRAF-mutant ... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramati... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
To explore the mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus oncogene homolog B1) ... DisGeNET Detail
Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous bo... DisGeNET Detail
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that gene... DisGeNET Detail
The aim of our study was to test sebaceous neoplasms for V600E BRAF or KRAS mutations to determine i... DisGeNET Detail
BRAF(V600E) mutation may be associated with an unfavorable prognosis among melanoma patients. DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
V600E point mutation was identified in the BRAF gene in 3 intramucosal nevi and in 2 melanomas. DisGeNET Detail
Both the HP and TSA exhibited the V600E BRAF mutation without MSI or MMR deficiency. DisGeNET Detail
V600E BRAF mutations occur in 29% of cases, all of them classified as serrated adenoma. DisGeNET Detail
When subclassified by combined BRAF V600E mutation and MMR status, loss of ARID1A expression was fou... DisGeNET Detail
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström... DisGeNET Detail
The effect of NRAS mutations on the pathological features and clinical outcomes in patients with cut... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
A previous study identified BRAF V600E mutations in approximately 90% of MA and found that similar B... DisGeNET Detail
Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyro... DisGeNET Detail
Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection... DisGeNET Detail
Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extra... DisGeNET Detail
This study hypothesized that the BRAF V600E mutation may be associated with mucinous morphology in e... DisGeNET Detail
In this study we investigated the application of a BRAF V600E mutation-specific antibody (clone VE1)... DisGeNET Detail
The association of BRAF V600E mutation and the presence of the CpG island methylator phenotype (CIMP... DisGeNET Detail
Associations with the BRAF(T1799A) mutation (P&lt;0.05) were as follows: low tumor thickness (odds r... DisGeNET Detail
A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic r... DisGeNET Detail
In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer p... DisGeNET Detail
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PL... DisGeNET Detail
The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways causes papillary thyr... DisGeNET Detail
We report the clinical course and management in 2 women with metastatic melanomas harboring the BRAF... DisGeNET Detail
We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresec... DisGeNET Detail
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, a... DisGeNET Detail
All neoplastic melanocytes within such a nevus would be expected to carry the BRAF mutation, and thu... DisGeNET Detail
The proportion of BRAF(V600E) mutation was significantly associated with the number of high-risk fac... DisGeNET Detail
We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild... DisGeNET Detail
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 exp... DisGeNET Detail
Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer... DisGeNET Detail
We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leuke... DisGeNET Detail
The most common recurring mutation in cutaneous melanoma is the prooncogenic BRAF V600E mutation tha... DisGeNET Detail
In addition to the diagnostic use, BRAF V600E mutation can also be used for tumor prognostication, a... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients w... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and pyrosequencing used to... DisGeNET Detail
The V600E mutation in the kinase BRAF is frequently detected in melanomas and results in constitutiv... DisGeNET Detail
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... DisGeNET Detail
Different types of aberrations of the BRAF gene in the classic and oligodendroglioma-like component ... DisGeNET Detail
In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ERK pathway, and targe... DisGeNET Detail
We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investiga... DisGeNET Detail
We demonstrate that SSA-associated synchronous colorectal carcinomas have a striking predilection fo... DisGeNET Detail
BRAF is the most mutated gene in melanoma, with approximately 50% of patients containing V600E mutan... DisGeNET Detail
To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, we conducted a compr... DisGeNET Detail
Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 l... DisGeNET Detail
The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 over... DisGeNET Detail
We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the der... DisGeNET Detail
The BRAF(V600E) mutation is the most common diagnostic/prognostic marker in papillary thyroid carcin... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
A single BRAF V600E mutation was identified in the fusion-negative extracerebellar PA of a very youn... DisGeNET Detail
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of he... DisGeNET Detail
The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patie... DisGeNET Detail
BRAF V600E mutation and CpG island methylation phenotype-positive status are similar in signet ring ... DisGeNET Detail
HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma and hairy cell leuke... DisGeNET Detail
In exon 15, one BRAF mutation (1796 thymine to adenine; V599E) was found in nonsmoking woman with we... DisGeNET Detail
they were normally maintained hypomethylated and over-expressed by BRAF V600E in thyroid cancer cell... DisGeNET Detail
These tumors showed a markedly better prognosis, with molecularly PXA-like tumors frequently harbori... DisGeNET Detail
The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways causes papillary thyr... DisGeNET Detail
Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome i... DisGeNET Detail
BRAF(V600E) mutations are frequent in melanomas originating from intermittently sun-exposed skin and... DisGeNET Detail
To determine whether specific mutations are clinically important to differentiate, tumor characteris... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary ... DisGeNET Detail
NA DisGeNET Detail
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohisto... DisGeNET Detail
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the futu... DisGeNET Detail
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyro... DisGeNET Detail
With the discovery of (V600E)BRAF in about 50% of cutaneous melanomas, there was an increased effort... DisGeNET Detail
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal canc... DisGeNET Detail
The molecular genetic study of the BRAF gene showed the presence of a missense thymine to adenine tr... DisGeNET Detail
Inadequate evidence was found regarding association of BRAF V600E mutation testing or loss of PTEN e... DisGeNET Detail
Recombinant insulin attenuated dacarbazine-induced cytotoxicity in both wild-type BRAF and BRAF(V600... DisGeNET Detail
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
Studies presented or published during the European Society for Medical Oncology conference demonstra... DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the futu... DisGeNET Detail
Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteris... DisGeNET Detail
Contrary to KRAS mutant tumors, BRAF(V600E)-induced tumors are benign adenomas that fail to progess. DisGeNET Detail
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool pan... DisGeNET Detail
Our findings indicate that the association of LCH and ECD is not fortuitous and suggest a link betwe... DisGeNET Detail
Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based r... DisGeNET Detail
We wanted to gain an understanding of the role of GNAQ, GNA11 and BRAF V600E in the pathogenesis of ... DisGeNET Detail
BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, inclu... DisGeNET Detail
Detection of BRAF(V600E) in cytology specimens by pyrosequencing is a useful diagnostic adjunctive t... DisGeNET Detail
This last observation led us to investigate the role of BRAF(V600E) and the MEK-ERK pathway in thyro... DisGeNET Detail
Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an importan... DisGeNET Detail
In conclusion, we used highly sensitive BRAF mutation detection methods and observed substantial evi... DisGeNET Detail
The T1799A BRAF mutation is present in iris melanoma. DisGeNET Detail
We identified a novel breakpoint region at 14q32.13 that was rearranged together with IGH/14q32.33 i... DisGeNET Detail
BRAF V600E mutation, common in papillary thyroid carcinoma (PTC), is helpful in fine needle aspirati... DisGeNET Detail
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. DisGeNET Detail
DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mutation in papillary t... DisGeNET Detail
Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates... DisGeNET Detail
Targeted expression of rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) and V6... DisGeNET Detail
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PL... DisGeNET Detail
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-1... DisGeNET Detail
We assessed phospho-ERK expression in 37 patients with hairy cell leukemia and 44 patients with neop... DisGeNET Detail
BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indi... DisGeNET Detail
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanth... DisGeNET Detail
The primary endpoint was the proportion of patients with Val600Glu BRAF-mutant melanoma who achieved... DisGeNET Detail
Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. DisGeNET Detail
Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful ... DisGeNET Detail
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. DisGeNET Detail
Besides confirming the presence of known melanoma driver mutations (BRAF(V600E), NRAS(Q61R) ), we id... DisGeNET Detail
Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the mutation in their met... DisGeNET Detail
Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic va... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. DisGeNET Detail
However, a subset of AUS/FLUS cases with the V600E BRAF mutation appeared to represent sampling vari... DisGeNET Detail
Thus, BRAF V600E immunostaining is a helpful marker for pediatric metanephric adenoma, and additiona... DisGeNET Detail
We also investigated the value of ultrasound features that predict malignancy and BRAF(V600E) mutati... DisGeNET Detail
miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regulated miRNA in CRCs w... DisGeNET Detail
Epidermal growth factor receptor (EGFR) overexpression (EGFR-H) is implicated in thyroid carcinoma d... DisGeNET Detail
The BRAF(V600E) mutation was absent in tumor DNA samples obtained from patients with benign follicul... DisGeNET Detail
Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mutations, and the CpG ... DisGeNET Detail
BRAF (V600E) mutation assay was performed to explore its value in the differential diagnosis for ser... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600... DisGeNET Detail
A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important to... DisGeNET Detail
Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation ... DisGeNET Detail
We found a high rate of V559E mutations in papillary thyroid carcinomas (47%), one V599E mutation in... DisGeNET Detail
The BRAF(V600E) mutation, which accounts for about 60-80% papillary thyroid carcinoma(PTC), has been... DisGeNET Detail
BRAF (V600E) might provide prognostic and diagnostic information for papillary thyroid carcinoma. DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Specific KRAS mutation is an informative prognostic factor in both sporadic and hereditary CRC and a... DisGeNET Detail
Absence of V599E BRAF mutations in desmoplastic melanomas. DisGeNET Detail
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorecta... DisGeNET Detail
In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary ca... DisGeNET Detail
Colorectal cancers arising from serrated polyps are characterized by the CpG island methylator pheno... DisGeNET Detail
The authors' data suggested that BRAF(V600E) mutation and p27(Kip1) down-regulation in cancer cells ... DisGeNET Detail
PCCL3 rat thyroid cells that conditionally overexpress either BRAF(V600E) or RET/PTC were also treat... DisGeNET Detail
Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration bi... DisGeNET Detail
In this review, clinicopathologic characteristics associated with BRAF-mutant tumors will be highlig... DisGeNET Detail
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency ... DisGeNET Detail
We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild... DisGeNET Detail
The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients with lymph node meta... DisGeNET Detail
Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillar... DisGeNET Detail
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3... DisGeNET Detail
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph... DisGeNET Detail
We evaluated CNS tumor cells with BRAF(V600E) and found that mutant (but not wild-type) cells displa... DisGeNET Detail
Multivariate logistic regression analysis confirmed that BRAF((V600E)) was an independent predictor ... DisGeNET Detail
Herein, we present the case of a patient with bulky V600E-mutant BRAF hepatic flexure colon carcinom... DisGeNET Detail
The prevalence (90%) of the BRAF (V600E) mutation in this study is the highest ever reported, confir... DisGeNET Detail
Decreased CPSF2 gene expression was associated with shorter disease-free survival (P = .03), large t... DisGeNET Detail
BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in ameloblastic fibromas... DisGeNET Detail
Genetic analyses revealed amplification of the BRAF gene in both the primary cerebellar pilocytic as... DisGeNET Detail
These results seem to indicate that Cdx2 may play a role in the serrated pathway to colorectal cance... DisGeNET Detail
This combinatorial effect was recapitulated in human melanoma-derived cell lines and was restricted ... DisGeNET Detail
Decreased CPSF2 gene expression was associated with shorter disease-free survival (P = .03), large t... DisGeNET Detail
One melanoma carried a BRAF point mutation that is frequently found in cutaneous melanomas (c.1799 T... DisGeNET Detail
Although BRAF(V600E) represents 95% of all BRAF mutations, uncommon BRAF mutations have been identif... DisGeNET Detail
The percentage of BRAF(V600E) alleles (P = 0.014), tumor volume (P = 0.012), and lymph node metastas... DisGeNET Detail
BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers from 206 sporadic c... DisGeNET Detail
To investigate the alternative methods like immunohistochemistry and exon 15 in the BRAF gene 1799 T... DisGeNET Detail
The BRAF-V600E hotspot mutation was found in 40% (82/206) of the sporadic MSI-H tumours analysed but... DisGeNET Detail
Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in th... DisGeNET Detail
The negative regulators of the cell cycle, p21 and p27, are strongly induced by transcriptional acti... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
The recognition of this functional trilogy provides insight on how BRAF(V600E) determines cancer ini... DisGeNET Detail
Additionally, preclinical and clinical studies investigating combination therapy with agents such as... DisGeNET Detail
Dabrafenib has activity and an acceptable safety profile in patients with Val600Glu BRAF-mutant mela... DisGeNET Detail
After surgery, 115 nodules were confirmed as conventional papillary thyroid carcinoma and 102 (88.70... DisGeNET Detail
The BRAF V600E mutation plays an important role in the tumorigenesis of papillary thyroid cancer (PT... DisGeNET Detail
The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation anal... DisGeNET Detail
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated ... DisGeNET Detail
The aim of this study is to compare the utility of methylation analysis of MLH1 and BRAF V600E mutat... DisGeNET Detail
We show that activation of the PI3K/AKT pathway is a mechanism of both innate and acquired resistanc... DisGeNET Detail
Metastatic melanoma has a high prevalence of V600-mutant BRAF, and clinical trials showed that dabra... DisGeNET Detail
We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases in Peking Union Medi... DisGeNET Detail
Approximately 45% of papillary thyroid carcinomas harbor BRAF p.V600E mutations and current practice... DisGeNET Detail
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström... DisGeNET Detail
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the der... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
The aim of this study was to relate the CpG island methylator phenotype (CIMP; characterized by exte... DisGeNET Detail
Both the HP and TSA exhibited the V600E BRAF mutation without MSI or MMR deficiency. DisGeNET Detail
Patients with BRAF(WT/V600E)-MPC should be closely followed because of the risk for multifocality/re... DisGeNET Detail
Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in ma... DisGeNET Detail
BRAF V600E was associated with extrathyroidal invasion (P &lt; 0.0001), multicentricity (P = 0.0026)... DisGeNET Detail
Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirat... DisGeNET Detail
In this study, we utilised genetically engineered melanoma cell lines and xenograft mouse models to ... DisGeNET Detail
The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, e... DisGeNET Detail
Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: ev... DisGeNET Detail
BRAF(V600E) mutation and p27(kip1) expression have been introduced as novel indicators that may pred... DisGeNET Detail
We strongly recommend preoperative evaluation of the BRAF V600E mutation in indeterminate thyroid no... DisGeNET Detail
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between th... DisGeNET Detail
The prevalence of the BRAF(V599E) mutation in PTC is the highest reported to date in human carcinoma... DisGeNET Detail
BRAF V600E mutation analysis was performed in 148 selected cases; mutations were found in 44/49 (90%... DisGeNET Detail
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. DisGeNET Detail
We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the der... DisGeNET Detail
We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom treatment with vemurafen... DisGeNET Detail
In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BR... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutioniz... DisGeNET Detail
To summarize the usefulness of several recently discovered immunohistochemical markers in the study ... DisGeNET Detail
What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on c... DisGeNET Detail
Advanced molecular techniques have identified distinct molecular aberrations in the Raf/MEK-ERK path... DisGeNET Detail
The T1799A BRAF mutation was identified in two of the five (40%) conjunctival melanomas. DisGeNET Detail
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72... DisGeNET Detail
We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases in Peking Union Medi... DisGeNET Detail
Among the 20 melanomas with completed BRAF-sequencing analysis, 6 (30%) harbored a mutation, of whic... DisGeNET Detail
We recommend that patients with a thyroid nodule with any suspicious sonographic feature undergo pre... DisGeNET Detail
This last observation led us to investigate the role of BRAF(V600E) and the MEK-ERK pathway in thyro... DisGeNET Detail
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E... DisGeNET Detail
Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 (3 melanomas and 1 n... DisGeNET Detail
Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic f... DisGeNET Detail
These findings indicate that adenomas might be less important in the cancer development in the group... DisGeNET Detail
The lesions were screened for the BRAF(V600E) and NRAS mutations and for RET/PTC and PAX8-PPARG rear... DisGeNET Detail
We consider that BRAF(V600E) mutation does not possess prognostic value in Korea, where it is preval... DisGeNET Detail
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic m... DisGeNET Detail
In 42 cases with LN metastases, 23 harbored the BRAF(V600E) mutation in the metastatic tumor and pre... DisGeNET Detail
The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5... DisGeNET Detail
Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-mutant thyroid cance... DisGeNET Detail
While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM studied (n = 21), th... DisGeNET Detail
Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population. DisGeNET Detail
These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiol... DisGeNET Detail
Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules ... DisGeNET Detail
Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation. DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
The activating BRAF mutation V600E and related mutations in this codon are most important for the ac... DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Rep... DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed that, paradoxically... DisGeNET Detail
KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 methylation and express... DisGeNET Detail
BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET/PT... DisGeNET Detail
Dual targeting of BRAF(V600E) and Hdm2 with vemurafenib and Nt-3, respectively, synergistically indu... DisGeNET Detail
After surgery, 115 nodules were confirmed as conventional papillary thyroid carcinoma and 102 (88.70... DisGeNET Detail
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs... DisGeNET Detail
The expression of both BRAF V600E and pS6 was associated with a worse postoperative seizure outcome ... DisGeNET Detail
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PT... DisGeNET Detail
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid ... DisGeNET Detail
In particular, V600E mutation is highly prevalent in papillary thyroid carcinoma (PTC). DisGeNET Detail
However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less freque... DisGeNET Detail
In a Phase I study (BRIM-1), a 960-mg BID dose achieved an objective response rate of 81% among 32 p... DisGeNET Detail
RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma; however, resistanc... DisGeNET Detail
However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors and become ineffect... DisGeNET Detail
In contrast to previous work with BRAF(V600E) in melanoma cells, feedback inhibition following BCR-A... DisGeNET Detail
The BRAF kinase is mutated, typically Val 600→Glu (V600E), to induce an active oncogenic state in a ... DisGeNET Detail
Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expre... DisGeNET Detail
The activating BRAF mutation V600E and related mutations in this codon are most important for the ac... DisGeNET Detail
The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. DisGeNET Detail
BRAF (V600E) mutation was more common in the conventional PTC (38 out of 62; 61%) than in the follic... DisGeNET Detail
Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. DisGeNET Detail
BRAF (v-raf murine sarcoma viral oncogene homologue B) V600E mutations have been detected with high ... DisGeNET Detail
In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer p... DisGeNET Detail
BRAF V600E mutation and CpG island methylation phenotype-positive status are similar in signet ring ... DisGeNET Detail
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian ca... DisGeNET Detail
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thy... DisGeNET Detail
BRAF V600E mutation was found in 74% of serrated polyps in MUTYH-negative patients and in none of th... DisGeNET Detail
These findings indicate that, although BRAF(V600E) mutation may play some roles in local carcinoma d... DisGeNET Detail
One such target is the V600E gain-of-function BRAF mutation found in 60% of melanomas; other mutatio... DisGeNET Detail
Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung ade... DisGeNET Detail
Colon cancers from 2008 to 2012 tested by pyrosequencing for BRAF V600E mutation were selected. DisGeNET Detail
Cells derived from papillary carcinoma harboring the mutant BRAF (V600E) allele were slightly more s... DisGeNET Detail
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-spe... DisGeNET Detail
Activating mutations in the BRAF serine/threonine kinase are found in more than 70% of human melanom... DisGeNET Detail
Compared to tumors without the mutation, the P131L mutant positive tumors were associated with incre... DisGeNET Detail
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that gene... DisGeNET Detail
However, as in humans, BRAF(V600E)-induced mouse PTC is indolent and does not lead to rapid developm... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
At clinically informative sites, we identified seven low-frequency point mutations (0.2%-4.7%), incl... DisGeNET Detail
VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be ... DisGeNET Detail
BRAF V600E status adds incremental value to current risk classification systems in predicting papill... DisGeNET Detail
Uncommon V599E BRAF mutations in Japanese patients with lung cancer. DisGeNET Detail
The BRAF(V600E) mutation was absent in tumor DNA samples obtained from patients with benign follicul... DisGeNET Detail
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal can... DisGeNET Detail
Finally, we conclude that inhibition of SHH-GLI signaling pathway in human melanoma by the specific ... DisGeNET Detail
Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inh... DisGeNET Detail
In this issue of Cancer Discovery, Shi and colleagues add further insight into the role of exon 3 ME... DisGeNET Detail
Expression of AID in malignant melanoma with BRAF(V600E) mutation. DisGeNET Detail
It has a higher rate of central nodal metastasis and BRAF V600E mutation in comparison with EFVPTC a... DisGeNET Detail
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... DisGeNET Detail
Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-mutant thyroid cance... DisGeNET Detail
BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinoma... DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a mar... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Assessment of BRAF p.V600E mutational status has become necessary for treatment of patients with met... DisGeNET Detail
Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma... DisGeNET Detail
Moreover, to our knowledge, there is no detailed report of the BRAF V600E mutation in an adult gliob... DisGeNET Detail
Combined, these data demonstrate that the BRAF(V600E) cooperates with either PIK3CA(H1074R) or with ... DisGeNET Detail
Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. DisGeNET Detail
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the futu... DisGeNET Detail
BRAF(V600E) mutations were identified in 22.2% of the carcinoma cases (n = 18, 15 PTCs and 3 anaplas... DisGeNET Detail
The aim of this study is to compare the utility of methylation analysis of MLH1 and BRAF V600E mutat... DisGeNET Detail
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. DisGeNET Detail
Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation, older patient age, ... DisGeNET Detail
In this review, clinicopathologic characteristics associated with BRAF-mutant tumors will be highlig... DisGeNET Detail
Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inh... DisGeNET Detail
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. DisGeNET Detail
BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, inclu... DisGeNET Detail
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylat... DisGeNET Detail
All 12 cases of HCL showed cytoplasmic BRAF V600E protein expression in leukemia cells by immunohist... DisGeNET Detail
It is evident that the detection of the BRAF V600E mutation is crucial in order to identify novel av... DisGeNET Detail
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that gene... DisGeNET Detail
Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed that, paradoxically... DisGeNET Detail
We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild... DisGeNET Detail
Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral... DisGeNET Detail
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in pati... DisGeNET Detail
NK cell frequencies were significantly enhanced by PLX4720 specifically in the lungs of mice with BR... DisGeNET Detail
The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patie... DisGeNET Detail
Our data suggest that one of the major functions of C-MYC overexpression in melanoma progression is ... DisGeNET Detail
Array comparative genomic hybridization analysis showed that CCND1 was amplified in 17% of BRAF V600... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangements have been disclo... DisGeNET Detail
Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) inhibitor indicated f... DisGeNET Detail
BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, inclu... DisGeNET Detail
We believe that our findings will help to decide the realistic usefulness of BRAF V600E mutation as ... DisGeNET Detail
We investigated 194 serrated lesions of the colon, comprising 42 sessile serrated adenomas/polyps, 1... DisGeNET Detail
Several transcription factors and signaling pathways involved in the regulation of MITF expression a... DisGeNET Detail
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E... DisGeNET Detail
The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of... DisGeNET Detail
An international, multicenter, randomized, open-label trial in 675 previously untreated patients wit... DisGeNET Detail
While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangements have been disclo... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patien... DisGeNET Detail
In addition, the combination of microsatellite instability testing, MLH1 promoter methylation analys... DisGeNET Detail
In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary ca... DisGeNET Detail
Others have demonstrated a BRAF T1799A-activating mutation in cutaneous but not uveal melanoma. DisGeNET Detail
Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. DisGeNET Detail
We assessed the utility of immunohistochemistry to detect BRAF p.V600E mutations in thyroid carcinom... DisGeNET Detail
Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15-30% of patients... DisGeNET Detail
The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunit... DisGeNET Detail
The BRAF-V600E mutation defines genetically hairy cell leukemia among B-cell leukemias and lymphomas... DisGeNET Detail
We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to... DisGeNET Detail
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström... DisGeNET Detail
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy... DisGeNET Detail
We tested our originally reported cohort of 8 E-GBMs and 2 rhabdoid GBMs (R-GBM) as well as 5 new E-... DisGeNET Detail
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we develope... DisGeNET Detail
BRAF(V600E) mutation status was assessed in thyroid fine-needle aspiration (FNA) specimens from 605 ... DisGeNET Detail
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of he... DisGeNET Detail
Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E-mutant melan... DisGeNET Detail
Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, and MITF) with qRT-PC... DisGeNET Detail
V600E BRAF gene mutation was demonstrated in 19/43 malignant nodules, in 0/56 benign nodules and in ... DisGeNET Detail
Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E) and a higher tumor... DisGeNET Detail
We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chro... DisGeNET Detail
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. DisGeNET Detail
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. DisGeNET Detail
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in thr... DisGeNET Detail
Here, we show a role for FOXO4 in mediating senescence by the human BRAF(V600E) oncogene, which aris... DisGeNET Detail
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutioniz... DisGeNET Detail
Further analyses suggested a complex mechanism driven by mutation BRAF (V600E) on melanoma tumorigen... DisGeNET Detail
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroi... DisGeNET Detail
Significantly, SAHA and the clinically available BRAF inhibitor vemurafenib cooperatively inhibited ... DisGeNET Detail
Clinicopathological characteristics were evaluated according to the Notch1/Notch3 receptors and BRAF... DisGeNET Detail
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 6... DisGeNET Detail
80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.... DisGeNET Detail
RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma; however, resistanc... DisGeNET Detail
These results provide a conceptual framework for the combined deployment of BRAF(V600E) plus PI3K pa... DisGeNET Detail
The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. DisGeNET Detail
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of he... DisGeNET Detail
WRO cells (a BRAF(V600E)-mutant follicular-derived papillary thyroid carcinoma cell line) were trans... DisGeNET Detail
MSI-H colorectal carcinomas were divided into sporadic (112/1292, 8.7%) and LS/probable LS-associate... DisGeNET Detail
VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be ... DisGeNET Detail
The BRAF(V600E) melanoma mutation, like the KIT exon 11 mutation in GIST, has the highest response t... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a part of exon 15 BRAF ... DisGeNET Detail
Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy, in combination with... DisGeNET Detail
Overall, this study supports the idea that additional NK cell-based immunotherapy (by checkpoint blo... DisGeNET Detail
reveal in vivo proof of MITF directly regulating tumor development in BRAF(V600E) melanomas. DisGeNET Detail
In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ERK pathway, and targe... DisGeNET Detail
CAST-PCR gave rapid and accurate results for the common V600E and V600K mutations, however additiona... DisGeNET Detail
PTC with any RET/PTC rearrangements had more aggressive behavior than BRAF(V600E)-positive tumors or... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
The detection of BRAF V600E by IHC is useful in the distinction of HCLs from other splenic-based lym... DisGeNET Detail
Somatic BRAF(V600E) and NRAS(Q61R) mutations of 127 primary invasive melanomas from the NHS cohort w... DisGeNET Detail
SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAF(V600E) m... DisGeNET Detail
Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four ... DisGeNET Detail
NA DisGeNET Detail
A previous study identified BRAF V600E mutations in approximately 90% of MA and found that similar B... DisGeNET Detail
The BRAF V600E genotype and an absence of primary melanoma ulceration were also independently associ... DisGeNET Detail
In many ERK1/2-dependent tumour cell lines, inhibition of BRAF(V600E) (v-raf murine sarcoma viral on... DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF(V60... DisGeNET Detail
We further showed that BRAF, a downstream signaling molecule of ARMS in ERK pathway, is not mutated ... DisGeNET Detail
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. DisGeNET Detail
Furthermore, high Mig-6 expression was independently predictive of greater disease-free survival in ... DisGeNET Detail
That this therapy was not effective in another primary cell culture led to the discovery of the onco... DisGeNET Detail
BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in ameloblastic fibromas... DisGeNET Detail
BRAF T1799A mutation occurring in a case of malignant struma ovarii. DisGeNET Detail
In this review, the current state of targeted therapy for melanoma is discussed, including the poten... DisGeNET Detail
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibito... DisGeNET Detail
In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch rep... DisGeNET Detail
A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonrespo... DisGeNET Detail
BRAF(V600E) mutation and the biology of papillary thyroid cancer. DisGeNET Detail
However, using immunomagnetic separation or laser-capture microdissection, we examined BRAF mutation... DisGeNET Detail
We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of s... DisGeNET Detail
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor... DisGeNET Detail
To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, we conducted a compr... DisGeNET Detail
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in or... DisGeNET Detail
Immunohistochemical Investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BR... DisGeNET Detail
Evidence suggesting that mitogen-activated protein kinase pathway activation in tumor cells contribu... DisGeNET Detail
Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF(V60... DisGeNET Detail
The detection of V600E BRAF mutation in melanoma is fundamental since here BRAF inhibitors represent... DisGeNET Detail
We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell lines, followed by ... DisGeNET Detail
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant ... DisGeNET Detail
This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E mutation, mutations... DisGeNET Detail
Analysis of the BRAF V600E mutation in primary cutaneous melanoma. DisGeNET Detail
The high mutation frequencies in pleomorphic xanthoastrocytomas, gangliogliomas and extra-cerebellar... DisGeNET Detail
Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (... DisGeNET Detail
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. DisGeNET Detail
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. DisGeNET Detail
KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 methylation and express... DisGeNET Detail
The aim of this study is to compare the utility of methylation analysis of MLH1 and BRAF V600E mutat... DisGeNET Detail
Moreover, in BRAF(V600E) melanoma cell lines, vemurafenib inhibits 4E-BP1 phosphorylation, thus prom... DisGeNET Detail
The diagnostic value of BRAF(V600E) in inconclusive FNAs was not hampered by thyroid lymphocytic inf... DisGeNET Detail
Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutatio... DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extra... DisGeNET Detail
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 exp... DisGeNET Detail
The highest frequencies of BRAF (V600E) mutations were found in WHO grade II pleomorphic xanthoastro... DisGeNET Detail
Targeting the BRAF V600E mutation in multiple myeloma. DisGeNET Detail
BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-ti... DisGeNET Detail
In this study, we show that the expression of LAT1 and ASCT2 is significantly increased in human mel... DisGeNET Detail
The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocyt... DisGeNET Detail
We constructed tissue microarrays of formalin-fixed and paraffin-embedded specimens of 534 gastroeso... DisGeNET Detail
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anapl... DisGeNET Detail
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasi... DisGeNET Detail
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. DisGeNET Detail
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implica... DisGeNET Detail
They also suggest that targeting the MAPKs and/or NRAS may provide a strategy to mitigate such resis... DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
Fourteen tumours (52%) had somatic mutations: BRAF-V600E mutation was observed in 9 out of the 22 PT... DisGeNET Detail
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cel... DisGeNET Detail
This tumour-specific inhibition of ERK signalling results in a broad therapeutic index and RAF inhib... DisGeNET Detail
We identified two miRNAs that are differentially expressed in PTC tissues with BRAF(V600E) and revea... DisGeNET Detail
BRAF V600E was associated with advanced TNM (P &lt; 0.001), more distant metastases (P = 0.025), and... DisGeNET Detail
We assessed phospho-ERK expression in 37 patients with hairy cell leukemia and 44 patients with neop... DisGeNET Detail
The aim of this study was to determine whether combined detection of BRAF(V600E) mutation and methyl... DisGeNET Detail
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cel... DisGeNET Detail
We conclude that the presence of pERK as detected by immunohistochemical staining is a useful surrog... DisGeNET Detail
BRAF(T1799A) mutation is the most prevalent genetic alteration in thyroid cancers and is specific fo... DisGeNET Detail
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cel... DisGeNET Detail
A 75-year-old woman was diagnosed with a BRAF V600E mutated metastatic melanoma. DisGeNET Detail
To verify the technical characteristics of the microarray system for the correct identification of t... DisGeNET Detail
Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcino... DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
CAST-PCR gave rapid and accurate results for the common V600E and V600K mutations, however additiona... DisGeNET Detail
The Korean population has a high iodine intake, high prevalence of BRAF V600E mutations, and family ... DisGeNET Detail
Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI stat... DisGeNET Detail
BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers from 206 sporadic c... DisGeNET Detail
The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of... DisGeNET Detail
Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an importan... DisGeNET Detail
Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in colorectal carcinom... DisGeNET Detail
The performance of the BRAF V600E-specific VE1 antibody was compared with that of allele-specific po... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
These results suggest that combination of selective BRAF inhibitors with ABT-737 or the related oral... DisGeNET Detail
We found that BRAF(V600E) mutation occurs selectively in PTC nodules and is associated with hyperact... DisGeNET Detail
The negative regulators of the cell cycle, p21 and p27, are strongly induced by transcriptional acti... DisGeNET Detail
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid ... DisGeNET Detail
In this study, we utilised genetically engineered melanoma cell lines and xenograft mouse models to ... DisGeNET Detail
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thy... DisGeNET Detail
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutioniz... DisGeNET Detail
BRAF(V600E) mutations in primary cutaneous melanomas were associated with residence in locations wit... DisGeNET Detail
Cell sensitivity to PLX4032 was dependent on BRAF(V600E) and independent from other gene alterations... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanth... DisGeNET Detail
The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients with lymph node meta... DisGeNET Detail
The results of the present study provide encouraging data supporting the possibility to take advanta... DisGeNET Detail
MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosup... DisGeNET Detail
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. DisGeNET Detail
Our findings highlight the role of BRAF(V600E) in activating the stroma and suggest a mechanistic li... DisGeNET Detail
In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four parental cell lines and t... DisGeNET Detail
The reactivation of senescence features and elimination of cells refractory to BRAF(V600E) inhibitio... DisGeNET Detail
The diagnostic subgroups of tuberous sclerosis complex were not correlated with BRAF(V600E) in patie... DisGeNET Detail
To examine the association between level and patterns of baseline intra-tumoural BRAF(V600E) protein... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. DisGeNET Detail
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian ca... DisGeNET Detail
The histopathology of BRAF-V600E-mutated lung adenocarcinoma. DisGeNET Detail
The absence of the BRAF V600E mutation within a changing naevus supports the theory that BRAFi stimu... DisGeNET Detail
Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patien... DisGeNET Detail
To investigate whether the frequency of the BRAF(V600E) (V-raf murine sarcoma virus oncogene homolog... DisGeNET Detail
In order to better understand the mechanistic basis for this resistance, we conducted a RNAi-based s... DisGeNET Detail
Specific KRAS mutation is an informative prognostic factor in both sporadic and hereditary CRC and a... DisGeNET Detail
These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation. DisGeNET Detail
The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. DisGeNET Detail
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thy... DisGeNET Detail
Surgery was recommended to all 45 patients with BRAF(V600E) mutation-positive ACUS nodules; among th... DisGeNET Detail
BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. DisGeNET Detail
We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell lines, followed by ... DisGeNET Detail
High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patien... DisGeNET Detail
Somatic BRAF(V600E) and NRAS(Q61R) mutations of 127 primary invasive melanomas from the NHS cohort w... DisGeNET Detail
Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis. DisGeNET Detail
Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in colorectal carcinom... DisGeNET Detail
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
The incidence of BRAF(V600E) was studied in 85 microdissected cases of IM detected in two series of ... DisGeNET Detail
The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highl... DisGeNET Detail
Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p &lt; 0.01), and lymph node metas... DisGeNET Detail
Here, we show that expression of BRAF(V600E), but not PIK3CA(H1047R), in the mouse pancreas leads to... DisGeNET Detail
We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; in addition, they ar... DisGeNET Detail
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth ... DisGeNET Detail
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to i... DisGeNET Detail
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of... DisGeNET Detail
The two groups did not show significant differences in clinical and prognostic features, whereas the... DisGeNET Detail
BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyro... DisGeNET Detail
The aim of the study was to explore TERT promoter mutations in various thyroid tumors and examine th... DisGeNET Detail
The BRAF V600E mutation is associated with sporadic MSI-H colorectal cancers (CRCs) harboring hMLH1 ... DisGeNET Detail
These findings suggest that CNS tumors with BRAF(V600E) are autophagy-dependent and should be target... DisGeNET Detail
We evaluated CNS tumor cells with BRAF(V600E) and found that mutant (but not wild-type) cells displa... DisGeNET Detail
Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. DisGeNET Detail
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasi... DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasi... DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyro... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high f... DisGeNET Detail
In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expression, which repres... DisGeNET Detail
The two most commonly observed alterations in BRAF in patients with brain tumor are the BRAF V600E p... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in mela... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Diagnostically, the BRAF(V600E) mutation is a powerful molecular marker for papillary thyroid carcin... DisGeNET Detail
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated ... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in or... DisGeNET Detail
All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH... DisGeNET Detail
Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma... DisGeNET Detail
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF... DisGeNET Detail
Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramati... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially... DisGeNET Detail
A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A598V) in one diffuse ... DisGeNET Detail
AZD6244 was evaluated against two JPA xenografts, BT-35 (wild-type BRAF) and BT-40 (mutant [V600E] B... DisGeNET Detail
We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of the BRAF V600E mutati... DisGeNET Detail
Among these, the recently identified BRAF(V600E) mutation has been found at high frequency in adult ... DisGeNET Detail
Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving... DisGeNET Detail
We therefore conclude that the common somatic BRAF mutation V599E does not contribute to polygenic a... DisGeNET Detail
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in a... DisGeNET Detail
We investigated BRAF mutations in 36 subjects with different forms of SM, but could not detect BRAF ... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and im... DisGeNET Detail
The presence of BRAF V600E and mitogen-activated protein kinase activation in a largely benign tumor... DisGeNET Detail
The BRAF(V600E) mutation, BRAF V600E IHC, low ΔCt, and high BRAF RNA ISH were significantly associat... DisGeNET Detail
Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (p... DisGeNET Detail
Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Sp... DisGeNET Detail
This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V6... DisGeNET Detail
Fourteen tumours (52%) had somatic mutations: BRAF-V600E mutation was observed in 9 out of the 22 PT... DisGeNET Detail
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approv... DisGeNET Detail
In conclusion, the T1799A BRAF mutation is present in a proportion of posterior uveal melanomas but ... DisGeNET Detail
Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation ... DisGeNET Detail
The reference tumor group contained 28 HNPCC with proven germ-line mutations or positive Amsterdam I... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and compar... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
In monoclonal BRAF V600E-positive mPTCs, BRAF V600E is not always present in all tumour foci, indica... DisGeNET Detail
In addition, the combination of microsatellite instability testing, MLH1 promoter methylation analys... DisGeNET Detail
Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving stand... DisGeNET Detail
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. DisGeNET Detail
Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these signif... DisGeNET Detail
The results showed that the BRAF (V600E) mutation was associated with extra-thyroidal extension (OR ... DisGeNET Detail
BRAF V600E mutation is a poor prognostic factor in MSI-H metastatic CRC. DisGeNET Detail
Apollon modulation and melanoma apoptosis were evaluated by Western blot and/or flow cytometry in re... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
NFAT2 and 4 are expressed in human metastatic melanoma cell lines and are activated by oncogenic BRA... DisGeNET Detail
These results provide a conceptual framework for the combined deployment of BRAF(V600E) plus PI3K pa... DisGeNET Detail
In this study a retrospective cohort of 198 pediatric low-grade gliomas (including 40 treated with a... DisGeNET Detail
Pharmacologic inhibition of BRAF(V600E) in human melanoma cell lines resulted in decreased expressio... DisGeNET Detail
We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines harboring BRAF V600E... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
To gain a better understanding of the molecular events leading to the development of conjunctival me... DisGeNET Detail
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutatio... DisGeNET Detail
Incorporating the use of the recently identified BRAF V600E point mutation, a highly specific biomar... DisGeNET Detail
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and me... DisGeNET Detail
A valine-to-glutamic acid substitution at position 600 of the serine/threonine-protein kinase BRAF (... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
We analyzed BRAF V600E mutational status in the primary lesion of 150 PTC cases in Peking Union Medi... DisGeNET Detail
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors. DisGeNET Detail
Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mutations, and the CpG ... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
Here we report the first clinical evidence that the combination of an anti-EGFR (panitumumab) and an... DisGeNET Detail
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in or... DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
Furthermore, we identify TP53/Trp53 as a UVR-target gene that cooperates with BRAF(V600E) to induce ... DisGeNET Detail
We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in their combinational tre... DisGeNET Detail
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease pro... DisGeNET Detail
Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? DisGeNET Detail
BRAF mutation (V600E) is found in MSI colorectal cancers. DisGeNET Detail
This focus has been justified by the recent success of BRAF and MEK inhibitors in prolonging the liv... DisGeNET Detail
PCCL3 cells conditionally expressing RET/PTC3, HRAS(G12V), or BRAF(V600E) and human thyroid cancer c... DisGeNET Detail
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF... DisGeNET Detail
Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytoma... DisGeNET Detail
This study evaluated the relationship between BRAF(V600E) status and known strategies of tumor-media... DisGeNET Detail
Both conventional melanomas had the exon 15 T1796A (V599E) mutation, but none of the MMSP was found ... DisGeNET Detail
This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7... DisGeNET Detail
We analyzed 29 gallbladder carcinomas (9 papillary and 20 nonpapillary adenocarcinomas), 16 adenomas... DisGeNET Detail
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PT... DisGeNET Detail
Conclusions.-The T1799A BRAF mutation does not appear to play a role in the tumorigenesis of CMVPTC. DisGeNET Detail
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas... DisGeNET Detail
One month following BRAF(V600E) expression, mice displayed increased thyroid size, widespread altera... DisGeNET Detail
KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 methylation and express... DisGeNET Detail
In this study, KIT exons 9, 11, 13, and 17, PDGFRA exons 12, 14, and 18, and a part of exon 15 BRAF ... DisGeNET Detail
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool pan... DisGeNET Detail
(V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression throug... DisGeNET Detail
Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibo... DisGeNET Detail
The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathy... DisGeNET Detail
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool pan... DisGeNET Detail
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanth... DisGeNET Detail
In a panel of 16 V600E BRAF-mutated melanoma cell lines consisting of four parental cell lines and t... DisGeNET Detail
BRAF(V600E) mutation confers constitutive BRAK kinase activation in melanoma cells, promoting tumor ... DisGeNET Detail
The absence of the BRAF(V600E) mutation does not support a role for the serrated neoplasia pathway i... DisGeNET Detail
Additionally, preclinical and clinical studies investigating combination therapy with agents such as... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
This study hypothesized that the BRAF V600E mutation may be associated with mucinous morphology in e... DisGeNET Detail
To investigate whether the frequency of the BRAF(V600E) (V-raf murine sarcoma virus oncogene homolog... DisGeNET Detail
Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation, older patient age, ... DisGeNET Detail
The BRAF(V600E) mutation is a useful diagnostic marker for differentiating papillary thyroid carcino... DisGeNET Detail
Histopathological analysis ascertained that all BRAF(V600E)-positive cases were papillary thyroid ca... DisGeNET Detail
We investigated 7 spindle cell oncocytomas, 4 pituicytomas, and 3 granular cell tumors for their gen... DisGeNET Detail
Activating mutations in the BRAF gene, primarily at V600E, are associated with poorer outcomes in pa... DisGeNET Detail
These findings suggest CNS tumors with BRAF(V600E) are autophagy-dependent and that identification o... DisGeNET Detail
High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patien... DisGeNET Detail
Through an RNAi screen, here we identify the transcriptional repressor MAFG as the pivotal factor re... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
One-hundred and twenty-nine papillary thyroid microcarcinomas were tested for BRAF(V600E) mutation b... DisGeNET Detail
BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of ... DisGeNET Detail
The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%) and RET/PTC in 55/... DisGeNET Detail
Unlike the most common BRAF mutation seen in PTC carcinoma (BRAF(V600E)), this patient's mutation wa... DisGeNET Detail
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tu... DisGeNET Detail
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
All patients with lateral cervical node metastasis (n=9), and all but one tumor with extrathyroidal ... DisGeNET Detail
The molecular tests on the thyroid nodule revealed the presence of BRAF-V600E mutation, but wild typ... DisGeNET Detail
Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. DisGeNET Detail
BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample im... DisGeNET Detail
This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and ... DisGeNET Detail
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated ... DisGeNET Detail
The BRAF V600E mutation is the most common genetic alteration in thyroid cancer. DisGeNET Detail
Of the drugs tested to date in patients with metastatic melanoma, those that have yielded the best r... DisGeNET Detail
Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E)... DisGeNET Detail
We used pyrosequencing, peptide nucleic acid (PNA)-clamping polymerase chain reaction (PCR), and rea... DisGeNET Detail
Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune sup... DisGeNET Detail
First, absent/faint staining for BRAF V600E correlates perfectly with the lack of the BRAF(T1799A) m... DisGeNET Detail
NA DisGeNET Detail
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and... DisGeNET Detail
We show that activation of the PI3K/AKT pathway is a mechanism of both innate and acquired resistanc... DisGeNET Detail
This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patients in Indian subcon... DisGeNET Detail
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. DisGeNET Detail
V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gast... DisGeNET Detail
Here we have used a zebrafish melanoma model to test genes in a recurrently amplified region of chro... DisGeNET Detail
Our results suggest that hypoxia-inducible factor-1alpha is expressed in papillary thyroid carcinoma... DisGeNET Detail
Analysis of frozen and fixed material from 21 CCS and 21 MM showed the presence of the V600E BRAF mu... DisGeNET Detail
The inability of MEK and RAF inhibitors, U0126 and sorafenib, respectively, to block the mitochondri... DisGeNET Detail
The current data showed instead that the BRAF V599E mutation was associated only with a subgroup of ... DisGeNET Detail
The US Food and Drug Administration (FDA) approved vemurafenib to treat patients with metastatic mel... DisGeNET Detail
In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expression, which repres... DisGeNET Detail
Preclinical studies revealed that GLV-1h68 combined with radiotherapy significantly increased cytoto... DisGeNET Detail
BRAF(V600E) allele was detected and quantified by an allele-specific real-time quantitative PCR assa... DisGeNET Detail
Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platel... DisGeNET Detail
BRAF(V600E) allele was detected in PTC and melanoma but not in MTC tissues. DisGeNET Detail
Screening for activating BRAF mutations in a series of 83 PTCs identified the most common V600E muta... DisGeNET Detail
Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving stand... DisGeNET Detail
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anapl... DisGeNET Detail
To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the FNAB specimens of thy... DisGeNET Detail
To explore the mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus oncogene homolog B1) ... DisGeNET Detail
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in on... DisGeNET Detail
Analysis of the BRAF V600E mutation in primary cutaneous melanoma. DisGeNET Detail
Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid car... DisGeNET Detail
We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcar... DisGeNET Detail
The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as a negative prognost... DisGeNET Detail
The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules. DisGeNET Detail
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. DisGeNET Detail
Recent studies in metastatic colorectal cancer found that an oncogenic activation of BRAF by a point... DisGeNET Detail
A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of ... DisGeNET Detail
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute t... DisGeNET Detail
In the current review, we discuss how knowledge about these new melanoma subgroups may lead to impro... DisGeNET Detail
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyro... DisGeNET Detail
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. DisGeNET Detail
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated ... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase was described as pre... DisGeNET Detail
Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorec... DisGeNET Detail
BRAF V600E also predicts poor prognosis in microsatellite stable colorectal cancers and may be a mar... DisGeNET Detail
These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinoge... DisGeNET Detail
It has been suggested that patients with papillary thyroid cancer (PTC) harbouring the BRAF(V600E) m... DisGeNET Detail
After surgery, 115 nodules were confirmed as conventional papillary thyroid carcinoma and 102 (88.70... DisGeNET Detail
The large BRAF V600E neoplastic cell subpopulations found in mutated cases is consistent with the vi... DisGeNET Detail
BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer. DisGeNET Detail
In a patient (whose melanoma showed to bear the BRAF V600E mutation in blood, but not at tissue leve... DisGeNET Detail
While dabrafenib has demonstrated comparable efficacy to vemurafenib in BRAF V600E mutant melanoma p... DisGeNET Detail
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. DisGeNET Detail
Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma proliferation, whereas ... DisGeNET Detail
Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemic... DisGeNET Detail
Recent studies in metastatic colorectal cancer found that an oncogenic activation of BRAF by a point... DisGeNET Detail
Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
We applied human immunodeficiency virus (HIV) lentivirus-mediated RNA interference (RNAi) to melanom... DisGeNET Detail
A correlation between MLH1 promoter methylation, specifically the 'C' region, and BRAF V600E status ... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphi... DisGeNET Detail
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers. DisGeNET Detail
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumor... DisGeNET Detail
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median foll... DisGeNET Detail
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BRE... DisGeNET Detail
they were normally maintained hypomethylated and over-expressed by BRAF V600E in thyroid cancer cell... DisGeNET Detail
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired ... DisGeNET Detail
The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation anal... DisGeNET Detail
To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, we conducted a compr... DisGeNET Detail
BRAF(V600E) mutation and the previously unreported BRAF(G593D) mutation along with p.G606G silent ch... DisGeNET Detail
BRAF V600E mutations are the most common found in melanoma; specific inhibitors of mutant BRAF have ... DisGeNET Detail
From September 2008 to December 2009, we performed routine analysis of the BRAF(V600E) mutation usin... DisGeNET Detail
BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigeni... DisGeNET Detail
A previous study identified BRAF V600E mutations in approximately 90% of MA and found that similar B... DisGeNET Detail
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tu... DisGeNET Detail
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that gene... DisGeNET Detail
To evaluate the role of oncogenic BRAF mutations in non-hereditary nonpolyposis colorectal cancer/no... DisGeNET Detail
The BRAF V600E mutation is one of the most frequent molecular abnormalities identified in hyperplast... DisGeNET Detail
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström... DisGeNET Detail
In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer p... DisGeNET Detail
Here, we show intralesional molecular heterogeneity in a progressing V600E BRAF-mutant melanoma meta... DisGeNET Detail
BRAF(V600E) was characterized in 113 PTC patients diagnosed with pT1aNo-x (one PTC focus with a diam... DisGeNET Detail
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibito... DisGeNET Detail
We found that BRAF(V600E) mutation occurs selectively in PTC nodules and is associated with hyperact... DisGeNET Detail
After surgery, 115 nodules were confirmed as conventional papillary thyroid carcinoma and 102 (88.70... DisGeNET Detail
Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in ma... DisGeNET Detail
The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients. DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
In our series, BRAF mutation was detected exclusively in papillary carcinoma (54%), and was exclusiv... DisGeNET Detail
Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation i... DisGeNET Detail
This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V6... DisGeNET Detail
Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carc... DisGeNET Detail
BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, inclu... DisGeNET Detail
The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients. DisGeNET Detail
Here, we show that expression of BRAF(V600E), but not PIK3CA(H1047R), in the mouse pancreas leads to... DisGeNET Detail
Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytoma... DisGeNET Detail
BRAF(V600E) was also seen in five of 11 (45%) non-brainstem GGs and one of eight (13%) brainstem PAs... DisGeNET Detail
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph... DisGeNET Detail
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanth... DisGeNET Detail
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal can... DisGeNET Detail
HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of p53 in 26 out of 62... DisGeNET Detail
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harbori... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status ... DisGeNET Detail
Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (p... DisGeNET Detail
To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, we conducted a compr... DisGeNET Detail
Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastroi... DisGeNET Detail
Our data indicate that the C57BL/6J Tyr::CreER(T2);PTEN(F-/-);BRAF(F-V600E/+) melanoma model could b... DisGeNET Detail
Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression. DisGeNET Detail
Inadequate evidence was found regarding association of BRAF V600E mutation testing or loss of PTEN e... DisGeNET Detail
These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FDG-avid than BRAF-WT ... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of ... DisGeNET Detail
Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24A1 expression and en... DisGeNET Detail
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopatholo... DisGeNET Detail
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thy... DisGeNET Detail
Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E) and a higher tumor... DisGeNET Detail
The patient with SSL as index lesions who developed CRC harbored V600E BRAF mutation in both index l... DisGeNET Detail
Of ten cases with diagnostic concomitant or incidental papillary carcinoma, three had a V600E point ... DisGeNET Detail
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) i... DisGeNET Detail
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endo... DisGeNET Detail
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with... DisGeNET Detail
Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillar... DisGeNET Detail
BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had identical mutations in ... DisGeNET Detail
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vem... DisGeNET Detail
Overall, BRAF(V600E) PTC tumors display a broadly immunosuppressive profile and evidence of disturbe... DisGeNET Detail
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in pap... DisGeNET Detail
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the futu... DisGeNET Detail
Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation ... DisGeNET Detail
We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; in addition, they ar... DisGeNET Detail
BRAF(V600E) mutation has emerged as a marker of aggressive behavior in papillary thyroid carcinoma b... DisGeNET Detail
The BRAF(V600E) mutation, the most common genetic alteration reported in papillary thyroid carcinoma... DisGeNET Detail
Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF ... DisGeNET Detail
BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma. DisGeNET Detail
Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mut... DisGeNET Detail
We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of s... DisGeNET Detail
We calculated and compared the diagnostic performances of DPO-PCR and real-time PCR to detect BRAF(V... DisGeNET Detail
Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyro... DisGeNET Detail
Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid c... DisGeNET Detail
The v-raf murine sarcoma viral oncogene homolog B1 V600E mutant melanoma cell line A375 was used as ... DisGeNET Detail
Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutati... DisGeNET Detail
Only one BRAF(V600E) negative case has shown extrathyroidal extension and lymph node metastasis. DisGeNET Detail
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migra... DisGeNET Detail
The presence of BRAF V600E and mitogen-activated protein kinase activation in a largely benign tumor... DisGeNET Detail
Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation, older patient age, ... DisGeNET Detail
B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival i... DisGeNET Detail
These data suggest that regulation of BIM expression by BRAF--&gt;MEK--&gt;ERK signaling is one mech... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
Discovery of the BRAF V600E mutation as a disease-defining genetic event in hairy cell leukemia can ... DisGeNET Detail
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis. DisGeNET Detail
The high frequency of methylation and BRAF V600E mutation suggests that many signet ring cell carcin... DisGeNET Detail
The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia. DisGeNET Detail
BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC); i... DisGeNET Detail
CAST-PCR gave rapid and accurate results for the common V600E and V600K mutations, however additiona... DisGeNET Detail
These results provide a conceptual framework for the combined deployment of BRAF(V600E) plus PI3K pa... DisGeNET Detail
An association between a BRAF(V600E) mutation and upregulation of mitogen-activated protein kinase (... DisGeNET Detail
In microsatellite stable tumors, homozygous carriers of the G39E polymorphism had an increased risk ... DisGeNET Detail
BRAF(V600E) mutation and p27(kip1) expression have been introduced as novel indicators that may pred... DisGeNET Detail
The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thy... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Of the patients with diffuse FVPTC, all had central lymph node metastasis (P &lt; .001), and 2 (50%)... DisGeNET Detail
The T1799A missense mutation in exon 15 of the BRAF gene and RET/PTC rearrangement have been identif... DisGeNET Detail
Mutation in BRAF and NRAS was present in 43% (88% V600E, 10% V600K) and 30% (48% Q61K, 40% Q61R) of ... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Mutational patterns identical to those in the primary tumors were found in 11/12 lymph node metastas... DisGeNET Detail
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tu... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Multivariate analysis showed that BRAF V600E mutation [OR (95% CI) = 4.2 (1.2-14.6)] and lymph node ... DisGeNET Detail
The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%) and RET/PTC in 55/... DisGeNET Detail
Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E ... DisGeNET Detail
Similar targeting of BRAF(V599E) or wild-type BRAF in human fibrosarcoma cells that lack the BRAF(V5... DisGeNET Detail
BRAF(V600E) mutation-positive cancers (55.3%) were more frequently associated with lymph node metast... DisGeNET Detail
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian ca... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool pan... DisGeNET Detail
The CREM complex is seen in the normal thyroid cells and BRAF (V600E) thyroid cancer cells (BHP 17-1... DisGeNET Detail
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600... DisGeNET Detail
Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. DisGeNET Detail
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid ... DisGeNET Detail
However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less freque... DisGeNET Detail
In contrast, age- and size-matched classic papillary microcarcinomas (n=26) showed no extrathyroidal... DisGeNET Detail
Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation. DisGeNET Detail
The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAF(V600E) in... DisGeNET Detail
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy... DisGeNET Detail
However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less freque... DisGeNET Detail
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors. DisGeNET Detail
The thymidine kinase inhibitor vemurafenib, which inhibits the V600E mutant of BRAF, was reported to... DisGeNET Detail
Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: c... DisGeNET Detail
The discovery of activating BRAF V600E mutations in 50% of all melanoma patients and the development... DisGeNET Detail
The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high f... DisGeNET Detail
Taken together, BRAF V600E is common in Finnish patients with low-risk PTC but does not predict recu... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
miR-21* and 203 were significantly dysregulated (P&lt;0.05) in PTC tissues with BRAF(V600E). DisGeNET Detail
The Korean population has a high iodine intake, high prevalence of BRAF V600E mutations, and family ... DisGeNET Detail
In this study, sensitive and quantitative BRAF V600E and V600K mutation-specific real-time quantitat... DisGeNET Detail
Our studies with melanoma tumor cells that are BRAF(V600E/K) and BRAF(WT) showed that, paradoxically... DisGeNET Detail
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. DisGeNET Detail
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract ... DisGeNET Detail
However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less freque... DisGeNET Detail
BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 express... DisGeNET Detail
Similarly to the results obtained by others, there was no coexistence of BRAF (V600E) mutation and R... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
After surgery, 115 nodules were confirmed as conventional papillary thyroid carcinoma and 102 (88.70... DisGeNET Detail
We present a case of a 56-year old woman with a history of stage IIIA malignant melanoma resected in... DisGeNET Detail
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant ... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma. DisGeNET Detail
BRAF V600E mutation and CpG island methylation phenotype-positive status are similar in signet ring ... DisGeNET Detail
BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroi... DisGeNET Detail
None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carr... DisGeNET Detail
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal ... DisGeNET Detail
BRAF V600E mutational status in pediatric thyroid cancer. DisGeNET Detail
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. DisGeNET Detail
The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid... DisGeNET Detail
A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonrespo... DisGeNET Detail
In this study, we conducted immunohistochemical determination of BRAF V600E mutation and correlated ... DisGeNET Detail
Combined, these data demonstrate that the BRAF(V600E) cooperates with either PIK3CA(H1074R) or with ... DisGeNET Detail
BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS... DisGeNET Detail
We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the der... DisGeNET Detail
Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, and MITF) with qRT-PC... DisGeNET Detail
Histiocytic sarcoma exhibited the highest rate of BRAF(V600E) (62.5%, five of eight), followed by La... DisGeNET Detail
We further showed that BRAF, a downstream signaling molecule of ARMS in ERK pathway, is not mutated ... DisGeNET Detail
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anapl... DisGeNET Detail
Furthermore, PTCs exhibiting BRAF V600E mutation (p = 0.01), ETE (p &lt; 0.01), and lymph node metas... DisGeNET Detail
Molecular studies demonstrated that the melanoma was positive for the 1799T&gt;A (V600E) mutation in... DisGeNET Detail
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in me... DisGeNET Detail
All neoplastic melanocytes within such a nevus would be expected to carry the BRAF mutation, and thu... DisGeNET Detail
ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compa... DisGeNET Detail
The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers wit... DisGeNET Detail
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. DisGeNET Detail
Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) m... DisGeNET Detail
We sought to examine the extent of intrapatient heterogeneity of BRAF(V600E) protein expression in p... DisGeNET Detail
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorecta... DisGeNET Detail
Outcome of thyroid nodules characterized as atypia of undetermined significance or follicular lesion... DisGeNET Detail
The DDFI was significantly shorter in patients with BRAF(V600K/R) versus BRAF(V600E) melanoma in uni... DisGeNET Detail
We also report the X-ray crystal structure of a BRAF/quinolol complex revealing the mode of inhibiti... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and... DisGeNET Detail
The detection of a BRAF V600E mutation further supports the exclusion of HNPCC. DisGeNET Detail
Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. DisGeNET Detail
However, the expressions of c-Fos and PCNA were elevated in BRAF(V600E)-positive PTC compared with t... DisGeNET Detail
Somatic BRAF-V600E mutations in familial colorectal cancer. DisGeNET Detail
These results reveal a novel (V600E)BRAF-induced mechanism in thyroid tumours progression and provid... DisGeNET Detail
Molecular studies have shown that the BRAF V600E mutation is found mainly in papillary and anaplasti... DisGeNET Detail
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusi... DisGeNET Detail
The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk... DisGeNET Detail
Besides confirming the presence of known melanoma driver mutations (BRAF(V600E), NRAS(Q61R) ), we id... DisGeNET Detail
In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targete... DisGeNET Detail
The five conventional PTC cell lines carry the BRAF V600E mutation and the follicular variant of PTC... DisGeNET Detail
HER2 overexpression (3+) was observed in 2 out of 62 patients, overexpression of p53 in 26 out of 62... DisGeNET Detail
The BRAF (V600E) mutation was associated with aggressive clinical behaviors including extrathyroid i... DisGeNET Detail
Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF revealed preferenti... DisGeNET Detail
Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progr... DisGeNET Detail
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. DisGeNET Detail
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical... DisGeNET Detail
Furthermore, ICAM-1 upregulation correlated with aggressive tumor features such as BRAF V600E mutati... DisGeNET Detail
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thy... DisGeNET Detail
MEK inhibitors are clinically active in BRAF(V600E) melanomas but only marginally so in KRAS mutant ... DisGeNET Detail
Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas... DisGeNET Detail
BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 express... DisGeNET Detail
The presence of PB was significantly correlated with tumor multifocality, extrathyroidal extension, ... DisGeNET Detail
We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom treatment with vemurafen... DisGeNET Detail
Due to the BRAF (V600E) mutation in her tumor and her poor functional status, we offered her off-lab... DisGeNET Detail
The activating BRAF mutation V600E and related mutations in this codon are most important for the ac... DisGeNET Detail
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-diffe... DisGeNET Detail
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samp... DisGeNET Detail
However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less freque... DisGeNET Detail
Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutati... DisGeNET Detail
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas s... DisGeNET Detail
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-t... DisGeNET Detail
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
In addition, the combination of microsatellite instability testing, MLH1 promoter methylation analys... DisGeNET Detail
Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute t... DisGeNET Detail
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harbori... DisGeNET Detail
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E ... DisGeNET Detail
Secondly, considering the alternative possibility, we identified genes whose DNA hypermethylation wa... DisGeNET Detail
A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A598V) in one diffuse ... DisGeNET Detail
High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using... DisGeNET Detail
Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carc... DisGeNET Detail
The BRAF(V600E) mutation was significantly associated with age (≥ 45 years), tumor size (&gt;1 cm), ... DisGeNET Detail
In 2011, the V600E mutation of the BRAF gene in exon 15 was identified in HCL; being present in HCL,... DisGeNET Detail
Taken together, our study demonstrates that ASCT2-mediated glutamine transport is a potential therap... DisGeNET Detail
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. DisGeNET Detail
Although BRAF(V600E) and XIAP expression are commonly seen in PTC, their presence together seems unr... DisGeNET Detail
PCCl3 rat thyroid cells, PCCl3 cells overexpressing BRAF(V600E), or primary cultured tumor cells fro... DisGeNET Detail
Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC... DisGeNET Detail
The reactivation of senescence features and elimination of cells refractory to BRAF(V600E) inhibitio... DisGeNET Detail
Recently, the BRAF V600E mutation was uniformly identified in one HCL series, which may provide insi... DisGeNET Detail
Advanced molecular techniques have identified distinct molecular aberrations in the Raf/MEK-ERK path... DisGeNET Detail
We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild... DisGeNET Detail
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic co... DisGeNET Detail
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. DisGeNET Detail
The performance of the BRAF V600E-specific VE1 antibody was compared with that of allele-specific po... DisGeNET Detail
Transgenic induction of BRAF(V600E)in the thyroid gland results in cancers resembling human papillar... DisGeNET Detail
The performance of the BRAF V600E-specific VE1 antibody was compared with that of allele-specific po... DisGeNET Detail
BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carcinomas, usu... DisGeNET Detail
BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had identical mutations in ... DisGeNET Detail
Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. DisGeNET Detail
Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a... DisGeNET Detail
Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed that phosphorylated (ac... DisGeNET Detail
Tumors were also screened for BRAF V600E mutations; patients with the mutation were considered as no... DisGeNET Detail
After molecular analysis, the BRAF V600E mutation was detected in 18/32 (56.2%) cases with a cytolog... DisGeNET Detail
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. DisGeNET Detail
Screening for activating BRAF mutations in a series of 83 PTCs identified the most common V600E muta... DisGeNET Detail
Although BRAF(V600E)/PIK3CA(H1047R) melanomas were sensitive to the antiproliferative effects of sel... DisGeNET Detail
The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunit... DisGeNET Detail
In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expression, which repres... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
After surgery, 115 nodules were confirmed as conventional papillary thyroid carcinoma and 102 (88.70... DisGeNET Detail
Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcar... DisGeNET Detail
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PT... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
Previous studies demonstrated a high prevalence of a BRAF p.V600E mutation in perineuriomas with ser... DisGeNET Detail
Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patie... DisGeNET Detail
The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharma... DisGeNET Detail
ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compa... DisGeNET Detail
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BR... DisGeNET Detail
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorecta... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in mela... DisGeNET Detail
Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extra... DisGeNET Detail
Our investigation evaluates associations between active and passive smoking and TP53, KRAS2, and BRA... DisGeNET Detail
In particular, gene instability caused by decreased expression of the hMLH1 gene, a DNA mismatch rep... DisGeNET Detail
We report here the detection of the BRAF V600E mutation in a patient with c-GBM and describe the pat... DisGeNET Detail
Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V600E)-mutated melanom... DisGeNET Detail
Histiocytic sarcoma exhibited the highest rate of BRAF(V600E) (62.5%, five of eight), followed by La... DisGeNET Detail
A high percentage of both melanomas and papillary carcinomas of the thyroid harbors a recurrent muta... DisGeNET Detail
The BRAF(V600E) mutation was associated with male sex (P = 0.028), large tumor size, extrathyroidal ... DisGeNET Detail
VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its u... DisGeNET Detail
We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; in addition, they ar... DisGeNET Detail
BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
The T1799A missense mutation in exon 15 of the BRAF gene and RET/PTC rearrangement have been identif... DisGeNET Detail
One such target is the V600E gain-of-function BRAF mutation found in 60% of melanomas; other mutatio... DisGeNET Detail
BRAF V600E mutation was found in 115 samples, 80 of which were also cytologically diagnosed as papil... DisGeNET Detail
KRAS codon 12/13 and 59/61 and BRAF V600E mutations, MSI, and MGMT and hMLH1 methylation and express... DisGeNET Detail
This study identified the expression of KIAA1549-BRAF fusion gene and BRAF V600E mutation, mutations... DisGeNET Detail
However, these findings are not specific enough to predict the presence or absence of the BRAF(V600E... DisGeNET Detail
Dual targeting of BRAF(V600E) and Hdm2 with vemurafenib and Nt-3, respectively, synergistically indu... DisGeNET Detail
Treatment of the most resistant cell line, 8505c, using lexatumumab in combination with the BRAF(V60... DisGeNET Detail
As the somatic T1799A BRAF mutation is highly prevalent in papillary thyroid cancer, the aim was to ... DisGeNET Detail
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-n... DisGeNET Detail
We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAF(V600E) inhibitor... DisGeNET Detail
The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunit... DisGeNET Detail
Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct se... DisGeNET Detail
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated ... DisGeNET Detail
The activating BRAF mutation V600E and related mutations in this codon are most important for the ac... DisGeNET Detail
CYP24A1 overexpression is a poor prognostic indicator for PTC and may reflect BRAF(V600E) mutation a... DisGeNET Detail
Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma. DisGeNET Detail
Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit ... DisGeNET Detail
In this issue of Cancer Discovery, Shi and colleagues add further insight into the role of exon 3 ME... DisGeNET Detail
BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of ... DisGeNET Detail
On the contrary, no link could be detected between expression of BRAF(V599E) and age at diagnosis, g... DisGeNET Detail
BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? DisGeNET Detail
The prevalence of BRAF(V600E) was considerably higher in older (age &gt; 70) females with KRAS wild-... DisGeNET Detail
Forty-six cases of papillary thyroid carcinoma have been evaluated for the presence of BRAF(V600E) m... DisGeNET Detail
To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in or... DisGeNET Detail
The paradoxically higher incidence of BRAF(V600E) mutations in medium-sized compared with giant CMNs... DisGeNET Detail
We were unable to identify peripheral BRAF(V600E) mutations in patients with papillary thyroid cance... DisGeNET Detail
RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced e... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
Recent developments in v-raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E)-specific small m... DisGeNET Detail
ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compa... DisGeNET Detail
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. DisGeNET Detail
We previously described a patient with BRAF V600E mutation in primary tumor and a new mutation (V600... DisGeNET Detail
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated ... DisGeNET Detail
Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progr... DisGeNET Detail
For the first time, we report concomitant presence of a somatic BRAF(V600E) mutation in an NF1 patie... DisGeNET Detail
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment o... DisGeNET Detail
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, a... DisGeNET Detail
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström... DisGeNET Detail
While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21%... DisGeNET Detail
Moreover, BRAF(V600E) mutation was not correlated with any of the prognostic factors including age ≥... DisGeNET Detail
This study compared the specificity and sensitivity of IHC with other methods for the detection of B... DisGeNET Detail
For the first time, we report concomitant presence of a somatic BRAF(V600E) mutation in an NF1 patie... DisGeNET Detail
Our BRAF(V600E) GEMM presented with sessile serrated adenomas/polyps, as seen in humans. DisGeNET Detail
Activating point mutation of the BRAF gene resulting in V600E (previously designated as V599E) is a ... DisGeNET Detail
These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiol... DisGeNET Detail
Blockade of BRAF(V600E) → MEK1/2 → ERK1/2 or class I PI3K inhibited melanoma proliferation, whereas ... DisGeNET Detail
Recently, an alternative pathway of tumorigenesis has been identified in the colorectum associated w... DisGeNET Detail
Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases. DisGeNET Detail
Ectopic MITF expression in conjunction with the BRAF(V600E) mutant transformed primary human melanoc... DisGeNET Detail
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopatholo... DisGeNET Detail
The demonstration of the BRAF V600E mutation in the pineal tumor made the patient eligible for intra... DisGeNET Detail
The increased incidence of cancer in FDRs of index CRC patients with the p.V600E BRAF mutation may b... DisGeNET Detail
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension... DisGeNET Detail
Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E) and a higher tumor... DisGeNET Detail
BRAF V600E was associated with advanced TNM (P &lt; 0.001), more distant metastases (P = 0.025), and... DisGeNET Detail
BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal tumourigenesis by st... DisGeNET Detail
CH5126766/RO5126766 induced G1 cell cycle arrest in two melanoma cell lines with the BRAF V600E or N... DisGeNET Detail
The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and hMLH1) were assessed... DisGeNET Detail
Patients with micro-PTC were evaluated separately, it was found that BRAF(V600E) mutation was more f... DisGeNET Detail
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600... DisGeNET Detail
Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in p... DisGeNET Detail
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thy... DisGeNET Detail
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements eval... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
Taken together, our study demonstrates that ASCT2-mediated glutamine transport is a potential therap... DisGeNET Detail
Analysis of frozen and fixed material from 21 CCS and 21 MM showed the presence of the V600E BRAF mu... DisGeNET Detail
The U.S. Food and Drug Administration approved the use of trametinib and dabrafenib in combination f... DisGeNET Detail
Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving... DisGeNET Detail
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive t... DisGeNET Detail
PCCL3 cells conditionally expressing RET/PTC3, HRAS(G12V), or BRAF(V600E) and human thyroid cancer c... DisGeNET Detail
Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correla... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
(V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression throug... DisGeNET Detail
These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinoge... DisGeNET Detail
Three (60%) of 5 PTCs and 1 out of 17 benign lesions had BRAF(V600E) mutation (only one false positi... DisGeNET Detail
The BRAF V600E mutation accounts for the majority of BRAF mutations found in cutaneous melanoma and ... DisGeNET Detail
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopatholo... DisGeNET Detail
BRAF(V600E) mutation and p27(kip1) expression have been introduced as novel indicators that may pred... DisGeNET Detail
Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer... DisGeNET Detail
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. DisGeNET Detail
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases o... DisGeNET Detail
This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7... DisGeNET Detail
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs... DisGeNET Detail
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-diffe... DisGeNET Detail
BRAF(V600E) positivity was a useful marker at thyroid nodules with suspicious for papillary thyroid ... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we ... DisGeNET Detail
Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carc... DisGeNET Detail
Continuing vemurafenib or dabrafenib therapy despite hypersensitivity reaction is especially importa... DisGeNET Detail
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal ca... DisGeNET Detail
Remarkably, abrogating MITF activity in BRAF(V600E)mitf melanoma leads to dramatic tumor regression ... DisGeNET Detail
From our patients and literature search, we found that BRAF-V600E mutations occur predominantly in f... DisGeNET Detail
The BRAF(V600E) mutation is present in 62% of radioactive iodine-resistant thyroid tumors and is ass... DisGeNET Detail
In conclusion, our study showed a high implication of TSHR gene methylation and its significant asso... DisGeNET Detail
BRAF(V600E) mutation analysis using ethanol-fixed PTC cells from a patient demonstrated both a T pea... DisGeNET Detail
The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopat... DisGeNET Detail
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papilla... DisGeNET Detail
The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thy... DisGeNET Detail
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .... DisGeNET Detail
Our data suggest that one of the major functions of C-MYC overexpression in melanoma progression is ... DisGeNET Detail
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. DisGeNET Detail
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu ... DisGeNET Detail
We postulated that BRAF could be a SBT susceptibility gene, and investigated both germ line and soma... DisGeNET Detail
Activating mutations in the BRAF serine/threonine kinase are found in more than 70% of human melanom... DisGeNET Detail
Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies... DisGeNET Detail
A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: in-house PCR assay for BRAF T179... DisGeNET Detail
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroi... DisGeNET Detail
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillar... DisGeNET Detail
High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but i... DisGeNET Detail
TPC-1/BRAF (WT) wild-type and BcPAP/BRAF (V600E) -mutated PTC cell lines were selected to study the ... DisGeNET Detail
One melanoma-sarcoma pair showed identical BRAF V600E mutations. DisGeNET Detail
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. DisGeNET Detail
The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. DisGeNET Detail
The presence of the BRAF c.1799T&gt;A V600E mutation was recently described in cases of hairy cell l... DisGeNET Detail
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumor... DisGeNET Detail
V600E BRAF mutation is emerging as an independent marker of papillary thyroid carcinoma aggressive b... DisGeNET Detail
We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal tumourigenesis by st... DisGeNET Detail
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brai... DisGeNET Detail
At clinically informative sites, we identified seven low-frequency point mutations (0.2%-4.7%), incl... DisGeNET Detail
The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways causes papillary thyr... DisGeNET Detail
We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAF(V600E) inhibitor... DisGeNET Detail
About 40% to 60% of cutaneous melanomas have BRAF mutations, and 90% of the mutations involve a spec... DisGeNET Detail
Researchers retrospectively reviewed medical records of all patients at our institution with surgica... DisGeNET Detail
An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors. DisGeNET Detail
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring t... DisGeNET Detail
In our study, BRAF V600E mutation revealed a strong association with specific histological variants ... DisGeNET Detail
Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in colorectal carcinom... DisGeNET Detail
BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardles... DisGeNET Detail
All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH... DisGeNET Detail
Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma... DisGeNET Detail
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600... DisGeNET Detail
Immunohistochemical detection of the mutated V600E BRAF protein in PTC may facilitate mutational ana... DisGeNET Detail
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. DisGeNET Detail
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. DisGeNET Detail
RET/PTC rearrangement and BRAF(V600E) mutation are the two prevalent molecular alterations associate... DisGeNET Detail
BRAF(V600E) mutation was more frequent in classic (75%), tall cell (91%), and other variants (&gt;70... DisGeNET Detail
Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) mutation. DisGeNET Detail
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopatholo... DisGeNET Detail
The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocyt... DisGeNET Detail
The objective of the study was to investigate the effects of the BRAF V600E mutation on expression o... DisGeNET Detail
These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FDG-avid than BRAF-WT ... DisGeNET Detail
Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and s... DisGeNET Detail
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid &lt;or=1 cm and t... DisGeNET Detail
The reactivation of senescence features and elimination of cells refractory to BRAF(V600E) inhibitio... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusi... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
A correlation between MLH1 promoter methylation, specifically the 'C' region, and BRAF V600E status ... DisGeNET Detail
Association of TERT promoter mutation 1,295,228 C&gt;T with BRAF V600E mutation, older patient age, ... DisGeNET Detail
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis. DisGeNET Detail
BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas. DisGeNET Detail
Together, the results indicate that AICAR-induced AMPK activation in BRAF V600E-mutant thyroid cance... DisGeNET Detail
The BRAF gene has been identified as an oncogene in human cancer and the V600E mutation has been sho... DisGeNET Detail
Neither CD34 expression nor BRAF(V600E) status was predictive of prognosis, except for PA tumors whe... DisGeNET Detail
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncolog... DisGeNET Detail
The authors' data suggested that BRAF(V600E) mutation and p27(Kip1) down-regulation in cancer cells ... DisGeNET Detail
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumor... DisGeNET Detail
The BRAF(V600E) mutation can be detected peripherally in the serum of patients with thyroid cancer. DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
BRAF V600E mutation is primarily present in conventional papillary thyroid cancer. DisGeNET Detail
To clarify which gene alteration, chromosome aberration, or point mutation preferentially occurs in ... DisGeNET Detail
Moreover, concomitant expression of BRAF(V600E) and TP53(R270H) result in lethal PDA. DisGeNET Detail
The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266 (4.1%) and RET/PTC in 55/... DisGeNET Detail
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcin... DisGeNET Detail
BRAF-V600E was detected at different time points during the disease course, even after therapy, poin... DisGeNET Detail
RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma; however, resistanc... DisGeNET Detail
BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carcinomas, usu... DisGeNET Detail
Additionally, there were significant associations (P&lt;0.05) between BRAF(V600E) and a higher tumor... DisGeNET Detail
We conducted comparative proteomic analysis of BRAF(V600E) melanoma and CRC cell lines, followed by ... DisGeNET Detail
We identified concurrent mutational inactivation of the PTEN and RB1 tumor suppressors as a mechanis... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
The reactivation of senescence features and elimination of cells refractory to BRAF(V600E) inhibitio... DisGeNET Detail
Though such data suggest that BRAF mutation is likely an early initiating event in tumors such as me... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy fo... DisGeNET Detail
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutat... DisGeNET Detail
While dabrafenib has demonstrated comparable efficacy to vemurafenib in BRAF V600E mutant melanoma p... DisGeNET Detail
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with... DisGeNET Detail
This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V6... DisGeNET Detail
Targeted expression of rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) and V6... DisGeNET Detail
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked dr... DisGeNET Detail
We therefore suggest screening of BRAF V600E-negative HCL for alternative exon 11 mutations in the d... DisGeNET Detail
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contri... DisGeNET Detail
The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers wit... DisGeNET Detail
All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH... DisGeNET Detail
We tested our originally reported cohort of 8 E-GBMs and 2 rhabdoid GBMs (R-GBM) as well as 5 new E-... DisGeNET Detail
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth ... DisGeNET Detail
The aim of this study was to evaluate the prevalence of both RET/PTC rearrangements and BRAF(V600E) ... DisGeNET Detail
This analysis suggests that differences in disease course of PTC in children versus adults are not s... DisGeNET Detail
This tumour-specific inhibition of ERK signalling results in a broad therapeutic index and RAF inhib... DisGeNET Detail
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III c... DisGeNET Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
dbSNP
rs113488022 dbSNP
Genome
hg19
Position
chr7:140,453,136-140,453,136
Variant Type
snv
Reference Allele
A
Alternative Allele
T
East Asian Chromosome Counts (ExAC)
8644
East Asian Allele Counts (ExAC)
0
East Asian Heterozygous Counts (ExAC)
0
East Asian Homozygous Counts (ExAC)
0
East Asian Allele Frequency (ExAC)
0.0
Chromosome Counts in All Race (ExAC)
121220
Allele Counts in All Race (ExAC)
2
Heterozygous Counts in All Race (ExAC)
2
Homozygous Counts in All Race (ExAC)
0
Allele Frequency in All Race (ExAC)
1.649892756970797E-5
Variant (CIViC) (CIViC Variant)
V600E
Transcript 1 (CIViC Variant)
ENST00000288602.6
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/12
Summary (CIViC Variant)
BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.
Genome browser